U.S. patent number RE46,762 [Application Number 15/288,271] was granted by the patent office on 2018-03-27 for 1'-substituted carba-nucleoside analogs for antiviral treatment.
This patent grant is currently assigned to GILEAD SCIENCES, INC. The grantee listed for this patent is Gilead Sciences, Inc.. Invention is credited to Thomas Butler, Aesop Cho, Choung U. Kim, Jay P. Parrish, Oliver L. Saunders, Lijun Zhang.
United States Patent |
RE46,762 |
Butler , et al. |
March 27, 2018 |
1'-substituted carba-nucleoside analogs for antiviral treatment
Abstract
Provided are pyrrolo[1,2-f][1,2,4]triazinyl,
imidazo[1,5-f][1,2,4]triazinyl, imidazo[1,2-f][1,2,4]triazinyl, and
[1,2,4]triazolo[4,3-f][1,2,4]triazinyl nucleosides, nucleoside
phosphates and prodrugs thereof, wherein the 1' position of the
nucleoside sugar is substituted. The compounds, compositions, and
methods provided are useful for the treatment of Flaviviridae virus
infections, particularly hepatitis C infections.
Inventors: |
Butler; Thomas (Carmel, CA),
Cho; Aesop (Mountain View, CA), Kim; Choung U. (San
Carlos, CA), Parrish; Jay P. (El Dorado Hills, CA),
Saunders; Oliver L. (Clovis, CA), Zhang; Lijun (Los
Altos Hills, CA) |
Applicant: |
Name |
City |
State |
Country |
Type |
Gilead Sciences, Inc. |
Foster City |
CA |
US |
|
|
Assignee: |
GILEAD SCIENCES, INC (Foster
City, CA)
|
Family
ID: |
40887058 |
Appl.
No.: |
15/288,271 |
Filed: |
October 7, 2016 |
Related U.S. Patent Documents
|
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
Issue Date |
|
|
13196117 |
Aug 2, 2011 |
8318682 |
|
|
|
12428176 |
Apr 22, 2009 |
8008264 |
|
|
|
61047263 |
Apr 23, 2008 |
|
|
|
|
61139449 |
Dec 19, 2008 |
|
|
|
Reissue of: |
13649511 |
Oct 11, 2012 |
8853171 |
Oct 7, 2014 |
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
A61P
31/20 (20180101); A61P 31/00 (20180101); C07H
19/23 (20130101); A61P 1/16 (20180101); A61P
31/12 (20180101); C07D 487/04 (20130101); A61P
31/16 (20180101); C07H 19/23 (20130101); A61P
43/00 (20180101); C07D 487/04 (20130101); A61P
31/14 (20180101) |
Current International
Class: |
A01N
43/04 (20060101); C07H 19/23 (20060101); C07D
487/04 (20060101); C07H 7/06 (20060101); C07H
5/04 (20060101); A61K 31/70 (20060101) |
References Cited
[Referenced By]
U.S. Patent Documents
Foreign Patent Documents
|
|
|
|
|
|
|
2367921 |
|
Sep 2000 |
|
CA |
|
1498221 |
|
May 2004 |
|
CN |
|
1852915 |
|
Oct 2006 |
|
CN |
|
101043893 |
|
Sep 2007 |
|
CN |
|
101611046 |
|
Dec 2009 |
|
CN |
|
201071170 |
|
Aug 2011 |
|
EA |
|
201171417 |
|
May 2012 |
|
EA |
|
201200525 |
|
Sep 2012 |
|
EA |
|
2 396 340 |
|
Dec 2013 |
|
EP |
|
41017629 |
|
Jan 1964 |
|
JP |
|
2004-520367 |
|
Jul 2004 |
|
JP |
|
2008-502685 |
|
Jan 2008 |
|
JP |
|
2008-518934 |
|
Jun 2008 |
|
JP |
|
91/19721 |
|
Dec 1991 |
|
WO |
|
00/56734 |
|
Sep 2000 |
|
WO |
|
01/32153 |
|
May 2001 |
|
WO |
|
01/60315 |
|
Aug 2001 |
|
WO |
|
01/90121 |
|
Nov 2001 |
|
WO |
|
02/18404 |
|
Mar 2002 |
|
WO |
|
02/32920 |
|
Apr 2002 |
|
WO |
|
02/057287 |
|
Jul 2002 |
|
WO |
|
02/057425 |
|
Jul 2002 |
|
WO |
|
03/093272 |
|
Nov 2003 |
|
WO |
|
03/093273 |
|
Nov 2003 |
|
WO |
|
WO 03/100009 |
|
Dec 2003 |
|
WO |
|
2004/046331 |
|
Jun 2004 |
|
WO |
|
2005/009418 |
|
Feb 2005 |
|
WO |
|
2005/123087 |
|
Dec 2005 |
|
WO |
|
2006/031725 |
|
Mar 2006 |
|
WO |
|
2006/050161 |
|
May 2006 |
|
WO |
|
2006/065335 |
|
Jun 2006 |
|
WO |
|
2006/121820 |
|
Nov 2006 |
|
WO |
|
2007/027248 |
|
Mar 2007 |
|
WO |
|
2007/056170 |
|
May 2007 |
|
WO |
|
2007/064883 |
|
Jun 2007 |
|
WO |
|
2007/064931 |
|
Jun 2007 |
|
WO |
|
WO 2007/097991 |
|
Aug 2007 |
|
WO |
|
WO 2007/135134 |
|
Nov 2007 |
|
WO |
|
2008/005542 |
|
Jan 2008 |
|
WO |
|
2008/041079 |
|
Apr 2008 |
|
WO |
|
2008/079206 |
|
Jul 2008 |
|
WO |
|
2008/082601 |
|
Jul 2008 |
|
WO |
|
2008/085508 |
|
Jul 2008 |
|
WO |
|
2008/089105 |
|
Jul 2008 |
|
WO |
|
2008/116064 |
|
Sep 2008 |
|
WO |
|
WO 2008/121634 |
|
Oct 2008 |
|
WO |
|
2008/141079 |
|
Nov 2008 |
|
WO |
|
WO 2009/009951 |
|
Jan 2009 |
|
WO |
|
2009/131926 |
|
Oct 2009 |
|
WO |
|
2009/132123 |
|
Oct 2009 |
|
WO |
|
2009/132135 |
|
Oct 2009 |
|
WO |
|
2010/002877 |
|
Jan 2010 |
|
WO |
|
2010/036407 |
|
Apr 2010 |
|
WO |
|
WO 2010/093608 |
|
Aug 2010 |
|
WO |
|
WO 2010/111381 |
|
Sep 2010 |
|
WO |
|
WO 2010/135569 |
|
Nov 2010 |
|
WO |
|
WO 2011/035231 |
|
Mar 2011 |
|
WO |
|
WO 2011/035250 |
|
Mar 2011 |
|
WO |
|
WO 2011/123672 |
|
Oct 2011 |
|
WO |
|
WO 2011/150288 |
|
Dec 2011 |
|
WO |
|
WO 2012/012465 |
|
Jan 2012 |
|
WO |
|
WO 2012/012776 |
|
Jan 2012 |
|
WO |
|
WO 2012/039787 |
|
Mar 2012 |
|
WO |
|
WO 2012/039791 |
|
Mar 2012 |
|
WO |
|
WO 2012/051570 |
|
Apr 2012 |
|
WO |
|
Other References
Arimilli, MN et al. (1997) "Synthesis, in vitro biological
evaluation and oral bioavailability of
9-[2-(phosphonomethoxy)propyl]adenine (PMPA) prodrugs", Antiviral
Chemistry & Chemotherapy, vol. 8(6), p. 557-564. cited by
applicant .
Benzaria, S. et al. (1996) "Synthesis in Vitro Antiviral
Evaluation, and Stability Studies of Bis(S-acyl-2-thioethyl) Ester
Derivatives of 9-[2-(Phosphonomethoxy)ethyl]adenine (PMEA) as
Potential PMEA Prodrugs with Improved Oral Bioavailability",
Journal of Medicinal Chemistry, vol. 39, pp. 4958-4965. cited by
applicant .
Bio, M. et al. (2004) , "Practical Synthesis of a Potent Hepatitis
C Virus RNA Replication Inhibitor", Journal of Organic Chemistry,
vol. 69, pp. 6257-6266. cited by applicant .
Bobeck D.R. et al. (2010) "Advances in nucleoside monophosphate
prodrugs as anti-HCV agents", Antiviral Therapy, vol. 15, pp.
935-950. cited by applicant .
Bojack G. et al. (2001), "Design and Synthesis of Inhibitors of
Adenosine and AMP Deaminases", Organic Letters, vol. 3(6), pp.
839-842. cited by applicant .
Boyer, N. et al. (2000), "Pathogenesis, diagnosis and management of
hepatitis C", Journal of Hepatology, vol. 32, pp. 98-112. cited by
applicant .
Calisher, C. et al. (1989) "Antigenic Relationships between
Flaviviruses as Determined by Cross-neutralization Tests with
Polyclonal Antisera", Journal of General Virology, vol. 70, pp.
37-43. cited by applicant .
De Clercq, E. (2001) "Antiviral drugs: current state of the art",
Journal of Clinical Virology, vol. 22, pp. 73-89. cited by
applicant .
De Clercq, E. (2001) "Molecular Targets for Antiviral Agents" The
Journal of Pharmacology and Experimental Therapeutics, vol. 297(1),
pp. 1-10. cited by applicant .
De Francesco, R. et al. (2003) "Approaching a new era for hepatitis
C virus therapy: inhibitors of the NS3-4A serine protease and the
NS5B RNA-dependent RNA polymerase", Antiviral Research , vol. 58,
pp. 1-16. cited by applicant .
De Lombaert, S. et al. (1994) "N-Phosphonomethyl Dipeptides and
Their Phosphonate Prodrugs, a New Generation of Neutral
Endopeptidase (NEP, EC 3.4.24.11) Inhibitors", Journal of Medicinal
Chemistry, vol. 37, pp. 498-511. cited by applicant .
Di Bisceglie, A. et al. (1999) "The Unmet Challenges of Hepatitis
C", Scientific American, Inc. Oct. pp. 80-85. cited by applicant
.
Dolzhenko, A.V. et al. (2008)
"Pyrazolo[1,5-a][1,3,5]Triazines(5-AZA-9-Deazapurines):Synthesis
and Biological Activity", Heterocycles, vol. 75, No. 7. cited by
applicant .
Dudfield, P. et al. (1999) "Synthesis of C-ribosyl
imidazo[2,1-f][1,2,4]triazines as inhibitors of adenosine and AMP
deaminases," J. Chem. Soc, Perkin Trans 1 2929-2936. cited by
applicant .
Dudfield, P.J. et al. (1999) "Synthesis of C-ribosyl
1,2,4-triazolo[3,4-f][1,2,4]triazines as inhibitors of adenosine
and AMP deaminases", J. Chem. Soc., Perkin Trans 1, pp. 2937-2942.
cited by applicant .
Dymock, B. et al. (2000) "Novel approaches to the treatment of
hepatits C virus infection", Antiviral Chemistry &
Chemotherapy, vol. 11, pp. 79-96. cited by applicant .
Farquhar, D. et al. (1983), "Biologically Reversible
Phosphate-Protective Groups", Journal of Pharmaceutical Sciences,
vol. 72(3), pp. 324-325. cited by applicant .
Gleeson, P.M. et al. "(2003) Prediction of the potency of
inhibitors of adenosine deaminase by QM/MM calculations," Chem.
Comm. pp. 2180-2181. cited by applicant .
Gordon, C.P. et al. (2005) "Control of Hepatitis C: A Medicinal
Chemistry Perspective", Journal of Medicinal Chemistry, vol. 48(1),
pp. 1-20. cited by applicant .
Haraguchi, K. et al. (1995) "Stereoselective Synthesis of
1'-C-Branched Uracil Nucleosides From Uridine," Nucleosides &
Nucleotides 14(3-5):417-420. cited by applicant .
Hayashi, M. et al. (1992) "C-Nucleosides, a Synthesis of
2-Substituted
7-((.beta.-D-Ribofuranosyl)-Pyrrolo[2,1-f]-1,2,4-Triazines. A New
Type of "Purine Like" C-Nucleoside," Heterocycles 34(3):569-574.
cited by applicant .
Hecker, S.J.et al. (2007) "Liver Targeted Prodrugs of
2'-C-Methyladenosine for Therapy of Hepatitis C Virus Infection",
Journal of Medicinal Chemistry, vol. 50, pp. 3891-3896. cited by
applicant .
International Search Report and Written Opinion for
PCT/US2009/041432 mailed on Aug. 11, 2009. cited by applicant .
International Search Report for PCT/US2009/041447, mailed on Aug.
7, 2009. cited by applicant .
International Search Report for PCT/US2010/049471, mailed Nov. 18,
2010. cited by applicant .
International Search Report for PCT/US2010/049508, filed Sep. 20,
2010, mail date Nov. 5, 2010. cited by applicant .
Itoh, Y. et al. (1995) "Divergent and Stereocontrolled Approach to
the Synthesis of Uracil Nucleosides Branched at the Anomeric
Position," J. Org. Chem,. 60:656-662. cited by applicant .
Khamnei, S. at al. (1996) "Neighboring Group Catalysis in the
Design of Nucleotide Prodrugs", Journal of Medicinal Chemistry,
vol. 39, pp. 4109-4115. cited by applicant .
Knutsen, L. et al. (1984) "Synthesis of Imidazo-fused
Bridgehead-nitrogen C-Nucleosides via Dehydrative Coupling
Reactions of 2,5-Anhydro-3,4,6-tri-O-benzoyl-D-allonic Acid," J.
Chem. Soc. Perkin Trans I pp. 229-238. cited by applicant .
Knutsen, L. et al. (1985) "Synthesis of Imidazo-fused
Bridgehead-nitrogen C-Nucleosides: Coupling-Elimination Reactions
of 2,5-Anhydro-3,4,6-tri-O-benzoyl-D-allonic Acid," J. Chem. Soc.
Perkin Trans I pp. 621-630. cited by applicant .
Kobe, B. et al. (1992) "Use of distance geometry approach for the
in vitro antiviral activity evaluation of N-bridgehead
C-nucleosides", European Journal of Medicinal Chemistry, vol. 27,
pp. 259-266. cited by applicant .
McGuigan, C. et al. (1993) "Intracellular Delivery of Bioactive AZT
Nucleotides by Aryl Phosphate Derivatives of AZT", Journal of
Medicinal Chemistry, vol. 36, pp. 1048-1052. cited by applicant
.
Mitchell, A.G. et al. (1992) "Bioreversible Protection for the
Phospho Group: Bioactivation of the Di(4-acyloxybenzyl) and Mono
(4-acyloxybenzyl) Phosphoesters of Methylphosphonate and
Phosphonoacetate", J. Chem. Soc. Perkin Trans. 1, pp. 2345-2353.
cited by applicant .
Mitchell, W. L. et al. (1984) "Synthesis of C-Nucleoside Isosteres
of 9-(2-Hydroxyethoxymethyl)guanine (Acyclovir) [1]", Journal of
Heterocyclic Chemistry, vol. 21, pp. 697-699. cited by applicant
.
Moennig, V. et al. (1992) "The Pestiviruses", Advances in Virus
Research, vol. 41, pp. 53-98. cited by applicant .
Moradpour, D. et al. (2007) "Replication of hepatitis C virus",
Nature Reviews Microbiology, June, vol. 5, pp. 453-463. cited by
applicant .
Nishimura, N. (2001) "Synthesis of pyrrolo[2,1-f][1,2,4]triazine
C-nucleosides. Isosteres of sangivamycin, tubercidin, and
toyocamycin," Carbohydrate Research 331:77-82. cited by applicant
.
Otter, B. et al. (1996) "Conformational Properties of Purine-Like
C-Nucleosides", Nucleosides & Nucleotides, vol. 15 (1-3), pp.
793-807. cited by applicant .
Patil, S. et al. (1994) "4-Aza-7,9-Dideazaadenosine, a New
Cytotoxic Synthetic C-Nucleoside Analogue of Adenosine,"
Tetrahedron Letters 35(30):5339-5342. cited by applicant .
Patil, S.A. et al. (1994) "Synthesis of
Pyrrolo[2,1-f][1,2,4]triazine Congeners of Nucleic Acid Purines via
the N-Amination of 2-Substituted Pyrroles[1]", Journal of
Heterocyclic Chemistry, vol. 31, pp. 781-786. cited by applicant
.
Puech, F. et al. (1993) "Intracellular delivery of nucleoside
monophosphates through a reductase-mediated activiation process",
Antiviral Research, vol. 22, pp. 155-174. cited by applicant .
Ramasamy, K. et al. (1986) "Synthesis and Antitumor Activity of
Certain
3-.beta.-D-Ribofuranosyl-1,2,4-triazolo[3,4-f]-1,2,4-triazines
Related to Formycin Prepared via Ring Closure of a 1,2,4-Triazine
Precursor", Journal of Medicinal Chemistry, vol. 29, pp. 2231-2235.
cited by applicant .
Reddy, K.R. et al. (2005) "Stereoselective synthesis of nucleoside
monophosphate HepDirect.TM. Prodrugs", Tetrahedron Letters vol. 46,
pp. 4321-4324. cited by applicant .
Schul, W. et al. (2007), "A Dengue Fever Viremia Model in Mice
Shows Reduction in Viral Replication and Suppression of the
Inflammatory Response after Treatment with Antiviral Drugs",
Journal of Infectious Diseases, vol. 195, pp. 665-674. cited by
applicant .
Scott, L. J. et al. (2002) "Interferon-.alpha.-2b Plus Ribavirin",
Drugs, vol. 62(3), pp. 507-556. cited by applicant .
Written Opinion for PCT/US2010/049471, mailed Nov. 18, 2010. cited
by applicant .
Written Opinion for PCT/US2010/049508, filed Sep. 20, 2010, mail
date Nov. 5, 2010. cited by applicant .
Yoshimura, Y. et al. (1996) "Synthesis and Biological Evaluation of
1'-C-Cyano-Pyrimidine Nucleosides," Nucleosides & Nucleotides
15(1-3):305-324. cited by applicant .
Silverman, R.B., "The Organic Chemistry of Drug Design and Drug
Action," 2nd Edition, Elsevier Academic Press, pp. 29-34 (2004).
cited by applicant .
Office Action issued in Chinese Patent Application No.
200980114224.2, issued on Nov. 30, 2012 (8 pages). cited by
applicant .
Office Action issued in Australian Patent Application No.
2009240642, issued on Aug. 2, 2012 (3 pages). cited by applicant
.
Notice of Allowance mailed Jan. 6, 2011 for U.S. Appl. No.
12/428,176. cited by applicant .
Notice of Allowance mailed Apr. 12, 2011 for U.S. Appl. No.
12/428,176. cited by applicant .
Office Action mailed Sep. 23, 2011 for U.S. Appl. No. 13/196,117.
cited by applicant .
Notice of Allowance mailed Mar. 27, 2012 for U.S. Appl. No.
13/196,117. cited by applicant .
Notice of Allowance mailed Jul. 16, 2012 for U.S. Appl. No.
13/196,117. cited by applicant .
Office Action mailed Dec. 23, 2010 for U.S. Appl. No. 12/428,234.
cited by applicant .
Notice of Allowance mailed Apr. 7, 2011 for U.S. Appl. No.
12/428,234. cited by applicant .
Office Action mailed Dec. 23, 2010 for U.S. Appl. No. 12/702,957.
cited by applicant .
Notice of Allowance mailed Apr. 26, 2011 for U.S. Appl. No.
12/702,957. cited by applicant .
Notice of Allowance mailed Feb. 17, 2011 for U.S. Appl. No.
12/885,917. cited by applicant .
Office Action mailed Mar. 27, 2012 for U.S. Appl. No. 13/050,820.
cited by applicant .
Office Action mailed Oct. 16, 2012 for U.S. Appl. No. 13/050,820.
cited by applicant .
Notice of Allowance mailed Jan. 31, 2013 for U.S. Appl. No.
13/050,820. cited by applicant .
Office Action (Restriction Requirement) mailed Sep. 14, 2012 for
U.S. Appl. No. 12/886,248. cited by applicant .
Office Action mailed Nov. 6, 2012 for U.S. Appl. No. 12/886,248.
cited by applicant .
Office Action mailed Mar. 4, 2013 for U.S. Appl. No. 12/886,248.
cited by applicant .
Notice of Allowance mailed Aug. 10, 2012 for U.S. Appl. No.
13/117,060. cited by applicant .
Notice of Allowance mailed Nov. 28, 2012 for U.S. Appl. No.
13/117,060. cited by applicant .
Office Action (Restriction Requirement) mailed Jul. 3, 2012 for
U.S. Appl. No. 13/189,373. cited by applicant .
Office Action mailed Sep. 14, 2012 for U.S. Appl. No. 13/189,373.
cited by applicant .
Written Opinion for PCT International Application No.
PCT/US2009/041447, mailed Aug. 7, 2009 (6 pages). cited by
applicant .
International Preliminary Report on Patentability for PCT
International Application No. PCT/US2009/041447, mailed Oct. 26,
2010 (7 pages). cited by applicant .
Written Opinion for PCT International Application No.
PCT/US2009/041432, mailed Aug. 11, 2009 (6 pages). cited by
applicant .
International Preliminary Report on Patentability for PCT
International Application No. PCT/US2009/041432, mailed Oct. 26,
2010 (7 pages). cited by applicant .
International Search Report for PCT International Application No.
PCT/US2010/023586, mailed Aug. 4, 2010 (4 pages). cited by
applicant .
Written Opinion for PCT International Application No.
PCT/US2010/023586, mailed Aug. 4, 2010 (5 pages). cited by
applicant .
International Preliminary Report on Patentability for PCT
International Application No. PCT/US2010/023586, mailed Aug. 16,
2011 (6 pages). cited by applicant .
International Preliminary Report on Patentability for PCT
International Application No. PCT/US2010/049471, mailed Mar. 27,
2012 (7 pages). cited by applicant .
International Search Report for PCT International Application No.
PCT/US2011/028897, mailed Aug. 1, 2011 (6 pages). cited by
applicant .
Written Opinion for PCT International Application No.
PCT/US2011/028897, mailed Aug. 1, 2011 (6 pages). cited by
applicant .
International Preliminary Report on Patentability for PCT
International Application No. PCT/US2011/028897, mailed Mar. 26,
2013 (7 pages). cited by applicant .
International Search Report for PCT International Application No.
PCT/US2011/029441, mailed Aug. 1, 2011 (6 pages). cited by
applicant .
Written Opinion for PCT International Application No.
PCT/US2011/029441, mailed Aug. 1, 2011 (6 pages). cited by
applicant .
International Preliminary Report on Patentability for PCT
International Application No. PCT/US2011/029441, mailed Mar. 26,
2013 (7 pages). cited by applicant .
International Preliminary Report on Patentability for PCT
International Application No. PCT/US2010/049508, mailed Mar. 27,
2012 (6 pages). cited by applicant .
International Search Report for PCT International Application No.
PCT/US2011/038253, mailed Jul. 29, 2011 (4 pages). cited by
applicant .
Written Opinion for PCT International Application No.
PCT/US2011/038253, mailed Jul. 29, 2011 (5 pages). cited by
applicant .
International Preliminary Report on Patentability for PCT
International Application No. PCT/US2011/038253, mailed Dec. 4,
2012 (6 pages). cited by applicant .
International Search Report for PCT International Application No.
PCT/US2011/044581, mailed Nov. 7, 2011 (4 pages). cited by
applicant .
Written Opinion for PCT International Application No.
PCT/US2011/044581, mailed Nov. 7, 2011 (6 pages). cited by
applicant .
International Preliminary Report on Patentability for PCT
International Application No. PCT/US2011/044581, mailed Jan. 22,
2013 (7 pages). cited by applicant .
International Search Report for PCT International Application No.
PCT/US2011/045102, mailed Nov. 9, 2011 (4 pages). cited by
applicant .
Written Opinion for PCT International Application No.
PCT/US2011/045102, mailed Nov. 9, 2011 (4 pages). cited by
applicant .
International Preliminary Report on Patentability for PCT
International Application No. PCT/US2011/045102, mailed Jan. 22,
2013 (5 pages). cited by applicant .
Office Action for CN Patent Application No. 200980114224.2, dated
Aug. 19, 2013 (with English translation). cited by applicant .
First Examination Report for CO Patent Application No. 10-121513-5,
dated Dec. 10, 2012. cited by applicant .
First Examination Report for EA Patent Application No. 201071170,
dated Apr. 25, 2012 (with English translation). cited by applicant
.
Second Examination Report for EA Patent Application No. 201071170,
dated Oct. 25, 2012 (with English translation). cited by applicant
.
First Examination Report for ID Patent Application No. W00 2010
03923, dated Apr. 5, 2013. cited by applicant .
First Examination Report for IL Patent Application No. 208515,
dated Jan. 6, 2013 (English translation). cited by applicant .
Supplement to First Examination Report for IL Patent Application
No. 208515, dated Jan. 15, 2013 (English translation). cited by
applicant .
First Examination Report for JP Patent Application No. 2011-506435,
dated Aug. 22, 2013 (with English translation). cited by applicant
.
First Examination Report for MX Patent Application No.
MX/a/2010/011661, dated Oct. 26, 2011. cited by applicant .
First Examination Report for NZ Patent Application No. 588400,
dated Apr. 11, 2011. cited by applicant .
Second Examination Report and Notice of Acceptance for NZ Patent
Application No. 588400 dated Jul. 27, 2012. cited by applicant
.
First Examination Report for TW Patent Application No. 098113324,
dated Oct. 30, 2012 (English translation). cited by applicant .
First Examination Report for VN Patent Application No.
1-2010-02653, dated Apr. 26, 2012 (with English translation). cited
by applicant .
First Examination Report for AU Patent Application No. 2009240642,
dated Aug. 2, 2012. cited by applicant .
First Examination Report for AU Patent Application No. 2009240630,
dated Jun. 14, 2012. cited by applicant .
Second Examination Report for CN Patent Application No.
200980120218.8, dated Jun. 21, 2013 (with English translation).
cited by applicant .
First Examination Report for CN Patent Application No.
200980120218.8, dated Nov. 13, 2012 (with English translation).
cited by applicant .
First Examination Report for CO Patent Application No. 10-131479,
dated Oct. 23, 2012. cited by applicant .
Second Examination Report for CO Patent Application No. 10-131479,
dated Jun. 20, 2013. cited by applicant .
First Examination Report for EA Patent Application No. 201071128,
dated Apr. 25, 2012 (with English translation). cited by applicant
.
Second Examination Report for EA Patent Application No. 201071128,
dated Oct. 24, 2012 (with English translation). cited by applicant
.
Third Examination Report for EA Patent Application No. 201071128,
dated Apr. 29, 2013 (with English translation). cited by applicant
.
First Examination Report for ID Patent Application No. W00 2010
03957, dated Apr. 25, 2013 (with English translation). cited by
applicant .
First Examination Report for IL Patent Application No. 208701,
dated Jan. 13, 2013 (English translation). cited by applicant .
First Examination Report for JP Patent Application No. 2011-506429,
dated Aug. 22, 2013 (with English translation). cited by applicant
.
First Examination Report for NZ Patent Application No. 588670,
dated Apr. 8, 2011. cited by applicant .
First Examination Report for UA Patent Application No. 2010 13030,
dated Mar. 2, 2013 (with English translation). cited by applicant
.
First Examination Report for VN Patent Application No.
1-2010-02939, dated Apr. 19, 2012 (with English translation). cited
by applicant .
Second Examination Report for VN Patent Application No.
1-2010-02939, dated Jul. 26, 2012 (with English translation). cited
by applicant .
First Office Action for CL Patent Application No. 1906-2011, dated
Aug. 9, 2011 (no English translation available). cited by applicant
.
First Office Action for CN Patent Application No. 201080011960.0,
dated Jun. 8, 2013 (with English translation). cited by applicant
.
First Office Action for EA Patent Application No. 201190110/28,
dated Apr. 26, 2012 (with English translation). cited by applicant
.
Second Office Action for EA Patent Application No. 201190110/28,
dated Jan. 28, 2013 (with English translation). cited by applicant
.
Communication under 161/162 for EP Patent Application No.
10704068.5, dated Sep. 6, 2011. cited by applicant .
First Office Action for EP Patent Application No. 10704068.5, dated
Jun. 18, 2012. cited by applicant .
First Office Action for IL Patent Application No. 214396, dated
Jul. 8, 2013 (English translation). cited by applicant .
Communication under 161/162 for EP Patent Application No.
10763083.2, dated May 11, 2012. cited by applicant .
Notification Prior to Examination for IL Patent Application No.
218599, dated Nov. 13, 2012 (English translation). cited by
applicant .
Communication under 161/162 for EP Patent Application No.
11715792.5, dated Apr. 26, 2013. cited by applicant .
Communication under 161/162 for EP Patent Application No.
11743400.1, dated Feb. 26, 2013. cited by applicant .
Communication under 161/162 for EP Patent Application No.
11743709.5, dated Mar. 1, 2013. cited by applicant .
First Office Action for VN Patent Application No. 1-2012-03895,
dated Feb. 8, 2013 (with English translation). cited by applicant
.
Alessandrini, L. et al., "Synthesis of Differently Protected
1-C-methyl-ribofuranoses Intermediates for the Preparation of
Biologically Active 1'-C-methyl-ribonucleosides," Journal of
Carbohydrate Chemistry, 27(5):332-344, 2008. cited by applicant
.
Ali, H.M. et al., "Quantitative structure-activity relationships
(QSAR) of two series of O-aryl or N-acyl O-ethyl phosphoramidate
and phosphorodiamidate fungicides incorporating amino acid ethyl
esters," Bulletin of Environmental Contamination and Toxicology,
65(4):415-420, 2000. cited by applicant .
Asbun, W. et al., "Synthesis of 5-substituted Pyrimidines. II,"
Journal of Organic Chemistry, 31:140-142, 1968. cited by applicant
.
Ballini, R. et al., "Enantioselective Synthesis of the Lactone
Moiety of the Mevinic Acids using D-Xylose as a Chiral Precursor,"
Journal of the Chemical Society, Perkin Transactions 1,
1991:490-491, 1991. cited by applicant .
Bandini, M. et al., "Indium tribromide: a highly effective catalyst
for the addition of trimethylsilyl cyanide to
.alpha.-hetero-substituted ketone," Tetrahedron Letters,
42:3041-3043, 2001. cited by applicant .
Barker, R. et al., "2,3,5-Tri-O-benzyl-D-ribosyl and -L-arabinosyl
Bromides," Journal of Organic Chemistry, 26(11):4605-4609, 1961.
cited by applicant .
Belokon, Y. et al., "Optimized catalysts for the asymmetric
addition of trimethylsilyl cyanide to aldehydes and ketones,"
Tetrahedron, 57:771-779, 2001. cited by applicant .
Benksim, A. et al., "A Novel Stereospecific Synthesis of Glycosyl
Cyanides from 1,2-O-sulfinyl Derivatives," Organic Letters,
6(22):3913-3915, 2004. cited by applicant .
Brown, N., "Progress towards improving antiviral therapy for
hepatitis C virus polymerase inhibitors. Part O: Nucleoside
analogues," Expert Opinion, 18:709-725, 2009. cited by applicant
.
Butora et al., "Synthesis and HCV inhibitory properties of 9-deaza-
and 7,9-dideaza-7-oxa-2'-C-methyladenosine," Bioorganic &
Medicinal Chemistry, 15(15)5219-5229, 2007. cited by applicant
.
Cabirol, F. et al., "robust and Efficient, yet Uncatalyzed,
Synthesis of Triarylsilyl-protected Cyanohydrins from Ketones,"
Journal of Organic Chemistry, 73:2446-2449, 2008. cited by
applicant .
Cales, P. et al., "Treatment of liver fibrosis: clinical aspects,"
Gastroenterologie Clinique et Biologique, 33(10-11):958-966, 2009.
cited by applicant .
Camps, P., "Studies on Structurally Simple
-.alpha..beta.-butenolides-II," Tetrahedron, 38(15):2395-2402,
1982. cited by applicant .
Carroll, S., "Robust Antiviral Efficacy upon Administration of a
Nucleoside Analog to Hepatitis C Virus-Infected Chimpanzees,"
Antimicrobial Agents and Chemotherapy, 53(3):926-934, 2009. cited
by applicant .
Chapman, J. et al., "RSV604, a Novel Inhibitor of Respiratory
Syncytial Virus Replication," Antimicrobial Agents and
Chemotherapy, 51(9):3346-53, 2007. cited by applicant .
Cihlar, T. et al., "Design and Profiling of GS-9148, a Novel
Nucleotide Analog Active against Nucleoside-resistant Variants of
Human Immunodeficiency Virus Type 1, and Its Orally Bioavailable
Phosphonoamidate Prodrug, GS-9131," Antimicrobial Agents and
Chemotherapy, 52(2):655-65, 2008. cited by applicant .
Clark, J. et al., "Design, Synthesis, and Antiviral Activity of
2'-Deoxy-2'-fluoro-2'-C-methylcytidine, a Potent Inhibitor of
Hepatitis C Virus Replication," Journal of Medicinal Chemistry,
48(17):5504-5508, 2005. cited by applicant .
Colacino, E. et al., "Synthesis and Biological Evaluation of Some
5-Nitro- and 5-Amino Derivatives of 2'-Deoxycytidine,
2',3'-Dideoxyuridine, and 2',3'-Dideoxycytidine," Nucleoside,
Nucleotides & Nucleic Acids, 22(11):2013-2026, 2003. cited by
applicant .
Dai, Q. et al., "Synthesis of 2'-C-.beta.-Fluoromethyluridine,"
Organic Letters, 5(6):807-810, 2003. cited by applicant .
De Las Heras, "Synthesis of Ribosyl and Arabinosyl Cyanides by
Reaction of 1-O-Acyl Sugars with Trimethylsilyl Cyanide," Journal
of the Chemical Society, Perkin Transactions 1, 1982:903-907, 1982.
cited by applicant .
Domingo, E. et al., "The quasispecies (extremely heterogeneous)
nature of viral RNA genome populations: biological relevance--a
review," Gene, 40:1-8, 1985. cited by applicant .
Dondoni, A. et al., "Thiazole-Based Synthesis of Formyl
C-Glycosides," Journal of Organic Chemistry, 59:6404-6414, 1994.
cited by applicant .
El Safadi, Y. et al., "5-Modified-2'-dU and 2'-dC as Mutagenic Anti
HIV-1 Proliferation Agents: Synthesis and Activity," Journal of
Medicinal Chemistry, 53(4):1534-1545, 2010. cited by applicant
.
Fukumoto, T. et al., "Viral Dynamics of Hepatiis C Early After
Orthotopic Liver Transplantation: Evidence for Rapid Turnover of
Serum Virions," Hepatology, 24:1351-1354, 1996. cited by applicant
.
Gardelli, C. et al., "Phosphoramidate Prodrugs of
2'-C-Methylcytidine for Therapy of Hepatitis C Virus Infection,"
Journal of Medicinal Chemistry, 52(17):5394-5407, 2009. cited by
applicant .
Greene, T.W., Protective Groups in Organic Chemistry (John Wiley
& Sons, New York, 1991). cited by applicant .
Gudmundsson, K. et al., "Synthesis of imidazo[1,2-a]pyridine
C-Nucleosides with an Unexpected Site of Ribosylation," Journal of
Organic Chemistry, 62:3453-3459, 1997. cited by applicant .
Gudmundsson, K. et al., "The Condensation of
2,6-dichloroimidazo[1,2-a]pyridine C-nucleoside with an Unexpected
Site of Ribosylation," Tetrahedron Letters, 37(14):2365-2368, 1996.
cited by applicant .
Gunic, E. et al.., "Cyclic monophosphate prodrugs of base-modified
2'-C-methyl ribonucleosides as ppotent inhibitors of hepatitis C
virus RNA replication," Bioorganic & Medicinal Chemistry
Letters, 17:2452-2455, 2007. cited by applicant .
Hamann, M. et al., "Synthesis and antiviral evaluation of
7,9-dideaza-8-thiapurine C-nucleoside derivatives," Collection
Symposium Series, 10:347-349, 2008. cited by applicant .
Hamann, M. et al., "Synthesis and antiviral evaluation of
thieno[3,4-d]pyrimidine C-nucleoside analogues of 2',3'-dideoxy-
and 2',3'-dideoxy-2',3'-didehydro-adenosine and -inosine,"
Bioorganic & Medicinal Chemistry, 17:2321-2326, 2009. cited by
applicant .
Han, H.K. et al., "Synthesis of
1-Chloroacetyl-1-dehydroxy-2,3,5-tri-O-benzoyl-.beta.-D-ribofuranose.
A Potentially Versatile Intermediate for the Synthesis of
C-Nucleosides," Synthetic Communications, 22(19):2815-2822, 1992.
cited by applicant .
Harki, D. et al., "Synthesis and Antiviral Activity of
5-Substituted Cytidine Analogues: Identification of Ptent Inhibitor
of Viral RNA-Dependent RNA Polymerases," Journal of Medicinal
Chemistry, 49(21):6166-6169, 2006. cited by applicant .
Hoffman, M. et al., "When, in the Context of Drug Design, Can a
Fluorine Atom Successfully Substitute a Hydroxyl Group?,"
International Journal of Quantum Chemistry, 89:419-427, 2002. cited
by applicant .
Jasko, M. et al., "5'-Phosphonates of Ribonucleosides and
2'-Deoxyribonucleosides: Synthesis and Antiviral Activity,"
Nucleosides & Nucleotides, 12(8):879-893, 1993. cited by
applicant .
Kabat, M. et al., "Nucleosides, CXLVIII, Synthesis of
6-(.beta.-D-Ribofuranosyl)picolinamide: A Novel C-Nucleoside from
D-Ribonolactone," Chemical & Pharmaceutical Bulletin,
36(2):634-640, 1988. cited by applicant .
Klumpp, K. et al., "The Novel Nucleoside Analog R1479
(4'-Azidocytidine) is a Potent Inhibitor of NS5B-dependent RNA
Synthesis and Hepatitis C virus Replication in Cell Culture,"
Journal of Biological Chemistry, 281(7):3793-3799, 2006. cited by
applicant .
Lefebvre, I. et al., "Mononucleoside Phosphotriester Derivatives
with S-Acyl-2-thioethyl Bioreversible Phosphate-Protecting Groups:
Intracellular Delivery of 3'-Azido-2',3'-dideoxythymidine
5'-Monophosphate," Journal of Medicinal Chemistry,
38(20):3941-3950, 1995. cited by applicant .
Lefebvre, I. et al., "Synthesis, Decomposition Pathways and `In
Vitro` Evaluation of Bioreversible Phosphotriesters of Azt,"
Nucleosides, Nucleotides & Nucleid Acids, 14(3-5):763-766,
1995. cited by applicant .
Lindell, S. D. et al., "Synthesis and Biochemical Testing of
3-(Carboxyphenylethyl)imidazo[2,1-f][1,2,4]triazines as Inhibitors
of AMP Deaminase," ACS Medicinal Chemistry Letters, 1(6):286-289,
2010. cited by applicant .
Lovelette, C.A., "1,2,4-Triazines. Synthesis of selected members of
the s-triazolo[3,4-f][1,2,4]triazine and
tetrazolo[1,5-f][1,2,4]triazine ring systems," Journal of
Heterocyclic Chemistry, 16:555-560, 1979. cited by applicant .
Martell, M. et al., "Hepatitis C Virus (HCV) Circulates as a
Population of Different but Closely Related Genomes: Quasispecies
Nature of HCV Genome Distribution," Journal of Virology,
6695:3225-3229, 1992. cited by applicant .
Mason, S. et al., "Polyadenylation-dependent screening assay for
respiratory syncytial virus RNA transcriptase activity and
idenification of an inhibitor," Nucleic Acids Research,
32:4758-4767, 2004. cited by applicant .
Matullic-Adamic, J. et al., "Synthesis of
3-(.beta.-D-Ribofuranosyl)-2-Fluoropyridine and
3-(.beta.-D-Ribofuranosyl)-Pyridin-2-one," Tetrahedron Letters,
38(2):203-206, 1997. cited by applicant .
Matullic-Adamic, J. et al., "Synthesis of
5-(.beta.-D-Ribofuranosyl)-Pyridin-2-one: a `Deletion-Modified`
Analogue of Uridine," Tetrahedron Letters, 38(10):1669-1672, 1997.
cited by applicant .
Meppen, M. et al., "Cyclic phosphoramidates as prodrugs of
2'-C-methylcytidine," European Journal of Medicinal Chemistry,
44(9):3765-3770, 2009. cited by applicant .
Meppen, M. et al., "Medi-404--A Prodrug Approach for the Treatment
of HCV Infection," Abstracts of papers, 236th ACS National Meeting,
Philadelphia, PA, United States, Aug. 17-21, 2008. cited by
applicant .
Migliaccio, G. et al., "Characterization of Resistance to
Non-obligate Chain-terminating Ribonucleoside Analogs That Inhibit
Hepatitis C Virus Replication in vitro," The Journal of Biological
Chemistry, 278(49):49164-49170, 2003. cited by applicant .
Moscow, J. et al., "Reduced Folate Carrier Gene (RFC1) Expression
and Anti-Folate Resistance in Transfected and Non-Selected Cell
Lines," International Journal of Cancer, 72:184-190, 1997. cited by
applicant .
Neumann, A. et al., "Hepatitis C Viral Dynamics in Vivoand the
Antiviral Efficacy of Interferon-.alpha. Therapy," Science,
282:103-107, 1998. cited by applicant .
Ogura, H. et al., "Reaction of Ethynyl Compounds with Lactones,"
Journal of Organic Chemistry, 37(1):72-75, 1972. cited by applicant
.
Pankiewicz, K. et al., "C-Nucleoside Analogues of Nicotinamide
Mononucleotide (NMN)," Nucleosides and Nucleotides,
7(5&6):589-593, 1988. cited by applicant .
Pankiewicz, K. et al., "Efficient Synthesis of
5-(.beta.-D-Ribofuranosyl)nicotinamide and its .alpha.-Isomer,"
Journal of Organic Chemistry, 53:3473-3479, 1988. cited by
applicant .
Patil, S et al., "C-Glycosylation of Substituted Heterocycles under
Friedel-Crafts Conditions (II): Robosylation of
Multi-Functionalized Thiophenes and Furans for the Synthesis of
Purine-Like C-Nucleosides," Nucleosides & Nucleotides,
9(7):937-956, 1990. cited by applicant .
Patil, S.A. et al., "Synthesis of some new thieno[3,4-d]pyrimidines
and their C-nucleosides," Journal of Heterocyclic Chemistry,
30(2):509-515, 1993. cited by applicant .
Perrone, P. et al., "Application of the Phosphoramidate ProTide
Approach to 4'-Azidouridine Confers Sub-micromolar Potency versus
Hepatitis C Virus on an Inactive Nucleoside," Journal of Medicinal
Chemistry, 50(8):1840-1849, 2007. cited by applicant .
Piccirilli, J. et al., "A Direct Route to
3-(D-Ribofuranosyl)pyridine Nucleosides," Helvetica Chimica Acta,
74:397-406, 1991. cited by applicant .
Pierra, C. et al., "Synthesis and Pharmacokinetics of
Valopicitabine (NM283), and Efficient Prodrug of the Potent
Anti-HCV Agent 2'-C-Methylcytidine," Journal of Medicinal
Chemistry, 49(22):6614-6620, 2006. cited by applicant .
Poduch, E. et al., "Design of Inhibitors of Orotidine Monophosphate
Decarboxylase Using Bioisosteric Replacement and Determination of
Inhibition Kinetics," Journal of Medicinal Chemistry,
49(16):4937-4945, 2006. cited by applicant .
Rao, S. et al., "C-Glycosylation of Substituted Heterocycles under
Friedel-Crafts Conditions (I): A Two-Step Synthesis of the
Thieno[3,4-d]Pyrimidine C-Nucleoside Analog of Inosine,"
Tetrahedron Letters, 29(29):3537-3540, 1988. cited by applicant
.
Schultz, C., "Prodrugs of Biologically Active Phosphate Esters,"
Bioorganic & Medicinal Chemistry, 11:885-898, 2003. cited by
applicant .
Srivastav, N. et al., "Antiviral Activity of Various
1-(2'-Deoxy-.beta.-D-Iyxofuranosyl),
1-(2'-Fluoro-.beta.-D-xylofuranosyl),
1-(3'-Fluor-.beta.-D-arabinofuranosyl), and
2'-Fluoro-2',3'-didehydro-2',3'-dideoxyribose Pyrimidine Nucleoside
Analogues against Duck Hepatitis B Virus (DHBV) and Human Hepatitis
B Virus (HBV) Replication," Journal of Medicinal Chemistry,
53(19):7156-7166, 2010. cited by applicant .
Tapia, N. et al., "Combination of a Mutagenic Agent with a Reverse
Transcriptase Inhibitor Results in Systematic Inhibition of HIV-1
Infection," Virology, 338:1-8, 2005. cited by applicant .
Vaghefi, M. et al., "Synthesis and Antiviral Activity of Certain
Nucleoside 5'-Phosphonoformate Derivatives," Journal of Medicinal
Chemistry, 29:1389-1393, 1986. cited by applicant .
Wu, Q. et al., "Synthetic Methodologies for C-Nucleosides,"
Synthesis, 10:1533-1553, 2004. cited by applicant .
Yamanaka, G. et al., "Metabolic Studies on BMS-200475, a New
Antiviral Compound Active against Hepatitis B Virus," Antimicrobial
Agents and Chemotherapy, 43(1):190, 1999. cited by applicant .
Zhang, P. et al., "A Practical Synthesis of
(2R)-3,5-di-O-benzoyl-2-fluoro-2-C-methyl-D-ribono-y-lactone,"
Tetrahedron: Asymmetry, 20:305-312, 2009. cited by applicant .
Office Action (English translation) for Mexican Patent Application
No. MX/a/2013/003179, dated Feb. 25, 2014. cited by applicant .
Office Action (with English translation) for Mexican Patent
Application No. MX/a/2013/000656, dated Apr. 22, 2014. cited by
applicant .
Office Action (with English translation) for Mexican Patent
Application No. MX/a/2013/000744, dated Apr. 22, 2014. cited by
applicant .
Official Action (ARIPO Form No. 18) with Substantive Search and
Examination Report for AP Application No. AP/P/2010/005414, dated
Mar. 14, 2014. cited by applicant .
Resolution No. 72986 for Columbian Patent Application No.
10-121513-5 with English translation, received Dec. 23, 2013 (12
pages). cited by applicant .
Third Examination Report for Eurasian Patent Application No.
201071170 with English translation, dated Oct. 10, 2013. cited by
applicant .
Statement of Opposition, Mar. 31, 2011, for Ecuador Patent
Application No. SP-10-10609, with English translation. cited by
applicant .
ARIPO Form 21 and Substantive Examination Report for African
Regional Intellectual Property Organization Application No.
AP/P/2010/005439, dated Mar. 18, 2014. cited by applicant .
Rejection Decision for Chinese Patent Application No.
200980120218.8 with English translation, dated Feb. 7, 2014. cited
by applicant .
Resolution No. 56673 for Columbian Patent Application No. 10-131479
with English translation, dated Sep. 27, 2013. cited by applicant
.
Search Report for African Regional Intellectual Property
Organization Patent Application No. AP/P/2011/005818, dated Sep.
19, 2013. cited by applicant .
Form 21 for African Regional Intellectual Property Organization
Patent Application No. AP/P/2011/005818, dated Sep. 19, 2013. cited
by applicant .
Second Office Action for Chilean Patent Application No. 1906-2011
dated Oct. 16, 2013 with English translation. cited by applicant
.
Notification of the Second Office Action and Search Report for
Chinese Patent Application No. 201080011690.0 with English
translation, dated Jan. 8, 2014. cited by applicant .
Third Office Action for Eurasian Patent Application No.
201190110/28, dated Oct. 18, 2013. cited by applicant .
Extended European Search Report for European Patent Application No.
13194605.5, dated Mar. 13, 2014. cited by applicant .
Notification of Defects for Israel Patent Application No. 214396
with English translation, dated Nov. 11, 2013. cited by applicant
.
Notice of Reasons for Rejection for Japanese Patent Application No.
2011-549324 with English translation, dated Mar. 26, 2014. cited by
applicant .
Office Action for Mexican Patent Application No. MX/a/2011/008409
with English translation, dated Mar. 25, 2014. cited by applicant
.
Further Examination Report for New Zealand Patent Application No.
594370, dated Oct. 8, 2013. cited by applicant .
Office Action for Peruvian Patent Application No. 1464 with English
translation, dated Sep. 12, 2013. cited by applicant .
Office Action for UA Patent Application No. a 2011 10568 with
English translation, received Apr. 7, 2014. cited by applicant
.
Patent Examination Report No. 1 for Australian Patent Application
No. 2011306066, dated Nov. 21, 2013. cited by applicant .
Opposition for Chilean Patent Application No. 727-2013 with English
translation, dated Oct. 15, 2013. cited by applicant .
Notification of the First Office Action and Search Report for
Chinese Patent Application No. 20100041902.X with English
translation, dated Nov. 12, 2013. cited by applicant .
Office Action No. 425 for Columbian Patent Application No. 12 050
579 with English translation, dated Jan. 21, 2014. cited by
applicant .
Opposition for Ecuador Patent Application No. SP-2012-11817, dated
May 27, 2013 (English translation not available). cited by
applicant .
Communication Pursuant to Article 94(3) EPC for European Patent
Application No. 11715792.5, dated Feb. 14, 2014. cited by applicant
.
First Examination Report for New Zealand Patent Application No.
608070, dated Nov. 7, 2013. cited by applicant .
Official Action for El Salvador National Phase Entry of PCT
International Application No. PCT/US2010/049471 with English
translation, dated Nov. 6, 2013. cited by applicant .
Notification of the First Office Action with Search Report for
Chinese Patent Application No. 201080041946.2 with English
translation, dated Dec. 18, 2013. cited by applicant .
Notification Prior to Examination for Israel Patent Application No.
218752 with English translation, dated Jan. 20, 2014. cited by
applicant .
Official Action for Eurasian Patent Application No. 201390133,
dated Mar. 27, 2014. cited by applicant .
Opposition for Ecuador Patent Application No. SP-13-12451,
notification date of Apr. 23, 2014 (English translation not yet
available). cited by applicant .
Notification of the First Office Action for Chinese Patent
Application No. 201180035776.1 with English translation, dated Feb.
27, 2014. cited by applicant .
Office Action for Columbian Patent Application No. 13 004212 with
English translation, dated Dec. 4, 2013. cited by applicant .
Office Action for Columbian Patent Application No. 11-109.501,
dated Nov. 27, 2012 (10 pages). cited by applicant .
Office Action for Eurasian Patent Application No. 201390152 with
English translation, dated Apr. 14, 2014 (9 pages). cited by
applicant .
Silverman et al., The Organic Chemistry of Drug Design and Drug
Action, 19-23, 1992. cited by applicant.
|
Primary Examiner: Johnson; Jerry D
Attorney, Agent or Firm: Mintz, Levin, Cohn, Ferris, Glovsky
and Popeo, P.C.
Parent Case Text
CROSS-REFERENCE TO RELATED APPLICATIONS
This application is a continuation application of U.S. patent
application Ser. No. 13/196,117, filed Aug. 2, 2011, which is a
continuation of U.S. patent application Ser. No. 12/428,176, filed
Apr. 22, 2009, which claims the benefit of U.S. Provisional
Application No. 61/047,263, filed Apr. 23, 2008 and U.S.
Provisional Application No. 61/139,449, filed Dec. 19, 2008. The
contents of the aforementioned applications are incorporated herein
by reference in their entirety.
Claims
What is claimed is:
1. A compound of Formula II: ##STR00406## or a pharmaceutically
acceptable salt, thereof; wherein: R.sup.1, R.sup.3, and R.sup.5
are H; R.sup.2 and R.sup.4 are, independently, OR.sup.a; R.sup.6 is
OR.sup.a, N.sub.3, CN, S(O).sub.nR.sup.a, --C(.dbd.O)R.sup.11,
--C(.dbd.O)OR.sup.11, --C(.dbd.O)NR.sup.11R.sup.12,
--C(.dbd.O)SR.sup.11, --S(O)R.sup.11, --S(O).sub.2R.sup.11,
--S(O)(OR.sup.11), --S(O).sub.2(OR.sup.11),
--SO.sub.2NR.sup.11R.sup.12, halogen, substituted methyl, ethenyl,
substituted ethenyl, ethynyl, or substituted ethynyl; each n is
independently 0, 1, or 2; each R.sup.a is independently H,
(C.sub.1-C.sub.8)alkyl, (C.sub.2-C.sub.8)alkenyl,
(C.sub.2-C.sub.8)alkynyl, aryl(C.sub.1-C.sub.8)alkyl,
(C.sub.4-C.sub.8)carbocyclylalkyl, --C(.dbd.O)R.sup.11,
--C(.dbd.O)OR.sup.11, --C(.dbd.O)NR.sup.11R.sup.12,
C(.dbd.O)SR.sup.11, S(O)R.sup.11, --S(O).sub.2R.sup.11,
--S(O)(OR.sup.11), --S(O).sub.2(OR.sup.11), or
--SO.sub.2NR.sup.11R.sup.12; R.sup.7 is H, --C(.dbd.O)R.sup.11,
--C(.dbd.O)OR.sup.11, --C(.dbd.O)NR.sup.11R.sup.12,
--C(.dbd.O)SR.sup.11, --S(O)R.sup.11, --S(O).sub.2R.sup.11,
--S(O)(OR.sup.11), --S(O).sub.2(OR.sup.11),
--SO.sub.2NR.sup.11R.sup.12, or ##STR00407## W.sup.1 and W.sup.2,
when taken together, are
--Y.sup.3(C(R.sup.y).sub.2).sub.3Y.sup.3--; or W.sup.1 and W.sup.2
are each, independently, a group of the Formula Ia: ##STR00408## Y
and each Y.sup.1 are independently O, S, NR, .[..sup.+N(O)(R).].
.Iadd..sup.+N(O.sup.-)(R).Iaddend., N(OR), .[..sup.+N(O)(OR).].
.Iadd..sup.+N(O.sup.-)(OR).Iaddend., or N--NR.sub.2; each Y.sup.2
is independently a bond, O, CR.sub.2, NR, .[..sup.+N(O)(R).].
.Iadd..sup.+N(O.sup.-)(R).Iaddend., N(OR), .[..sup.+N(O)(OR).].
.Iadd..sup.+N(O.sup.-)(OR).Iaddend., N--NR.sub.2, S, S--S, S(O), or
S(O).sub.2; each Y.sup.3 is independently O, S, or NR; M2 is 0, 1
or 2; each R.sup.x is independently R.sup.y or the formula:
##STR00409## wherein: each M1a, M1c, and M1d is independently 0 or
1; M12c is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12; each R.sup.y
is independently H, F, Cl, Br, I, OH, R, --C(.dbd.Y.sup.1)R,
--C(.dbd.Y.sup.1)OR, --C(.dbd.Y.sup.1)N(R).sub.2, --N(R).sub.2,
.[.--+N(R).sub.3.]. .Iadd.--.sup.+N(R).sub.3.Iaddend., --SR,
--S(O)R, --S(O).sub.2R, --S(O)(OR), --S(O).sub.2(OR),
--OC(.dbd.Y.sup.1)R, --OC(.dbd.Y.sup.1)OR,
--OC(.dbd.Y.sup.1)(N(R).sub.2), --SC(.dbd.Y.sup.1)R,
--SC(.dbd.Y.sup.1)OR, --SC(.dbd.Y.sup.1)(N(R).sub.2),
--N(R)C(.dbd.Y.sup.1)R, --N(R)C(.dbd.Y.sup.1)OR,
--N(R)C(.dbd.Y.sup.1)N(R).sub.2, --SO.sub.2NR.sub.2, --CN,
--N.sub.3, --NO.sub.2, --OR, or W.sup.3; or when taken together,
two R.sup.y on the same carbon atom form a carbocyclic ring of 3 to
7 carbon atoms; each R is independently H, (C.sub.1-C.sub.8) alkyl,
(C.sub.1-C.sub.8) substituted alkyl, (C.sub.2-C.sub.8)alkenyl,
(C.sub.2-C.sub.8) substituted alkenyl, (C.sub.2-C.sub.8) alkynyl,
(C.sub.2-C.sub.8) substituted alkynyl, C.sub.6-C.sub.20 aryl,
C.sub.6-C.sub.20 substituted aryl, C.sub.2-C.sub.20 heterocyclyl,
C.sub.2-C.sub.20 substituted heterocyclyl, arylalkyl or substituted
arylalkyl; W.sup.3 is W.sup.4 or W.sup.5; W.sup.4 is R,
--C(Y.sup.1)R.sup.y, --C(Y.sup.1)W.sup.5, --SO.sub.2R.sup.y, or
--SO.sub.2W.sup.5; and W.sup.5 is a carbocycle or a heterocycle
wherein W.sup.5 is independently substituted with 0 to 3 R.sup.y
groups; X.sup.2 is C--R.sup.10 and X.sup.1 is C--R.sup.10 or N;
R.sup.8 is halogen, NR.sup.11R.sup.12, N(R.sup.11)OR.sup.11,
NR.sup.11NR.sup.11R.sup.12, N.sub.3, NO, NO.sub.2, CHO, CN,
--CH(.dbd.NR.sup.11), --CH.dbd.NHNR.sup.11, --CH.dbd.N(OR.sup.11),
--CH(OR.sup.11).sub.2, --C(.dbd.O)NR.sup.11R.sup.12,
--C(.dbd.S)NR.sup.11R.sup.12, --C(.dbd.O)OR.sup.11,
(C.sub.1-C.sub.8)alkyl, (C.sub.2-C.sub.8)alkenyl,
(C.sub.2-C.sub.8)alkynyl, (C.sub.4-C.sub.8)carbocyclylalkyl,
optionally substituted aryl, optionally substituted heteroaryl,
--C(.dbd.O)(C.sub.1-C.sub.8)alkyl,
.[.--S(O).sub.nC.sub.1-C.sub.8)alkyl.].
.Iadd.--S(O).sub.n(C.sub.1-C.sub.8)alkyl.Iaddend.,
aryl(C.sub.1-C.sub.8)alkyl, OR.sup.11 or SR.sup.11; R.sup.9 and
each R.sup.10 are independently H, halogen, NR.sup.11R.sup.12,
N(R.sup.11)OR.sup.11, NR.sup.11NR.sup.11R.sup.12, N.sub.3, NO,
NO.sub.2, CHO, CN, --CH(.dbd.NR.sup.11), --CH.dbd.NHNR.sup.11,
--CH.dbd.N(OR.sup.11), --CH(OR.sup.11).sub.2,
--C(.dbd.O)NR.sup.11R.sup.12, --C(.dbd.S)NR.sup.11R.sup.12,
--C(.dbd.O)OR.sup.11, R.sup.11, OR.sup.11 or SR.sup.11; each
R.sup.11 and each R.sup.12 are independently H,
(C.sub.1-C.sub.8)alkyl, (C.sub.2-C.sub.8)alkenyl,
(C.sub.2-C.sub.8)alkynyl, (C.sub.4-C.sub.8)carbocyclylalkyl,
optionally substituted aryl, optionally substituted heteroaryl,
--C(.dbd.O)(C.sub.1-C.sub.8)alkyl,
--S(O).sub.n(C.sub.1-C.sub.8)alkyl or aryl(C.sub.1-C.sub.8)alkyl;
or R.sup.11 and R.sup.12 taken together with a nitrogen to which
they are both attached .Iadd.to .Iaddend.form a 3 to 7 membered
heterocyclic ring wherein any one carbon atom of said heterocyclic
ring can optionally be replaced with --O--, --S-- or --NR.sup.a--;
wherein substituted methyl, substituted ethenyl and substituted
ethynyl of R.sup.6 and each (C.sub.1-C.sub.8)alkyl,
(C.sub.2-C.sub.8)alkenyl, (C.sub.2-C.sub.8)alkynyl or
aryl(C.sub.1-C.sub.8)alkyl of each of R.sup.11 and R.sup.12 are
independently, optionally substituted with one or more halo,
hydroxy, CN, N.sub.3, N(R.sup.a).sub.2 or OR.sup.a; and wherein one
or more of the non-terminal carbon atoms of each said
(C.sub.1-C.sub.8)alkyl is optionally replaced with --O--, --S-- or
--NR.sup.a--.
2. The compound according to claim 1, wherein R.sup.6 is OR.sup.a,
N.sub.3, halogen, CN, substituted methyl, ethenyl, substituted
ethenyl, ethynyl, or substituted ethynyl.
3. The compound according to claim 1, wherein R.sup.2 and R.sup.4
are OH.
4. The compound according to claim 2, wherein R.sup.2 and R.sup.4
are OH.
5. The compound according to claim 1, wherein R.sup.6 is CN.
6. The compound according to claim 4, wherein R.sup.6 is CN.
7. The compound according to claim 4, wherein R.sup.9 is
NR.sup.11R.sup.12.
8. The compound according to claim 7, wherein X.sup.2 is C--H.
9. The compound according to claim 8, wherein X.sup.1 is C--H.
10. The compound according to claim 9, wherein R.sup.7 is H.
11. The compound according to claim 9, wherein ##STR00410##
12. A compound selected from the group consisting of ##STR00411##
or a pharmaceutically acceptable salt thereof.
13. A pharmaceutical composition comprising a therapeutically
effective amount of a compound of claim 1 and a pharmaceutically
acceptable carrier.
14. The pharmaceutical composition of claim 13 further comprising
at least one additional therapeutic agent selected from the group
consisting of interferons, ribavirin analogs, NS3 protease
inhibitors, NS5a inhibitors, NS5b polymerase inhibitors,
.[.alphaglucosidase.]. .Iadd.alpha-glucosidase .Iaddend.1
inhibitors, cyclophilin inhibitors, hepatoprotectants,
non-nucleoside inhibitors of HCV, and other drugs for treating
HCV.
15. A method of inhibiting HCV polymerase comprising administering
to a mammal in need thereof a therapeutically effective amount of a
compound of claim 1.
16. A method of treating a viral infection caused by a virus
selected from the group consisting of dengue virus, yellow fever
virus, West Nile virus, Japanese encephalitis virus, tick-borne
encephalitis virus, Kunjin virus, Murray Valley encephalitis virus,
St. Louis encephalitis virus, Omsk hemorrhagic fever virus, bovine
viral diarrhea virus, Zika virus and Hepatitis C virus comprising
administering to a mammal in need thereof a therapeutically
effective amount of a compound or pharmaceutical composition of
claim 1.
17. The method of claim 16, wherein the viral infection is caused
by Hepatitis C virus.
18. The method of claim 17 further comprising administering at
least one additional therapeutic agent selected from the group
consisting of interferons, ribavirin analogs, NS3 protease
inhibitors, NS5b polymerase inhibitors, NS5a inhibitors,
alpha-glucosidase 1 inhibitors, cyclophilin inhibitors,
hepatoprotectants, non-nucleoside inhibitors of HCV, and other
drugs for treating HCV.
.Iadd.19. The method of claim 16, wherein the viral infection is
caused by Zika virus. .Iaddend.
.Iadd.20. A compound of ##STR00412## or a pharmaceutically
acceptable salt, thereof; wherein: R.sup.1, R.sup.3, and R.sup.5
are H; R.sup.2 and R.sup.4 are OH; R.sup.6 is CN; each R.sup.a is
independently H, (C.sub.1-C.sub.8)alkyl, (C.sub.2-C.sub.8)alkenyl,
(C.sub.2-C.sub.8)alkynyl, aryl(C.sub.1-C.sub.8)alkyl,
(C.sub.4-C.sub.8)carbocyclylalkyl, --C(.dbd.O)R.sup.11,
--C(.dbd.O)OR.sup.11, --C(.dbd.O)NR.sup.11R.sup.12,
C(.dbd.O)SR.sup.11, S(O)R.sup.11, --S(O).sub.2R.sup.11,
--S(O)(OR.sup.11), --S(O).sub.2(OR.sup.11), or
--SO.sub.2NR.sup.11R.sup.12; R.sup.7 is ##STR00413## W.sup.1 and
W.sup.2, when taken together, are
--Y.sup.3(C(R.sup.y).sub.2).sub.3Y.sup.3--; or W.sup.1 and W.sup.2
are each, independently, a group of the Formula Ia: ##STR00414## Y
and each Y.sup.1 are O, S, NR, .sup.+N(O.sup.-)(R), N(OR),
.sup.+N(O.sup.-)(OR), or N--NR.sub.2; each Y.sup.2 is independently
a bond, O, CR.sub.2, NR, .sup.+N(O.sup.-)(R), N(OR),
.sup.+N(O.sup.-)(OR), N--NR.sub.2, S, S--S, S(O), or S(O).sub.2;
each Y.sup.3 is independently O, S, or NR; M2 is 0, 1 or 2; each
R.sup.x is independently R.sup.y or the formula: ##STR00415##
wherein: each M1a, M1c, and M1d is independently 0 or 1; M12c is 0,
1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12; each R.sup.y is
independently H, F, Cl, Br, I, OH, R, --C(.dbd.Y.sup.1)R,
--C(.dbd.Y.sup.1)OR, --C(.dbd.Y.sup.1)N(R).sub.2, --N(R).sub.2,
--.sup.+N(R).sub.3, --SR, --S(O)R, --S(O).sub.2R, --S(O)(OR),
--S(O).sub.2(OR), --OC(.dbd.Y.sup.1)R, --OC(.dbd.Y.sup.1)OR,
--OC(.dbd.Y.sup.1)(N(R).sub.2), --SC(.dbd.Y.sup.1)R,
--SC(.dbd.Y.sup.1)OR, --SC(.dbd.Y.sup.1)(N(R).sub.2),
--N(R)C(.dbd.Y.sup.1)R, --N(R)C(.dbd.Y.sup.1)OR,
--N(R)C(.dbd.Y.sup.1)N(R).sub.2, --SO.sub.2NR.sub.2, --CN,
--N.sub.3, --NO.sub.2, --OR, or W.sup.3; or when taken together,
two R.sup.y on the same carbon atom form a carbocyclic ring of 3 to
7 carbon atoms; each R is independently H, (C.sub.1-C.sub.8) alkyl,
(C.sub.1-C.sub.8) substituted alkyl, (C.sub.2-C.sub.8)alkenyl,
(C.sub.2-C.sub.8) substituted alkenyl, (C.sub.2-C.sub.8) alkenyl,
(C.sub.2-C.sub.8) substituted alkenyl, C.sub.6-C.sub.20 aryl,
C.sub.6-C.sub.20 substituted aryl, C.sub.2-C.sub.20 heterocyclyl,
C.sub.2-C.sub.20 substituted heterocyclyl, arylalkyl or substituted
arylalkyl; W.sup.3 is W.sup.4 or W.sup.5; W.sup.4 is R,
--C(Y.sup.1)R.sup.y, --C(Y.sup.1)W.sup.5, --SO.sub.2R.sup.y, or
--SO.sub.2W.sup.5; and W.sup.5 is a carbocycle or a heterocycle
wherein W.sup.5 is independently substituted with 0 to 3 R.sup.y
groups; X.sup.2 is C--H and X.sup.1 is C--H; R.sup.8 is halogen,
NR.sup.11R.sup.12, N(R.sup.11)OR.sup.11,
NR.sup.11NR.sup.11R.sup.12, N.sub.3, NO, NO.sub.2, CHO, CN,
--CH(.dbd.NR.sup.11), --CH.dbd.NHNR.sup.11, --CH.dbd.N(OR.sup.11),
--CH(OR.sup.11).sub.2, --C(.dbd.O)NR.sup.11R.sup.12 ,
--C(.dbd.S)NR.sup.11R.sup.12, --C(.dbd.O)OR.sup.11,
(C.sub.1-C.sub.8)alkyl, (C.sub.2-C.sub.8)alkenyl,
(C.sub.2-C.sub.8)alkynyl, (C.sub.4-C.sub.8)carbocyclylalkyl,
optionally substituted aryl, optionally substituted heteroaryl,
--C(.dbd.O)(C.sub.1-C.sub.8)alkyl,
--S(O).sub.n(C.sub.1-C.sub.8)alkyl, aryl(C.sub.1-C.sub.8)alkyl,
OR.sup.11 or SR.sup.11; R.sup.9 is H, halogen, NR.sup.11R.sup.12,
N(R.sup.11)OR.sup.11, NR.sup.11NR.sup.11R.sup.12, N.sub.3, NO,
NO.sub.2, CHO, CN, --CH(.dbd.NR.sup.11), --CH.dbd.NHNR.sup.11,
--CH.dbd.N(OR.sup.11), --CH(OR.sup.11).sub.2,
--C(.dbd.O)NR.sup.11R.sup.12, --C(.dbd.S)NR.sup.11R.sup.12,
--C(.dbd.O)OR.sup.11, R.sup.11, OR.sup.11 or SR.sup.11; each
R.sup.11 and each R.sup.12 are independently H,
(C.sub.1-C.sub.8)alkyl, (C.sub.2-C.sub.8)alkenyl,
(C.sub.2-C.sub.8)alkynyl, (C.sub.4-C.sub.8)carbocyclylalkyl,
optionally substituted aryl, optionally substituted heteroaryl,
--C(.dbd.O)(C.sub.1-C.sub.8)alkyl,
--S(O).sub.n(C.sub.1-C.sub.8)alkyl or aryl(C.sub.1-C.sub.8)alkyl;
or R.sup.11 and R.sup.12 taken together with a nitrogen to which
they are both attached to form a 3 to 7 membered heterocyclic ring
wherein any one carbon atom of said heterocyclic ring can
optionally be replaced with --O--, --S-- or --NR.sup.a--; wherein
each (C.sub.1-C.sub.8)alkyl, (C.sub.2-C.sub.8)alkenyl,
(C.sub.2-C.sub.8)alkynyl or aryl(C.sub.1-C.sub.8)alkyl of each of
R.sup.11 and R.sup.12 are independently, optionally substituted
with one or more halo, hydroxy, CN, N.sub.3, N(R.sup.a).sub.2 or
OR.sup.a; and wherein one or more of the non-terminal carbon atoms
of each said (C.sub.1-C.sub.8)alkyl is optionally replaced with
--O--, --S-- or --NR.sup.a--. .Iaddend.
.Iadd.21. The compound of claim 20, wherein ##STR00416## is
selected from ##STR00417## wherein Y.sup.2 is, independently, a
bond, O, or CR.sub.2. .Iaddend.
.Iadd.22. The compound of claim 20, wherein W.sup.1 and W.sup.2 are
each, independently, a group of the Formula Ia. .Iaddend.
.Iadd.23. A pharmaceutical composition comprising the compound of
claim 20. .Iaddend.
.Iadd.24. A method of treating a Flaviviridae viral infection in a
human in need thereof by administering the compound of claim 20.
.Iaddend.
.Iadd.25. The method of treating a Flaviviridae viral infection of
claim 24 wherein the Flaviviridae viral infection is caused by a
Zika virus. .Iaddend.
.Iadd.26. A method of treating a Flaviviridae viral infection by
contacting a cell with the compound of claim 20. .Iaddend.
.Iadd.27. The method of treating a Flaviviridae viral infection of
claim 26 wherein the Flaviviridae viral infection is caused by a
Zika virus. .Iaddend.
.Iadd.28. A compound:.Iaddend. ##STR00418##
.Iadd.29. A pharmaceutical composition comprising the compound of
claim 28. .Iaddend.
.Iadd.30. A method of treating a Flaviviridae viral infection in a
human in need thereof by administering the compound of claim 28.
.Iaddend.
.Iadd.31. The method of treating a Flaviviridae viral infection of
claim 30 wherein the Flaviviridae viral infection is caused by a
Zika virus. .Iaddend.
.Iadd.32. A method of treating a Flaviviridae viral infection by
contacting a cell with the compound of claim 28. .Iaddend.
.Iadd.33. The method of treating a Flaviviridae viral infection of
claim 32 wherein the Flaviviridae viral infection is caused by a
Zika virus. .Iaddend.
Description
FIELD OF THE INVENTION
The invention relates generally to compounds with antiviral
activity, more particularly nucleosides active against Flaviviridae
infections and most particularly to inhibitors of hepatitis C virus
RNA-dependent RNA polymerase.
BACKGROUND OF THE INVENTION
Viruses comprising the Flaviviridae family comprise at least three
distinguishable genera including pestiviruses, flaviviruses, and
hepaciviruses (Calisher, et al., J. Gen. Virol., 1993, 70, 37-43).
While pestiviruses cause many economically important animal
diseases such as bovine viral diarrhea virus (BVDV), classical
swine fever virus (CSFV, hog cholera) and border disease of sheep
(BDV), their importance in human disease is less well characterized
(Moennig, V., et al., Adv. Vir. Res. 1992, 48, 53-98). Flaviviruses
are responsible for important human diseases such as dengue fever
and yellow fever while hepaciviruses cause hepatitis C virus
infections in humans. Other important viral infections caused by
the Flaviviridae family include West Nile virus (WNV) Japanese
encephalitis virus (JEV), tick-borne encephalitis virus, Junjin
virus, Murray Valley encephalitis, St Louis enchaplitis, Omsk
hemorrhagic fever virus and Zika virus. Combined, infections from
the Flaviviridae virus family cause significant mortality,
morbidity and economic losses throughout the world. Therefore,
there is a need to develop effective treatments for Flaviviridae
virus infections.
The hepatitis C virus (HCV) is the leading cause of chronic liver
disease worldwide (Boyer, N. et al. J. Hepatol. 32:98-112, 2000) so
a significant focus of current antiviral research is directed
toward the development of improved methods of treatment of chronic
HCV infections in humans (Di Besceglie, A. M. and Bacon, B. R.,
Scientific American, October: 80-85, (1999); Gordon, C. P., et al.,
J. Med. Chem. 2005, 48, 1-20; Maradpour, D.; et al., Nat. Rev.
Micro. 2007, 5(6), 453-463). A number of HCV treatments are
reviewed by Bymock et al. in Antiviral Chemistry &
Chemotherapy, 11:2; 79-95 (2000).
RNA-dependent RNA polymerase (RdRp) is one of the best studied
targets for the development of novel HCV therapeutic agents. The
NS5B polymerase is a target for inhibitors in early human clinical
trials (Sommadossi, J., WO 01/90121 A2, US 2004/0006002 A1). These
enzymes have been extensively characterized at the biochemical and
structural level, with screening assays for identifying selective
inhibitors (De Clercq, E. (2001) J. Pharmacol. Exp. Ther. 297:1-10;
De Clercq, E. (2001) J. Clin. Virol. 22:73-89). Biochemical targets
such as NS5B are important in developing HCV therapies since HCV
does not replicate in the laboratory and there are difficulties in
developing cell-based assays and preclinical animal systems.
Currently, there are primarily two antiviral compounds, ribavirin,
a nucleoside analog, and interferon-alpha (.alpha.) (IFN), which
are used for the treatment of chronic HCV infections in humans.
Ribavirin alone is not effective in reducing viral RNA levels, has
significant toxicity, and is known to induce anemia. The
combination of IFN and ribavirin has been reported to be effective
in the management of chronic hepatitis C (Scott, L. J., et al.
Drugs 2002, 62, 507-556) but less than half the patients given this
treatment show a persistent benefit. Other patent applications
disclosing the use of nucleoside analogs to treat hepatitis C virus
include WO 01/32153, WO 01/60315, WO 02/057425, WO 02/057287, WO
02/032920, WO 02/18404, WO 04/046331, WO2008/089105 and
WO2008/141079 but additional treatments for HCV infections have not
yet become available for patients. Therefore, drugs having improved
antiviral and pharmacokinetic properties with enhanced activity
against development of HCV resistance, improved oral
bioavailability, greater efficacy, fewer undesirable side effects
and extended effective half-life in vivo (De Francesco, R. et al.
(2003) Antiviral Research 58:1-16) are urgently needed.
Certain ribosides of the nucleobases pyrrolo[1,2-f][1,2,4]triazine,
imidazo[1,5-f][1,2,4]triazine, imidazo[1,2-f][1,2,4]triazine, and
[1,2,4]triazolo[4,3-f][1,2,4]triazine have been disclosed in
Carbohydrate Research 2001, 331(1), 77-82; Nucleosides &
Nucleotides (1996), 15(1-3), 793-807; Tetrahedron Letters (1994),
35(30), 5339-42; Heterocycles (1992), 34(3), 569-74; J. Chem. Soc.
Perkin Trans. 1 1985, 3, 621-30; J. Chem. Soc. Perkin Trans. 1
1984, 2, 229-38; WO 2000056734; Organic Letters (2001), 3(6),
839-842; J. Chem. Soc. Perkin Trans. 1 1999, 20, 2929-2936; and J.
Med. Chem. 1986, 29(11), 2231-5. However, these compounds have not
been disclosed as useful for the treatment of HCV. Babu, Y. S.,
WO2008/089105 and WO2008/141079, discloses ribosides of
pyrrolo[1,2-f][1,2,4]triazine nucleobases with antiviral, anti-HCV,
and anti-RdRp activity.
SUMMARY OF THE INVENTION
The instant invention provides compounds that inhibit viruses of
the Flaviviridae family. The invention also comprises compounds
that inhibit viral nucleic acid polymerases, particularly HCV
RNA-dependent RNA polymerase (RdRp), rather than cellular nucleic
acid polymerases. Therefore, the compounds of the instant invention
are useful for treating Flaviviridae infections in humans and other
animals.
In one aspect, this invention provides a compound of Formula I:
##STR00001##
or a pharmaceutically acceptable salt, thereof;
wherein:
each R.sup.1, R.sup.2, R.sup.3, R.sup.4, or R.sup.5 is
independently H, OR.sup.a, N(R.sup.a).sub.2, N.sub.3, CN, NO.sub.2,
S(O).sub.nR.sup.a, halogen, (C.sub.1-C.sub.8)alkyl,
(C.sub.4-C.sub.8)carbocyclylalkyl, (C.sub.1-C.sub.8)substituted
alkyl, (C.sub.2-C.sub.8)alkenyl, (C.sub.2-C.sub.8)substituted
alkenyl, (C.sub.2-C.sub.8)alkynyl, (C.sub.2-C.sub.8)substituted
alkynyl, or aryl(C.sub.1-C.sub.8)alkyl;
or any two R.sup.1, R.sup.2, R.sup.3, R.sup.4, or R.sup.5 on
adjacent carbon atoms when taken together are --O(CO)O-- or when
taken together with the ring carbon atoms to which they are
attached form a double bond;
R.sup.6 is OR.sup.a, N(R.sup.a).sub.2, N.sub.3, CN, NO.sub.2,
S(O).sub.nR.sup.a, --C(.dbd.O)R.sup.11, --C(.dbd.O)OR.sup.11,
--C(.dbd.O)NR.sup.11R.sup.12, --C(.dbd.O)SR.sup.11, --S(O)R.sup.11,
--S(O).sub.2R.sup.11, --S(O)(OR.sup.11), --S(O).sub.2(OR.sup.11),
--SO.sub.2NR.sup.11R.sup.12, halogen, (C.sub.1-C.sub.8)alkyl,
(C.sub.4-C.sub.8)carbocyclylalkyl, (C.sub.1-C.sub.8)substituted
alkyl, (C.sub.2-C.sub.8)alkenyl, (C.sub.2-C.sub.8)substituted
alkenyl, (C.sub.2-C.sub.8)alkynyl, (C.sub.2-C.sub.8)substituted
alkynyl, or aryl(C.sub.1-C.sub.8)alkyl or R.sup.6 and either
R.sup.1 or R.sup.2 when taken together are --O(CO)O--;
each n is independently 0, 1, or 2;
each R.sup.a is independently H, (C.sub.1-C.sub.8)alkyl,
(C.sub.2-C.sub.8)alkenyl, (C.sub.2-C.sub.8)alkynyl,
aryl(C.sub.1-C.sub.8)alkyl, (C.sub.4-C.sub.8)carbocyclylalkyl,
--C(.dbd.O)R.sup.11, --C(.dbd.O)OR.sup.11,
--C(.dbd.O)NR.sup.11R.sup.12, --C(.dbd.O)SR.sup.11, --S(O)R.sup.11,
--S(O).sub.2R.sup.11, --S(O)(OR.sup.11), --S(O).sub.2(OR.sup.11),
or --SO.sub.2NR.sup.11R.sup.12;
R.sup.7 is H, --C(.dbd.O)R.sup.11, --C(.dbd.O)OR.sup.11,
--C(.dbd.O)NR.sup.11R.sup.12, --C(.dbd.O)SR.sup.11, --S(O)R.sup.11,
--S(O).sub.2R.sup.11, --S(O)(OR.sup.11), --S(O).sub.2(OR.sup.11),
--SO.sub.2NR.sup.11R.sup.12, or
##STR00002##
each Y or Y.sup.1 is, independently, O, S, NR, .sup.+N(O)(R),
N(OR), .sup.+N(O)(OR), or N--NR.sub.2;
W.sup.1 and W.sup.2, when taken together, are
--Y.sup.3(C(R.sup.y).sub.2).sub.3Y.sup.3--; or one of W.sup.1 or
W.sup.2 together with either R.sup.3 or R.sup.4 is --Y.sup.3-- and
the other of W.sup.1 or W.sup.2 is Formula Ia; or W.sup.1 and
W.sup.2 are each, independently, a group of the Formula Ia:
##STR00003##
wherein:
each Y.sup.2 is independently a bond, O, CR.sub.2, NR,
.sup.+N(O)(R), N(OR), .sup.+N(O)(OR), N--NR.sub.2, S, S--S, S(O),
or S(O).sub.2;
each Y.sup.3 is independently O, S, or NR;
M2 is 0, 1 or 2;
each R.sup.x is independently R.sup.y or the formula:
##STR00004##
wherein:
each M1a, M1c, and M1d is independently 0 or 1;
M12c is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12;
each R.sup.y is independently H, F, Cl, Br, I, OH, R,
--C(Y.sup.1)R, --C(.dbd.Y.sup.1)OR, --C(.dbd.Y.sup.1)N(R).sub.2,
--N(R).sub.2, --.sup.+N(R).sub.3, --SR, --S(O)R, --S(O).sub.2R,
--S(O)(OR), --S(O).sub.2(OR), --OC(.dbd.Y.sup.1)R,
--OC(.dbd.Y.sup.1)OR, --OC(.dbd.Y.sup.1)(N(R).sub.2),
--SC(.dbd.Y.sup.1)R, --SC(.dbd.Y.sup.1)OR,
--SC(.dbd.Y.sup.1)(N(R).sub.2), --N(R)C(.dbd.Y.sup.1)R,
--N(R)C(.dbd.Y.sup.1)OR, --N(R)C(.dbd.Y.sup.1)N(R).sub.2,
--SO.sub.2NR.sub.2, --CN, --N.sub.3, --NO.sub.2, --OR, or W.sup.3;
or when taken together, two R.sup.y on the same carbon atom form a
carbocyclic ring of 3 to 7 carbon atoms;
each R is independently H, (C.sub.1-C.sub.8) alkyl,
(C.sub.1-C.sub.8) substituted alkyl, (C.sub.2-C.sub.8)alkenyl,
(C.sub.2-C.sub.8) substituted alkenyl, (C.sub.2C.sub.8) alkynyl,
(C.sub.2-C.sub.8) substituted alkynyl, C.sub.6-C.sub.20 aryl,
C.sub.6-C.sub.20 substituted aryl, C.sub.2-C.sub.20 heterocyclyl,
C.sub.2-C.sub.20 substituted heterocyclyl, arylalkyl or substituted
arylalkyl;
W.sup.3 is W.sup.4 or W.sup.5; W.sup.4 is R, --C(Y.sup.1)R.sup.y,
--C(Y.sup.1)W.sup.5, --SO.sub.2R.sup.y, or --SO.sub.2W.sup.5; and
W.sup.5 is a carbocycle or a heterocycle wherein W.sup.5 is
independently substituted with 0 to 3 R.sup.y groups;
each X.sup.1 or X.sup.2 is independently C--R.sup.10 or N;
each R.sup.8 is halogen, NR.sup.11R.sup.12, N(R.sup.11)OR.sup.11,
NR.sup.11NR.sup.11R.sup.12, N.sub.3, NO, NO.sub.2, CHO, CN,
--CH(.dbd.NR.sup.11), --CH.dbd.NNHR.sup.11, --CH.dbd.N(OR.sup.11),
--CH(OR.sup.11).sub.2, --C(.dbd.O)NR.sup.11R.sup.12,
--C(.dbd.S)NR.sup.11R.sup.12, --C(.dbd.O)OR.sup.11,
(C.sub.1-C.sub.8)alkyl, (C.sub.2-C.sub.8)alkenyl,
(C.sub.2-C.sub.8)alkynyl, (C.sub.4-C.sub.8)carbocyclylalkyl,
optionally substituted aryl, optionally substituted heteroaryl,
--C(.dbd.O)(C.sub.1-C.sub.8)alkyl,
--S(O).sub.n(C.sub.1-C.sub.8)alkyl, aryl(C.sub.1-C.sub.8)alkyl,
OR.sup.11 or SR.sup.11;
each R.sup.9 or R.sup.10 is independently H, halogen,
NR.sup.11R.sup.12, N(R.sup.11)OR.sup.11,
NR.sup.11NR.sup.11R.sup.12, N.sub.3, NO, NO.sub.2, CHO, CN,
--CH(.dbd.NR.sup.11), --CH.dbd.NHNR.sup.11, --CH.dbd.N(OR.sup.11),
--CH(OR.sup.11).sub.2, --C(.dbd.O)NR.sup.11R.sup.12,
--C(.dbd.S)NR.sup.11R.sup.12, --C(.dbd.O)OR.sup.11, R.sup.11,
OR.sup.11 or SR.sup.11;
each R.sup.11 or R.sup.12 is independently H,
(C.sub.1-C.sub.8)alkyl, (C.sub.2-C.sub.8)alkenyl,
(C.sub.2-C.sub.8)alkynyl, (C.sub.4-C.sub.8)carbocyclylalkyl,
optionally substituted aryl, optionally substituted heteroaryl,
--C(.dbd.O)(C.sub.1-C.sub.8)alkyl,
--S(O).sub.n(C.sub.1-C.sub.8)alkyl or aryl(C.sub.1-C.sub.8)alkyl;
or R.sup.11 and R.sup.12 taken together with a nitrogen to which
they are both attached form a 3 to 7 membered heterocyclic ring
wherein any one carbon atom of said heterocyclic ring can
optionally be replaced with --O--, --S-- or --NR.sup.a--;
wherein each (C.sub.1-C.sub.8)alkyl, (C.sub.2-C.sub.8)alkenyl,
(C.sub.2-C.sub.8)alkynyl or aryl(C.sub.1-C.sub.8)alkyl of each
R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.11 or
R.sup.12 is, independently, optionally substituted with one or more
halo, hydroxy, CN, N.sub.3, N(R.sup.a).sub.2 or OR.sup.a; and
wherein one or more of the non-terminal carbon atoms of each said
(C.sub.1-C.sub.8)alkyl may be optionally replaced with --O--, --S--
or --NR.sup.a--.
In another aspect, the present invention includes compounds of
Formula I and pharmaceutically acceptable salts thereof and all
racemates, enantiomers, diastereomers, tautomers, polymorphs,
pseudopolymorphs and amorphous forms thereof.
In another aspect, the present invention provides novel compounds
of Formula I with activity against infectious Flaviviridae viruses.
Without wishing to be bound by theory, the compounds of the
invention may inhibit viral RNA-dependent RNA polymerase and thus
inhibit the replication of the virus. They are useful for treating
human patients infected with a human virus such as hepatitis C.
In another aspect, the invention provides a pharmaceutical
composition comprising an effective amount of a Formula I compound,
or a pharmaceutically acceptable salt thereof, in combination with
a pharmaceutically acceptable diluent or carrier.
In another embodiment, the present application provides for
combination pharmaceutical agent comprising:
a) a first pharmaceutical composition comprising a compound of
Formula I; or a pharmaceutically acceptable salt, solvate, or ester
thereof; and
b) a second pharmaceutical composition comprising at least one
additional therapeutic agent selected from the group consisting of
interferons, ribavirin analogs, NS3 protease inhibitors, NS5a
inhibitors, alpha-glucosidase 1 inhibitors, cyclophilin inhibitors,
hepatoprotectants, non-nucleoside inhibitors of HCV, and other
drugs for treating HCV.
In another embodiment, the present application provides for a
method of inhibiting HCV polymerase, comprising contacting a cell
infected with HCV with an effective amount of a compound of Formula
I; or a pharmaceutically acceptable salts, solvate, and/or ester
thereof.
In another embodiment, the present application provides for a
method of inhibiting HCV polymerase, comprising contacting a cell
infected with HCV with an effective amount of a compound of Formula
I; or a pharmaceutically acceptable salts, solvate, and/or ester
thereof; and at least one additional therapeutic agent.
In another embodiment, the present application provides for a
method of treating and/or preventing a disease caused by a viral
infection wherein the viral infection is caused by a virus selected
from the group consisting of dengue virus, yellow fever virus, West
Nile virus, Japanese encephalitis virus, tick-borne encephalitis
virus, Junjin virus, Murray Valley encephalitis virus, St Louis
encephalitis virus, Omsk hemorrhagic fever virus, bovine viral
diarrhea virus, Zika virus and Hepatitis C virus; by administering
to a subject in need thereof a therapeutically effective amount of
a compound of Formula I, or a pharmaceutically acceptable salt
thereof.
In another embodiment, the present application provides for a
method of treating HCV in a patient, comprising administering to
said patient a therapeutically effective amount of a compound of
Formula I; or a pharmaceutically acceptable salt, solvate, and/or
ester thereof.
In another embodiment, the present application provides for a
method of treating HCV in a patient, comprising administering to
said patient a therapeutically effective amount of a compound of
Formula I; or a pharmaceutically acceptable salt, solvate, and/or
ester thereof; and at least one additional therapeutic agent.
Another aspect of the invention provides a method for the treatment
or prevention of the symptoms or effects of an HCV infection in an
infected animal which comprises administering to, i.e. treating,
said animal with a pharmaceutical combination composition or
formulation comprising an effective amount of a Formula I compound,
and a second compound having anti-HCV properties.
In another aspect, the invention also provides a method of
inhibiting HCV, comprising administering to a mammal infected with
HCV an amount of a Formula I compound, effective to inhibit the
replication of HCV in infected cells in said mammal.
In another aspect, the invention also provides processes and novel
intermediates disclosed herein which are useful for preparing
Formula I compounds of the invention.
In other aspects, novel methods for synthesis, analysis,
separation, isolation, purification, characterization, and testing
of the compounds of this invention are provided.
DETAILED DESCRIPTION OF EXEMPLARY EMBODIMENTS
Reference will now be made in detail to certain embodiments of the
invention, examples of which are illustrated in the accompanying
description, structures and formulas. While the invention will be
described in conjunction with the enumerated embodiments, it will
be understood that they are not intended to limit the invention to
those embodiments. On the contrary, the invention is intended to
cover all alternatives, modifications, and equivalents, which may
be included within the scope of the present invention.
In another aspect, compounds of Formula I are represented by
Formula II:
##STR00005##
or a pharmaceutically acceptable salt, thereof;
wherein:
each R.sup.1, R.sup.2, R.sup.3, R.sup.4, or R.sup.5 is
independently H, OR.sup.a, N(R.sup.a).sub.2, N.sub.3, CN, NO.sub.2,
S(O).sub.nR.sup.a, halogen, (C.sub.1-C.sub.8)alkyl,
(C.sub.4-C.sub.8)carbocyclylalkyl, (C.sub.1-C.sub.8)substituted
alkyl, (C.sub.2-C.sub.8)alkenyl, (C.sub.2-C.sub.8)substituted
alkenyl, (C.sub.2-C.sub.8)alkynyl, (C.sub.2-C.sub.8)substituted
alkynyl, or aryl(C.sub.1-C.sub.8)alkyl;
or any two R.sup.1, R.sup.2, R.sup.3, R.sup.4, or R.sup.5 on
adjacent carbon atoms when taken together are --O(CO)O-- or when
taken together with the ring carbon atoms to which they are
attached form a double bond;
R.sup.6 is OR.sup.a, N(R.sup.a).sub.2, N.sub.3, CN, NO.sub.2,
S(O).sub.nR.sup.a, --C(.dbd.O)R.sup.11, --C(.dbd.O)OR.sup.11,
--C(.dbd.O)NR.sup.11R.sup.12, --C(.dbd.O)SR.sup.11, --S(O)R.sup.11,
--S(O).sub.2R.sup.11, --S(O)(OR.sup.11), --S(O).sub.2(OR.sup.11),
--SO.sub.2NR.sup.11R.sup.12, halogen, (C.sub.1-C.sub.8)alkyl,
(C.sub.4-C.sub.8)carbocyclylalkyl, (C.sub.1-C.sub.8)substituted
alkyl, (C.sub.2-C.sub.8)alkenyl, (C.sub.2-C.sub.8)substituted
alkenyl, (C.sub.2-C.sub.8)alkynyl, (C.sub.2-C.sub.8)substituted
alkynyl, or aryl(C.sub.1-C.sub.8)alkyl or R.sup.6 and either
R.sup.1 or R.sup.2 when taken together are --O(CO)O--;
each n is independently 0, 1, or 2;
each R.sup.a is independently H, (C.sub.1-C.sub.8)alkyl,
(C.sub.2-C.sub.8)alkenyl, (C.sub.2-C.sub.8)alkynyl,
aryl(C.sub.1-C.sub.8)alkyl, (C.sub.4-C.sub.8)carbocyclylalkyl,
--C(.dbd.O)R.sup.11, --C(.dbd.O)OR.sup.11,
--C(.dbd.O)NR.sup.11R.sup.12, --C(.dbd.O)SR.sup.11, --S(O)R.sup.11,
--S(O).sub.2R.sup.11, --S(O)(OR.sup.11), --S(O).sub.2(OR.sup.11),
or --SO.sub.2NR.sup.11R.sup.12;
R.sup.7 is H, --C(.dbd.O)R.sup.11, --C(.dbd.O)OR.sup.11,
--C(.dbd.O)NR.sup.11R.sup.12, --C(.dbd.O)SR.sup.11, --S(O)R.sup.11,
--S(O).sub.2R.sup.11, --S(O)(OR.sup.11), --S(O).sub.2(OR.sup.11),
--SO.sub.2NR.sup.11R.sup.12, or
##STR00006##
each Y or Y.sup.1 is, independently, O, S, NR, .sup.+N(O)(R),
N(OR), .sup.+N(O)(OR), or N--NR.sub.2;
W.sup.1 and W.sup.2, when taken together, are
--Y.sup.3(C(R.sup.y).sub.2).sub.3Y.sup.3--; or one of W.sup.1 or
W.sup.2 together with either R.sup.3 or R.sup.4 is --Y.sup.3-- and
the other of W.sup.1 or W.sup.2 is Formula Ia; or W.sup.1 and
W.sup.2 are each, independently, a group of the Formula Ia:
##STR00007##
wherein:
each Y.sup.2 is independently a bond, O, CR.sub.2, NR,
.sup.+N(O)(R), N(OR), .sup.+N(O)(OR), N--NR.sub.2, S, S--S, S(O),
or S(O).sub.2;
each Y.sup.3 is independently O, S, or NR;
M2 is 0, 1 or 2;
each R.sup.x is independently R.sup.y or the formula:
##STR00008##
wherein:
each M1a, M1c, and M1d is independently 0 or 1;
M12c is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12;
each R.sup.y is independently H, F, Cl, Br, I, OH, R,
--C(.dbd.Y.sup.1)R, --C(.dbd.Y.sup.1)OR,
--C(.dbd.Y.sup.1)N(R).sub.2, --N(R).sub.2, --.sup.+N(R).sub.3,
--SR, --S(O)R, --S(O).sub.2R, --S(O).sub.2(OR), --S(O).sub.2(OR),
--OC(.dbd.Y.sup.1)R, --OC(.dbd.Y.sup.1)OR,
--OC(.dbd.Y.sup.1)(N(R).sub.2), --SC(.dbd.Y.sup.1)R,
--SC(.dbd.Y.sup.1)OR, --SC(.dbd.Y.sup.1)(N(R).sub.2),
--N(R)C(.dbd.Y.sup.1)R, --N(R)C(.dbd.Y.sup.1)OR,
--N(R)C(.dbd.Y.sup.1)N(R).sub.2, --SO.sub.2NR.sub.2, --CN,
--N.sub.3, --NO.sub.2, --OR, or W.sup.3; or when taken together,
two R.sup.y on the same carbon atom form a carbocyclic ring of 3 to
7 carbon atoms;
each R is independently H, (C.sub.1-C.sub.8) alkyl,
(C.sub.1-C.sub.8) substituted alkyl, (C.sub.2-C.sub.8)alkenyl,
(C.sub.2-C.sub.8) substituted alkenyl, (C.sub.2-C.sub.8) alkynyl,
(C.sub.2-C.sub.8) substituted alkynyl, C.sub.6-C.sub.20 aryl,
C.sub.6-C.sub.20 substituted aryl, C.sub.2-C.sub.20 heterocyclyl,
C.sub.2-C.sub.20 substituted heterocyclyl, arylalkyl or substituted
arylalkyl;
W.sup.3 is W.sup.4 or W.sup.5; W.sup.4 is R, --C(Y.sup.1)R.sup.y,
--C(Y.sup.1)W.sup.5, --SO.sub.2R.sup.y, or --SO.sub.2W.sup.5; and
W.sup.5 is a carbocycle or a heterocycle wherein W.sup.5 is
independently substituted with 0 to 3 R.sup.y groups;
X.sup.2 is C--R.sup.10 and each X.sup.1 is independently
C--R.sup.10 or N;
each R.sup.8 is independently halogen, NR.sup.11R.sup.12,
N(R.sup.11)OR.sup.11, NR.sup.11NR.sup.11R.sup.12, N.sub.3, NO,
NO.sub.2, CHO, CN, --CH(.dbd.NR.sup.11), --CH.dbd.NHNR.sup.11,
--CH.dbd.N(OR.sup.11), --CH(OR.sup.11).sub.2,
--C(.dbd.O)NR.sup.11R.sup.12, --C(.dbd.S)NR.sup.11R.sup.12,
--C(.dbd.O)OR.sup.11, (C.sub.1-C.sub.8)alkyl,
(C.sub.2-C.sub.8)alkenyl, (C.sub.2-C.sub.8)alkynyl,
(C.sub.4-C.sub.8)carbocyclylalkyl, optionally substituted aryl,
optionally substituted heteroaryl,
--C(.dbd.O)(C.sub.1-C.sub.8)alkyl,
--S(O).sub.1(C.sub.1-C.sub.8)alkyl, aryl(C.sub.1-C.sub.8)alkyl,
OR.sup.11 or SR.sup.11;
each R.sup.9 or R.sup.10 is independently H, halogen,
NR.sup.11R.sup.12, N(R.sup.11)OR.sup.11,
NR.sup.11NR.sup.11R.sup.12, N.sub.3, NO, NO.sub.2, CHO, CN,
--CH(.dbd.NR.sup.11), --CH.dbd.NHNR.sup.11, --CH.dbd.N(OR.sup.11),
--CH(OR.sup.11).sub.2, --C(.dbd.O)NR.sup.11R.sup.12,
--C(.dbd.S)NR.sup.11R.sup.12, --C(.dbd.O)OR.sup.11, R.sup.11,
OR.sup.11 or SR.sup.11;
each R.sup.11 or R.sup.12 is independently H,
(C.sub.1-C.sub.8)alkyl, (C.sub.2-C.sub.8)alkenyl,
(C.sub.2-C.sub.8)alkynyl, (C.sub.4-C.sub.8)carbocyclylalkyl,
optionally substituted aryl, optionally substituted heteroaryl,
--C(.dbd.O)(C.sub.1-C.sub.8)alkyl,
--S(O).sub.n(C.sub.1-C.sub.8)alkyl or aryl(C.sub.1-C.sub.8)alkyl;
or R.sup.11 and R.sup.12 taken together with a nitrogen to which
they are both attached form a 3 to 7 membered heterocyclic ring
wherein any one carbon atom of said heterocyclic ring can
optionally be replaced with --O--, --S-- or --NR.sup.a--;
wherein each (C.sub.1-C.sub.8)alkyl, (C.sub.2-C.sub.8)alkenyl,
(C.sub.2-C.sub.8)alkynyl or aryl(C.sub.1-C.sub.8)alkyl of each
R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.11 or
R.sup.12 is, independently, optionally substituted with one or more
halo, hydroxy, CN, N.sub.3, N(R.sup.a).sub.2 or OR.sup.a; and
wherein one or more of the non-terminal carbon atoms of each said
(C.sub.1-C.sub.8)alkyl may be optionally replaced with --O--, --S--
or --NR.sup.a.
In one embodiment of the invention of Formula II, R.sup.1 is
(C.sub.1-C.sub.8)alkyl, (C.sub.2-C.sub.8) alkenyl or
(C.sub.2-C.sub.8)alkynyl. In another aspect of this embodiment,
R.sup.1 is (C.sub.1-C.sub.8)alkyl. In another aspect of this
embodiment, R.sup.1 is methyl, CH.sub.2OH, CH.sub.2F, ethenyl, or
ethynyl. In a preferred aspect of this embodiment, R.sup.1 is
methyl. In another preferred aspect of this embodiment, R.sup.1 is
H.
In one embodiment of Formula II, R.sup.2 is H, OR.sup.a,
N(R.sup.a).sub.2, N.sub.3, CN, NO.sub.2, S(O).sub.nR.sup.a,
halogen, (C.sub.1-C.sub.8)alkyl, (C.sub.1-C.sub.8)substituted
alkyl, (C.sub.2-C.sub.8)alkenyl, (C.sub.2-C.sub.8)substituted
alkenyl, (C.sub.2-C.sub.8)alkynyl, or (C.sub.2-C.sub.8)substituted
alkynyl. In another aspect of this embodiment, R.sup.2 is H,
OR.sup.a, N(R.sup.a).sub.2, N.sub.3, CN, SR.sup.a or halogen. In
another aspect of this embodiment, R.sup.2 is H, OH, NH.sub.2,
N.sub.3, CN, or halogen. In another aspect of this embodiment,
R.sup.2 is OR.sup.a or halogen and R.sup.1 is H,
(C.sub.1-C.sub.8)alkyl, (C.sub.2-C.sub.8) alkenyl or
(C.sub.2-C.sub.8)alkynyl. In another aspect of this embodiment,
R.sup.2 is OR.sup.a or F and R.sup.1 is H, methyl, CH.sub.2OH,
CH.sub.2F, ethenyl, or ethynyl. In a preferred aspect of this
embodiment, R.sup.2 is OH and R.sup.1 is H, methyl, CH.sub.2OH,
CH.sub.2F, ethenyl, or ethynyl. In another preferred aspect of this
embodiment, R.sup.2 is OR.sup.a and R.sup.1 is H. In another
preferred aspect of this embodiment, R.sup.2 is OH and R.sup.1 is
H. In another preferred aspect of this embodiment, R.sup.2 is F and
R.sup.1 is H, methyl, CH.sub.2OH, CH.sub.2F, ethenyl, or ethynyl.
In another preferred aspect of this embodiment, R.sup.2 is OR.sup.a
and R.sup.1 is methyl. In a particularly preferred aspect of this
embodiment, R.sup.2 is OH and R.sup.1 is methyl.
In one embodiment of Formula II, R.sup.3 is H, OR.sup.a,
N(R.sup.a).sub.2, N.sub.3, CN, SR.sup.a, halogen,
(C.sub.1-C.sub.8)alkyl, (C.sub.2-C.sub.8)alkenyl or
(C.sub.2-C.sub.8)alkynyl. In one aspect of this embodiment, R.sup.3
is H or F. In a preferred aspect of this embodiment, R.sup.3 is H.
In another preferred aspect of this embodiment, R.sup.3 is H,
R.sup.2 is OR.sup.a or halogen and R.sup.1 is H,
(C.sub.1-C.sub.8)alkyl, (C.sub.2-C.sub.8) alkenyl or
(C.sub.2-C.sub.8)alkynyl. In another aspect of this embodiment,
R.sup.3 is H, R.sup.2 is OR.sup.a or F and R.sup.1 is H, methyl,
CH.sub.2OH, CH.sub.2F, ethenyl, or ethynyl. In another aspect of
this embodiment, R.sup.3 is H, R.sup.2 is OR.sup.a and R.sup.1 is
methyl. In another aspect of this embodiment, R.sup.3 is H, R.sup.2
is OH and R.sup.1 is methyl. In another aspect of this embodiment,
R.sup.3 is H, R.sup.2 is OR.sup.a or F and R.sup.1 is H. In another
aspect of this embodiment, R.sup.3 is H, R.sup.2 is OH and R.sup.1
is H. In another aspect of this embodiment, each R.sup.1, R.sup.3
and R.sup.5 is H and R.sup.2 is OH.
In one embodiment of Formula II, R.sup.4 is H, OR.sup.a,
N(R.sup.a).sub.2, N.sub.3, CN, SR.sup.a, halogen,
(C.sub.1-C.sub.8)alkyl, (C.sub.2-C.sub.8)alkenyl or
(C.sub.2-C.sub.8)alkynyl. In a preferred aspect of this embodiment,
R.sup.4 is OR.sup.a. In another preferred aspect of this
embodiment, R.sup.4 is OR.sup.a, R.sup.2 is OR.sup.a or halogen and
R.sup.1 is H, (C.sub.1-C.sub.8)alkyl, (C.sub.2-C.sub.8)alkenyl or
(C.sub.2-C.sub.8)alkynyl. In another preferred aspect of this
embodiment, R.sup.4 is OR.sup.a, R.sup.2 is OR.sup.a or halogen and
R.sup.1 is H. In another preferred aspect of this embodiment,
R.sup.4 is OR.sup.a, R.sup.2 is OR.sup.a or halogen, R.sup.3 is H
and R.sup.1 is H, (C.sub.1-C.sub.8)alkyl, (C.sub.2-C.sub.8)alkenyl
or (C.sub.2-C.sub.8)alkynyl. In another preferred embodiment
R.sup.4 is OR.sup.a, R.sup.2 is OR.sup.a or F and R.sup.1 is H,
methyl, CH.sub.2OH, CH.sub.2F, ethenyl, or ethynyl. In another
preferred aspect of this embodiment, R.sup.4 is OR.sup.a, R.sup.2
is OR.sup.a or F, R.sup.3 is H and R.sup.1 is H, methyl,
CH.sub.2OH, CH.sub.2F, ethenyl, or ethynyl. In another preferred
aspect of this embodiment, R.sup.4 and R.sup.2 are, independently,
OR.sup.a and R.sup.1 is methyl. In another preferred aspect of this
embodiment, R.sup.4 and R.sup.2 are, independently OR.sup.a,
R.sup.3 is H and R.sup.1 is methyl. In another preferred aspect of
this embodiment, R.sup.4 and R.sup.2, taken together, are
--O(CO)O--, R.sup.3 is H and R.sup.1 is methyl. In another
preferred aspect of this embodiment, one of R.sup.4 or R.sup.2 is
OR.sup.a and the other of R.sup.4 or R.sup.2 is OH. In another
preferred aspect of this embodiment, one of R.sup.4 or R.sup.2 is
OR.sup.a wherein R.sup.a is not H and the other of R.sup.4 or
R.sup.2 is OH, R.sup.3 is H, and R.sup.1 is methyl. In another
preferred aspect of this embodiment, R.sup.4 and R.sup.2 are OH,
R.sup.3 is H, and R.sup.1 is methyl. In another preferred aspect of
this embodiment, R.sup.4 is OR.sup.a, R.sup.2 is OR.sup.a or F, and
each R.sup.1 and R.sup.3 is H. In another preferred aspect of this
embodiment, R.sup.4 and R.sup.2 are, independently, OR.sup.a and
R.sup.1 is H. In another preferred aspect of this embodiment,
R.sup.4 and R.sup.2 are, independently OR.sup.a and each R.sup.1
and R.sup.3 is H. In another preferred aspect of this embodiment,
R.sup.4 and R.sup.2, taken together, are --O(CO)O--, and each
R.sup.1 and R.sup.3 is H.
In one embodiment of Formula II, R.sup.5 is H, OR.sup.a,
N(R.sup.a).sub.2, N.sub.3, CN, SR.sup.a, halogen,
(C.sub.1-C.sub.8)alkyl, (C.sub.2-C.sub.8)alkenyl or
(C.sub.2-C.sub.8)alkynyl. In another aspect of this embodiment,
R.sup.6 is OR.sup.a, N(R.sup.a).sub.2, N.sub.3, CN, NO.sub.2,
S(O).sub.nR.sup.a, --C(.dbd.O)R.sup.11, --C(.dbd.O)OR.sup.11,
--C(.dbd.O)NR.sup.11R.sup.12, --C(.dbd.O)SR.sup.11, --S(O)R.sup.11,
--S(O).sub.2R.sup.11, --S(O)(OR.sup.11), --S(O).sub.2(OR.sup.11),
--SO.sub.2NR.sup.11R.sup.12, halogen, (C.sub.1-C.sub.8)alkyl,
(C.sub.4-C.sub.8)carbocyclylalkyl, (C.sub.1-C.sub.8)substituted
alkyl, (C.sub.2-C.sub.8)alkenyl, (C.sub.2-C.sub.8)substituted
alkenyl, (C.sub.2-C.sub.8)alkynyl, (C.sub.2-C.sub.8)substituted
alkynyl, or aryl(C.sub.1-C.sub.8)alkyl. In another aspect of this
embodiment, R.sup.6 is OR.sup.a, N(R.sup.a).sub.2, N.sub.3, CN,
NO.sub.2, S(O).sub.nR.sup.a, --C(.dbd.O)R.sup.11,
--C(.dbd.O)OR.sup.11, --C(.dbd.O)NR.sup.11R.sup.12,
--C(.dbd.O)SR.sup.11, --S(O)R.sup.11, --S(O).sub.2R.sup.11,
--S(O)(OR.sup.11), --S(O).sub.2(OR.sup.11),
--SO.sub.2NR.sup.11R.sup.12, halogen, (C.sub.1-C.sub.8)alkyl,
(C.sub.4-C.sub.8)carbocyclylalkyl, (C.sub.1-C.sub.8)substituted
alkyl, (C.sub.2-C.sub.8)alkenyl, (C.sub.2-C.sub.8)substituted
alkenyl, (C.sub.2-C.sub.8)alkynyl, (C.sub.2-C.sub.8)substituted
alkynyl, or aryl(C.sub.1-C.sub.8)alkyl and R.sup.5 is H, N.sub.3,
CN, (C.sub.1-C.sub.8)alkyl, (C.sub.2-C.sub.8)alkenyl or
(C.sub.2-C.sub.8)alkynyl. In another aspect of this embodiment,
R.sup.6 is OR.sup.a, N.sub.3, CN, S(O).sub.nR.sup.a,
--C(.dbd.O)R.sup.11, --C(.dbd.O)OR.sup.11,
--C(.dbd.O)NR.sup.11R.sup.12, --C(.dbd.O)SR.sup.11, --S(O)R.sup.11,
--S(O).sub.2R.sup.11, --S(O)(OR.sup.11), --S(O).sub.2(OR.sup.11),
--SO.sub.2NR.sup.11R.sup.12, halogen, (C.sub.1-C.sub.8)substituted
alkyl, (C.sub.2-C.sub.8)alkenyl, (C.sub.2-C.sub.8)substituted
alkenyl, (C.sub.2-C.sub.8)alkynyl, or (C.sub.2-C.sub.8)substituted
alkynyl; R.sup.5 is H, N.sub.3, CN, methyl, ethenyl or ethynyl;
R.sup.4 is OR.sup.a and R.sup.3 is H. In another aspect of this
embodiment, R.sup.6 is OR.sup.a, N.sub.3, CN, S(O).sub.nR.sup.a,
--C(.dbd.O)R.sup.11, --C(.dbd.O)OR.sup.11,
--C(.dbd.O)NR.sup.11R.sup.12, --C(.dbd.O)SR.sup.11, --S(O)R.sup.11,
--S(O).sub.2R.sup.11, --S(O)(OR.sup.11), --S(O).sub.2(OR.sup.11),
--SO.sub.2NR.sup.11R.sup.12, halogen, substituted methyl, ethenyl,
substituted ethenyl, ethynyl, or substituted ethynyl, R.sup.5 is H
or N.sub.3, R.sup.4 is OR.sup.a, R.sup.3 is H, and R.sup.2 is F or
OR.sup.a. In another aspect of this embodiment, R.sup.6 is
OR.sup.a, N.sub.3, CN, S(O).sub.nR.sup.a, --C(.dbd.O)R.sup.11,
--C(.dbd.O)OR.sup.11, --C(.dbd.O)NR.sup.11R.sup.12,
--C(.dbd.O)SR.sup.11, --S(O)R.sup.11, --S(O).sub.2R.sup.11,
--S(O)(OR.sup.11), --S(O).sub.2(OR.sup.11),
--SO.sub.2NR.sup.11R.sup.12, halogen, substituted methyl, ethenyl,
substituted ethenyl, ethynyl, or substituted ethynyl, R.sup.5 is H
or N.sub.3, R.sup.4 is OR.sup.a, R.sup.3 is H, R.sup.2 is OR.sup.a
and R.sup.1 is methyl, CH.sub.2OH, CH.sub.2F, ethenyl, or ethynyl.
In another aspect of this embodiment, R.sup.6 is OR.sup.a, N.sub.3,
CN, S(O).sub.nR.sup.a, --C(.dbd.O)R.sup.11, --C(.dbd.O)OR.sup.11,
--C(.dbd.O)NR.sup.11R.sup.12, --C(.dbd.O)SR.sup.11, --S(O)R.sup.11,
--S(O).sub.2R.sup.11, --S(O)(OR.sup.11), --S(O).sub.2(OR.sup.11),
--SO.sub.2NR.sup.11R.sup.12, halogen, substituted methyl, ethenyl,
substituted ethenyl, ethynyl, or substituted ethynyl, R.sup.3 and
R.sup.5 are H, R.sup.2 and R.sup.4 are, independently, OR.sup.a,
and R.sup.1 is methyl. In another aspect of this embodiment,
R.sup.6 is OR.sup.a, N.sub.3, CN, S(O).sub.nR.sup.a,
--C(.dbd.O)R.sup.11, --C(.dbd.O)OR.sup.11,
--C(.dbd.O)NR.sup.11R.sup.12, --C(.dbd.O)SR.sup.11, --S(O)R.sup.11,
--S(O).sub.2R.sup.11, --S(O)(OR.sup.11), --S(O).sub.2(OR.sup.11),
--SO.sub.2NR.sup.11R.sup.12, halogen, substituted methyl, ethenyl,
substituted ethenyl, ethynyl, or substituted ethynyl, each
R2.sup.1, R.sup.3 and R.sup.5 is H, and R.sup.2 and R.sup.4 are,
independently, OR.sup.a. In another aspect of this embodiment,
R.sup.6 is OR.sup.a, N.sub.3, CN, S(O).sub.nR.sup.a,
--C(.dbd.O)R.sup.11, --C(.dbd.O)OR.sup.11,
--C(.dbd.O)NR.sup.11R.sup.12, --C(.dbd.O)SR.sup.11, --S(O)R.sup.11,
--S(O).sub.2R.sup.11, --S(O)(OR.sup.11), --S(O).sub.2(OR.sup.11),
--SO.sub.2NR.sup.11R.sup.12, halogen, substituted methyl, ethenyl,
substituted ethenyl, ethynyl, or substituted ethynyl, R.sup.3 and
R.sup.5 are H, R.sup.2 and R.sup.4 are OH, and R.sup.1 is methyl.
In another aspect of this embodiment, R.sup.6 is OR.sup.a, N.sub.3,
CN, S(O).sub.nR.sup.a, --C(.dbd.O)R.sup.11, --C(.dbd.O)OR.sup.11,
--C(.dbd.O)NR.sup.11R.sup.12, --C(.dbd.O)SR.sup.11, --S(O)R.sup.11,
--S(O).sub.2R.sup.11, --S(O)(OR.sup.11), --S(O).sub.2(OR.sup.11),
--SO.sub.2NR.sup.11R.sup.12, halogen, substituted methyl, ethenyl,
substituted ethenyl, ethynyl, or substituted ethynyl, R.sup.1,
R.sup.3 and R.sup.5 are each H and R.sup.2 and R.sup.4 are OH. In
another aspect of this embodiment, R.sup.6 is OR.sup.a, N.sub.3,
CN, S(O).sub.nR.sup.a, --C(.dbd.O)R.sup.11, --C(.dbd.O)OR.sup.11,
--C(.dbd.O)NR.sup.11R.sup.12, --C(.dbd.O)SR.sup.11, --S(O)R.sup.11,
--S(O).sub.2R.sup.11, --S(O)(OR.sup.11), --S(O).sub.2(OR.sup.11),
--SO.sub.2NR.sup.11R.sup.12, halogen, substituted methyl, ethenyl,
substituted ethenyl, ethynyl, or substituted ethynyl, R.sup.3 and
R.sup.5 are H, R.sup.2 and R.sup.4, taken together, are --O(CO)O--,
and R.sup.1 is methyl. In another aspect of this embodiment,
R.sup.6 is OR.sup.a, N.sub.3, CN, S(O).sub.nR.sup.a,
--C(.dbd.O)R.sup.11, --C(.dbd.O)OR.sup.11,
--C(.dbd.O)NR.sup.11R.sup.12, --C(.dbd.O)SR.sup.11, --S(O)R.sup.11,
--S(O).sub.2R.sup.11, --S(O)(OR.sup.11), --S(O).sub.2(OR.sup.11),
--SO.sub.2NR.sup.11R.sup.12, halogen, substituted methyl, ethenyl,
substituted ethenyl, ethynyl, or substituted ethynyl, R.sup.1,
R.sup.3 and R.sup.5 are each. H and R.sup.2 and R.sup.4, taken
together, are --O(CO)O--. In another aspect of this embodiment,
R.sup.6 is OR.sup.a, N.sub.3, CN, S(O).sub.nR.sup.11,
--C(.dbd.O)R.sup.11, --C(.dbd.O)OR.sup.11,
--C(.dbd.O)NR.sup.11R.sup.12, --C(.dbd.O)SR.sup.11, --S(O)R.sup.11,
--S(O).sub.2R.sup.11, --S(O)(OR.sup.11), --S(O).sub.2(OR.sup.11),
--SO.sub.2NR.sup.11R.sup.12, halogen, substituted methyl, ethenyl,
substituted ethenyl, ethynyl, or substituted ethynyl, R.sup.1 and
R.sup.3 are each H, R.sup.2 and R.sup.4 are independently OR.sup.a
and R.sup.5 is N.sub.3.
In one embodiment of Formula II, R.sup.2 and R.sup.4 are each
OR.sup.a and at least one of R.sup.1, R.sup.3, or R.sup.5 is not H.
In another aspect of this embodiment, R.sup.2 and R.sup.4 are each
OR.sup.a and R.sup.1 is (C.sub.1-C.sub.8)alkyl,
(C.sub.1-C.sub.8)substituted alkyl, (C.sub.2-C.sub.8)alkenyl,
(C.sub.2-C.sub.8)substituted alkenyl, (C.sub.2-C.sub.8)alkynyl,
(C.sub.2-C.sub.8)substituted alkynyl or aryl(C.sub.1-C.sub.8)alkyl.
In another embodiment, R.sup.2 and R.sup.4 are each OR.sup.a and
R.sup.3 is (C.sub.1-C.sub.8)alkyl, (C.sub.1-C.sub.8)substituted
alkyl, (C.sub.2-C.sub.8)alkenyl, (C.sub.2-C.sub.8)substituted
alkenyl, (C.sub.2-C.sub.8)alkynyl, (C.sub.2-C.sub.8)substituted
alkynyl or aryl(C.sub.1-C.sub.8)alkyl. In another aspect of this
embodiment, R.sup.2 and R.sup.4 are each OR.sup.a and R.sup.5 is
OR.sup.a, N(R.sup.a).sub.2, N.sub.3, CN, NO.sub.2,
S(O).sub.nR.sup.a, halogen, (C.sub.1-C.sub.8)alkyl,
(C.sub.1-C.sub.8)substituted alkyl, (C.sub.2-C.sub.8)alkenyl,
(C.sub.2-C.sub.8)substituted alkenyl, (C.sub.2-C.sub.8)alkynyl,
(C.sub.2-C.sub.8)substituted alkynyl or aryl
(C.sub.1-C.sub.8)alkyl. In another aspect of this embodiment,
R.sup.2 and R.sup.4 are each OR.sup.a and R.sup.6 is OR.sup.a,
N(R.sup.a).sub.2, N.sub.3, CN, NO.sub.2, S(O).sub.nR.sup.a,
--C(.dbd.O)R.sup.11, --C(.dbd.O)OR.sup.11,
--C(.dbd.O)NR.sup.11R.sup.12, --C(.dbd.O)SR.sup.11, --S(O)R.sup.11,
--S(O).sub.2R.sup.11, --S(O)(OR.sup.11), --S(O).sub.2(OR.sup.11),
--SO.sub.2NR.sup.11R.sup.12, halogen, (C.sub.1-C.sub.8)alkyl,
(C.sub.1-C.sub.8)substituted alkyl, (C.sub.2-C.sub.8)alkenyl,
(C.sub.2-C.sub.8)substituted alkenyl, (C.sub.2-C.sub.8)alkynyl,
(C.sub.2-C.sub.8)substituted alkynyl or aryl(C.sub.1-C.sub.8)alkyl.
In another aspect of this embodiment, R.sup.2 and R.sup.4 are both
OH and R.sup.6 is OR.sup.a, N.sub.3, CN, S(O).sub.nR.sup.a,
--C(.dbd.O)R.sup.11, --C(.dbd.O)OR.sup.11,
--C(.dbd.O)NR.sup.11R.sup.12, --C(.dbd.O)SR.sup.11, --S(O)R.sup.11,
--S(O).sub.2R.sup.11, --S(O)(OR.sup.11), --S(O).sub.2(OR.sup.11),
--SO.sub.2NR.sup.11R.sup.12, halogen, (C.sub.1-C.sub.8)alkyl,
(C.sub.1-C.sub.8)substituted alkyl, (C.sub.2-C.sub.8)alkenyl,
(C.sub.2-C.sub.8)substituted alkenyl, (C.sub.2-C.sub.8)alkynyl, or
(C.sub.2-C.sub.8)substituted alkynyl.
In another embodiment of Formula II, each R.sup.1 and R.sup.2 is H,
one of R.sup.3 or R.sup.4 is OR.sup.a and the other of R.sup.3 or
R.sup.4 is (C.sub.1-C.sub.8)alkyl, (C.sub.1-C.sub.8)substituted
alkyl, (C.sub.2-C.sub.8)alkenyl, (C.sub.2-C.sub.8)substituted
alkenyl, (C.sub.2-C.sub.8)alkynyl, (C.sub.2-C.sub.8)substituted
alkynyl or aryl(C.sub.1-C.sub.8)alkyl. In another aspect of this
embodiment, each R.sup.1 and R.sup.2 is H, one of R.sup.3 or
R.sup.4 is OH and the other of R.sup.3 or R.sup.4 is
(C.sub.1-C.sub.8)alkyl, (C.sub.1-C.sub.8)substituted alkyl,
(C.sub.2-C.sub.8)alkenyl, (C.sub.2-C.sub.8)substituted alkenyl,
(C.sub.2-C.sub.8)alkynyl, (C.sub.2-C.sub.8)substituted alkynyl or
aryl(C.sub.1-C.sub.8)alkyl.
In another embodiment of Formula II, R.sup.6 is OR.sup.a,
N(R.sup.a).sub.2, N.sub.3, CN, NO.sub.2, S(O).sub.nR.sup.a,
--C(.dbd.O)R.sup.11, --C(.dbd.O)OR.sup.11,
--C(.dbd.O).sub.NR.sup.11R.sup.12, --C(.dbd.O)SR.sup.11,
--S(O)R.sup.11, --S(O).sub.2R.sup.11, --S(O)(OR.sup.11),
--S(O).sub.2(OR.sup.11), --SO.sub.2NR.sup.11R.sup.12, halogen,
(C.sub.1-C.sub.8)alkyl, (C.sub.4-C.sub.8)carbocyclylalkyl,
(C.sub.1-C.sub.8)substituted alkyl, (C.sub.2-C.sub.8)alkenyl,
(C.sub.2-C.sub.8)substituted alkenyl, (C.sub.2-C.sub.8)alkynyl,
(C.sub.2-C.sub.8)substituted alkynyl, or
aryl(C.sub.1-C.sub.8)alkyl. In another aspect of this embodiment,
R.sup.5 is H, OR.sup.a, N(R.sup.a).sub.2, N.sub.3, CN, SR.sup.a,
halogen, (C.sub.1-C.sub.8)alkyl, (C.sub.2-C.sub.8)alkenyl or
(C.sub.2-C.sub.8)alkynyl. In another aspect of this embodiment,
R.sup.5 is H, N.sub.3, CN, (C.sub.1-C.sub.8)alkyl,
(C.sub.2-C.sub.8)alkenyl or (C.sub.2-C.sub.8)alkynyl. In another
aspect of this embodiment, R.sup.1 is H, methyl, CH.sub.2OH,
CH.sub.2F, ethenyl, or ethynyl. In another aspect of this
embodiment, R.sup.1 is H, methyl, CH.sub.2OH, CH.sub.2F, ethenyl,
or ethynyl and R.sup.2 and R.sup.4 are each OR.sup.a. In another
aspect of this embodiment, R.sup.1 is H, methyl, CH.sub.2OH,
CH.sub.2F, ethenyl, or ethynyl; R.sup.2 and R.sup.4 are each
OR.sup.a; and R.sup.3 and R.sup.5 are each H. In another aspect of
this embodiment, R.sup.5 is H, N.sub.3, CN, methyl, ethenyl or
ethynyl; R.sup.4 is OR.sup.a and R.sup.3 is H. In another aspect of
this embodiment, R.sup.6 is OR.sup.a, N.sub.3, halogen, CN, methyl,
substituted methyl, ethenyl, substituted ethenyl, ethynyl, or
substituted ethynyl; R.sup.5 is H or N.sub.3; R.sup.4 is OR.sup.a;
R.sup.3 is H; and R.sup.2 is OR.sup.a. In another aspect of this
embodiment, R.sup.6 is OR.sup.a, N.sub.3, halogen, CN, methyl,
substituted methyl, ethenyl, substituted ethenyl, ethynyl, or
substituted ethynyl; R.sup.3 and R.sup.5 are H and R.sup.2 and
R.sup.4 are, independently, OR.sup.a. In another aspect of this
embodiment, R.sup.6 is OR.sup.a, N.sub.3, halogen, CN, methyl,
substituted methyl, ethenyl, substituted ethenyl, ethynyl, or
substituted ethynyl; R.sup.3 and R.sup.5 are H; and R.sup.2 and
R.sup.4 are each OH. In another aspect of this embodiment, R.sup.6
is OR.sup.a, N.sub.3, halogen, CN, methyl, substituted methyl,
ethenyl, substituted ethenyl, ethynyl, or substituted ethynyl;
R.sup.3 and R.sup.5 are H; and R.sup.2 and R.sup.4, taken together,
are --O(CO)O--. In another aspect of this embodiment, R.sup.6 is
OR.sup.a, N.sub.3, halogen, CN, methyl, substituted methyl,
ethenyl, substituted ethenyl, ethynyl, or substituted ethynyl;
R.sup.3 is H; R.sup.2 and R.sup.4 are independently OR.sup.a and
R.sup.5 is N.sub.3. In another aspect of this of this embodiment,
R.sup.6 is N.sub.3, halogen, CN, methyl, hydroxymethyl, ethenyl or
ethynyl. In another aspect of this of this embodiment, R.sup.6 is
N.sub.3, halogen, CN, methyl, hydroxymethyl, ethenyl or ethynyl;
R.sup.1 is H, methyl, CH.sub.2OH, CH.sub.2F, ethenyl, or ethynyl;
and R.sup.2 and R.sup.4 are each OR.sup.a. In another aspect of
this of this embodiment, R.sup.6 is N.sub.3, halogen, CN, methyl,
hydroxymethyl, ethenyl or ethynyl; R.sup.1 is H, methyl,
CH.sub.2OH, CH.sub.2F, ethenyl, or ethynyl; R.sup.2 and R.sup.4 are
each OR.sup.a; and R.sup.3 and R.sup.5 are each H.
In one embodiment of Formula II, R.sup.7 is H, --C(.dbd.O)R.sup.11,
--C(.dbd.O)OR.sup.11, --C(.dbd.O)SR.sup.11 or
##STR00009## In a preferred aspect of this embodiment, R.sup.7 is
H. In another preferred aspect of this embodiment, R.sup.7 is
--C(.dbd.O)R.sup.11. In another preferred aspect of this
embodiment, R.sup.7 is --C(.dbd.O)R.sup.11 wherein R.sup.11 is
(C.sub.1-C.sub.8)alkyl. In another preferred aspect of this
embodiment, R.sup.7 is
##STR00010##
In one embodiment of Formula II, X.sup.1 is N or C--R.sup.10. In
another aspect of this embodiment, X.sup.1 is N. In another aspect
of this embodiment, X.sup.1 is C--R.sup.10. In another aspect of
this embodiment, X.sup.2 is C--H. In another aspect of this
embodiment, X.sup.1 is N and X.sup.2 is C--H. In another aspect of
this embodiment, X.sup.1 is C--R.sup.10 and X.sup.2 is CH. In
another aspect of this embodiment, X.sup.1 is C--H and X.sup.2 is
CH. In another aspect of this embodiment, X.sup.1 is CR.sup.10 and
R.sup.6 is OR.sup.a, N.sub.3, halogen, --C(.dbd.O)R.sup.11,
--C(.dbd.O)OR.sup.11, --C(O)NR.sup.11R.sup.12,
--C(.dbd.O)SR.sup.11, --S(O)R.sup.11, --S(O).sub.2R.sup.11,
--S(O)(OR.sup.11), --S(O).sub.2(OR.sup.11),
--SO.sub.2NR.sup.11R.sup.12, CN, methyl, substituted methyl,
ethenyl, substituted ethenyl, ethynyl, or substituted ethynyl. In
another aspect of this embodiment, X.sup.1 is CR.sup.10, X.sup.2 is
CH; and R.sup.6 is OR.sup.a, N.sub.3, halogen, CN, methyl,
substituted methyl, ethenyl, substituted ethenyl, ethynyl, or
substituted ethynyl. In another aspect of this embodiment, X.sup.1
is CR.sup.10, X.sup.2 is CH; R.sup.1 is H, methyl, CH.sub.2OH,
CH.sub.2F, ethenyl, or ethynyl; R.sup.3 is H; R.sup.2 and R.sup.4
are each OR.sup.a; and R.sup.6 is OR.sup.a, N.sub.3, halogen, CN,
methyl, substituted methyl, ethenyl, substituted ethenyl, ethynyl,
or substituted ethynyl. In another aspect of this embodiment,
X.sup.1 is C--R.sup.10; X.sup.2 is CH; R.sup.1 is H, methyl,
CH.sub.2OH, CH.sub.2F, ethenyl, or ethynyl; each R.sup.3 and
R.sup.5 is H; R.sup.2 and R.sup.4 are each OR.sup.a; and R.sup.6 is
methyl, hydroxymethyl, N.sub.3, halogen or CN. In another aspect of
this embodiment, X.sup.1 is N and R.sup.6 is OR.sup.a, N.sub.3,
halogen, --C(.dbd.O)R.sup.11, --C(.dbd.O)OR.sup.11,
--C(.dbd.O)NR.sup.11R.sup.12, --C(.dbd.O)SR.sup.11, --S(O)R.sup.11,
--S(O).sub.2R.sup.11, --S(O)(OR.sup.11), --S(O).sub.2(OR.sup.11),
SO.sub.2NR.sup.11R.sup.12, CN, methyl, substituted methyl, ethenyl,
substituted ethenyl, ethynyl, or substituted ethynyl. In another
aspect of this embodiment, X.sup.1 is N; X.sup.2 is CH; and R.sup.6
is OR.sup.a, N.sub.3, halogen, CN, methyl, substituted methyl,
ethenyl, substituted ethenyl, ethynyl, or substituted ethynyl. In
another aspect of this embodiment, X.sup.1 is N; X.sup.2 is CH;
R.sup.1 is H, methyl, CH.sub.2OH, CH.sub.2F, ethenyl, or ethynyl;
R.sup.3 is H; R.sup.2 and R.sup.4 are each OR.sup.a; and R.sup.6 is
OR.sup.a, N.sub.3, halogen, CN, methyl, substituted methyl,
ethenyl, substituted ethenyl, ethynyl, or substituted ethynyl. In
another aspect of this embodiment, X.sup.1 is N; X.sup.2 is CH;
R.sup.1 is H, methyl, CH.sub.2OH, CH.sub.2F, ethenyl, or ethynyl;
each R.sup.3 and R.sup.5 is H; R.sup.2 and R.sup.4 are each
OR.sup.a; and R.sup.6 is methyl, hydroxymethyl, N.sub.3, halogen or
CN.
In another embodiment of Formula II, each R.sup.8 is independently
halogen, NR.sup.11R.sup.12, N(R.sup.11)OR.sup.11,
NR.sup.11NR.sup.11R.sup.12, N.sub.3, NO, NO.sub.2, CHO, CN,
--CH(.dbd.NR.sup.11), --CH.dbd.NHNR.sup.11, --CH.dbd.N(OR.sup.11),
--CH(OR.sup.11).sub.2, --C(.dbd.O)NR.sup.11R.sup.12,
--C(.dbd.S)NR.sup.11R.sup.12, --C(.dbd.O)OR.sup.11,
--(C.sub.1-C.sub.8)alkyl, (C.sub.2-C.sub.8)alkenyl,
(C.sub.2-C.sub.8)alkynyl, (C.sub.4-C.sub.8)carbocyclylalkyl,
optionally substituted aryl, optionally substituted heteroaryl,
--C(.dbd.O)(C.sub.1-C.sub.8)alkyl,
--S(O).sub.n(C.sub.1-C.sub.8)alkyl, aryl(C.sub.1-C.sub.8)alkyl,
OR.sup.11 or SR.sup.11. In another aspect of this embodiment, each
R.sup.8 is, independently, halogen, NR.sup.11R.sup.12,
N(R.sup.11)OR.sup.11, NR.sup.11NR.sup.11R.sup.12, OR.sup.11 or
SR.sup.11. In another aspect of this embodiment, each R.sup.8 is,
independently, halogen, NR.sup.11R.sup.12, N(R.sup.11)OR.sup.11,
NR.sup.11NR.sup.11R.sup.12, OR.sup.11 or SR.sup.11 and R.sup.1 is
H, methyl, CH.sub.2OH, CH.sub.2F, ethenyl, or ethynyl. In another
aspect of this embodiment, each R.sup.8 is, independently, halogen,
NR.sup.11R.sup.12, N(R.sup.11)OR.sup.11,
NR.sup.11NR.sup.11R.sup.12, OR.sup.11 or SR.sup.11 and R.sup.9 is
H, halogen, or NR.sup.11R.sup.12. In another aspect of this
embodiment, each R.sup.8 is, independently, halogen,
NR.sup.11R.sup.12, N(R.sup.11)OR.sup.11,
NR.sup.11NR.sup.11R.sup.12, OR.sup.11 or SR.sup.11 and R.sup.9 is
H, halogen, or NR.sup.11R.sup.12 and R.sup.1 is H, methyl,
CH.sub.2OH, CH.sub.2F, ethenyl, or ethynyl. In another preferred
aspect of this embodiment, R.sup.8 is NH.sub.2 and R.sup.9 is H or
halogen. In another preferred aspect of this embodiment, R.sup.8 is
NH.sub.2 and R.sup.9 is H or halogen and R.sup.1 is H, methyl,
CH.sub.2OH, CH.sub.2F, ethenyl, or ethynyl. In another preferred
aspect of this embodiment, R.sup.8 and R.sup.9 are each NH.sub.2.
In another preferred aspect of this embodiment, R.sup.8 and R.sup.9
are each NH.sub.2 and R.sup.1 is H, methyl, CH.sub.2OH, CH.sub.2F,
ethenyl, or ethynyl. In another preferred aspect of this
embodiment, R.sup.8 is OH and R.sup.9 is NH.sub.2. In another
preferred aspect of this embodiment, R.sup.8 is OH and R.sup.9 is
NH.sub.2 and R.sup.1 is H, methyl, CH.sub.2OH, CH.sub.2F, ethenyl,
or ethynyl.
In another embodiment of Formula II, each R.sup.10 is,
independently, H, halogen, NR.sup.11R.sup.12, N(R.sup.11)OR.sup.11,
NR.sup.11NR.sup.11R.sup.12, N.sub.3, NO, NO.sub.2, CHO, CN,
--CH(.dbd.NR.sup.11), --CH.dbd.NHNR.sup.11, --CH.dbd.N(OR.sup.11),
--CH(OR.sup.11).sub.2, --C(.dbd.O)NR.sup.11R.sup.12,
--C(.dbd.S)NR.sup.11R.sup.12, --C(.dbd.O)OR.sup.11, R.sup.11,
OR.sup.11 or SR.sup.11. In another aspect of this embodiment, each
R.sup.10 is H, halogen, CN or optionally substituted
heteroaryl.
In another aspect, compounds of Formula I are represented by
Formula III:
##STR00011##
or a pharmaceutically acceptable salt, thereof;
wherein:
R.sup.1 is H or CH.sub.3;
each R.sup.2, R.sup.3, R.sup.4, or R.sup.5 is independently H,
OR.sup.a, N(R.sup.a).sub.2, N.sub.3, CN, NO.sub.2,
S(O).sub.nR.sup.a, halogen, (C.sub.1-C.sub.8)alkyl,
(C.sub.4-C.sub.8)carbocyclylalkyl, (C.sub.1-C.sub.8)substituted
alkyl, (C.sub.2-C.sub.8)alkenyl, (C.sub.2-C.sub.8)substituted
alkenyl, (C.sub.2-C.sub.8)alkynyl, (C.sub.2-C.sub.8)substituted
alkynyl, or aryl(C.sub.1-C.sub.8)alkyl;
or any two R.sup.2, R.sup.3, R.sup.4, or R.sup.5 on adjacent carbon
atoms when taken together are --O(CO)O-- or when taken together
with the ring carbon atoms to which they are attached four a double
bond;
R.sup.6 is OR.sup.a, N(R.sup.a).sub.2, N.sub.3, CN, NO.sub.2,
S(O).sub.nR.sup.a, C(.dbd.O)R.sup.11, --C(.dbd.O)OR.sup.11,
--C(.dbd.O)NR.sup.11R.sup.12, --C(.dbd.O)SR.sup.11, --S(O)R.sup.11,
--S(O).sub.2R.sup.11, --S(O)(OR.sup.11), --S(O).sub.2(OR.sup.11),
--SO.sub.2NR.sup.11R.sup.12, halogen, (C.sub.1-C.sub.8)alkyl,
(C.sub.4-C.sub.8)carbocyclylalkyl, (C.sub.1-C.sub.8)substituted
alkyl, (C.sub.2-C.sub.8)alkenyl, (C.sub.2-C.sub.8)substituted
alkenyl, (C.sub.2-C.sub.8)alkynyl, (C.sub.2-C.sub.8)substituted
alkynyl, or aryl(C.sub.1-C.sub.8)alkyl or R.sup.6 and R.sup.2 when
taken together are --O(CO)O--;
wherein each (C.sub.1-C.sub.8)alkyl, (C.sub.2-C.sub.8)alkenyl,
(C.sub.2-C.sub.8)alkynyl or aryl(C.sub.1-C.sub.8)alkyl of each
R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.11 or R.sup.12
is, independently, optionally substituted with one or more halo,
hydroxy, CN, N.sub.3, N(R.sup.a).sub.2 or OR.sup.a; and wherein one
or more of the non-terminal carbon atoms of each said
(C.sub.1-C.sub.8)alkyl may be optionally replaced with --O--, --S--
or --NR.sup.a--; and
all remaining variables are defined as for Formula I.
In one embodiment of Formula III, R.sup.1 is H.
In one embodiment of Formula III, R.sup.1 is CH.sub.3.
In one embodiment of Formula III, R.sup.2 is H, OR.sup.a,
N(R.sup.a).sub.2, N.sub.3, CN, NO.sub.2, S(O).sub.nR.sup.a,
halogen, (C.sub.1-C.sub.8)alkyl, (C.sub.1-C.sub.8)substituted
alkyl, (C.sub.2-C.sub.8)alkenyl, (C.sub.2-C.sub.8)substituted
alkenyl, (C.sub.2-C.sub.8)alkynyl, or (C.sub.2-C.sub.8)substituted
alkynyl. In another aspect of this embodiment, R.sup.2 is H,
OR.sup.a, N(R.sup.a).sub.2, N.sub.3, CN, SR.sup.a or halogen. In
another aspect of this embodiment, R.sup.2 is H, OH, NH.sub.2,
N.sub.3, CN, or halogen. In another aspect of this embodiment,
R.sup.2 is OR.sup.a or halogen and R.sup.1 is methyl. In another
aspect of this embodiment, R.sup.2 is OR.sup.a or halogen and
R.sup.1 is H. In another aspect of this embodiment, R.sup.2 is
OR.sup.a or F and R.sup.1 is methyl. In another aspect of this
embodiment, R.sup.2 is OR.sup.a or F and R.sup.1 is H. In a
preferred aspect of this embodiment, R.sup.2 is OH and R.sup.1 is
methyl. In another preferred aspect of this embodiment, R.sup.2 is
OR.sup.a and R.sup.1 is H. In another preferred aspect of this
embodiment, R.sup.2 is OH and R.sup.1 is H. In another preferred
aspect of this embodiment, R.sup.2 is F. In another preferred
aspect of this embodiment, R.sup.2 is OR.sup.a and R.sup.1 is
methyl.
In one embodiment of Formula III, R.sup.3 is H, OR.sup.a,
N(R.sup.a).sub.2, N.sub.3, CN, SR.sup.a, halogen,
(C.sub.1-C.sub.8)alkyl, (C.sub.2-C.sub.3)alkenyl or
(C.sub.2-C.sub.8)alkynyl. In one aspect of this embodiment, R.sup.3
is H or F. In a preferred aspect of this embodiment, R.sup.3 is H.
In another preferred aspect of this embodiment, R.sup.3 is H,
R.sup.2 is OR.sup.a or halogen and R.sup.1 is methyl. In another
preferred aspect of this embodiment, R.sup.3 is H, R.sup.2 is
OR.sup.a or halogen and R.sup.1 is H. In another aspect of this
embodiment, R.sup.3 is H, R.sup.2 is OR.sup.a or F and R.sup.1 is
methyl. In another aspect of this embodiment, R.sup.3 is H, R.sup.2
is OR.sup.a or F and R.sup.1 is H. In another aspect of this
embodiment, R.sup.3 is H, R.sup.2 is OR.sup.a and R.sup.1 is
methyl. In another aspect of this embodiment, R.sup.3 is H, R.sup.2
is OH and R.sup.1 is methyl. In another aspect of this embodiment,
R.sup.3 is H, R.sup.2 is OR.sup.a and R.sup.1 is H. In another
aspect of this embodiment, R.sup.3 is H, R.sup.2 is OH and R.sup.1
is H. In another aspect of this embodiment, each R.sup.1, R.sup.3
and R.sup.5 is H and R.sup.2 is OH.
In one embodiment of Formula III, R.sup.4 is H, OR.sup.a,
N(R.sup.a).sub.2, N.sub.3, CN, SR.sup.a, halogen,
(C.sub.1-C.sub.8)alkyl, (C.sub.2-C.sub.8)alkenyl or
(C.sub.2-C.sub.8)alkynyl. In a preferred aspect of this embodiment,
R.sup.4 is OR.sup.a. In another preferred aspect of this
embodiment, R.sup.4 is OR.sup.a, R.sup.2 is OR.sup.a or halogen and
R.sup.1 is methyl. In another preferred aspect of this embodiment,
R.sup.4 is OR.sup.a, R.sup.2 is OR.sup.a or halogen and R.sup.1 is
H. In another preferred aspect of this embodiment, R.sup.4 is
OR.sup.a, R.sup.2 is OR.sup.a or halogen, R.sup.3 is H and R.sup.1
is methyl. In another preferred aspect of this embodiment, R.sup.4
is OR.sup.a, R.sup.2 is OR.sup.a or halogen, R.sup.3 is H and
R.sup.1 is H. In another preferred embodiment R.sup.4 is OR.sup.a,
R.sup.2 is OR.sup.a or F and R.sup.1 is methyl. In another
preferred embodiment R.sup.4 is OR.sup.a, R.sup.2 is OR.sup.a or F
and R.sup.1 is H. In another preferred aspect of this embodiment,
R.sup.4 is OR.sup.a, R.sup.2 is OR.sup.a or F, R.sup.3 is H and
R.sup.1 is methyl. In another preferred aspect of this embodiment,
R.sup.4 and R.sup.2 are, independently, OR.sup.a and R.sup.1 is
methyl. In another preferred aspect of this embodiment, R.sup.4 and
R.sup.2 are, independently OR.sup.a, R.sup.3 is H and R.sup.1 is
methyl. In another preferred aspect of this embodiment, R.sup.4 and
R.sup.2, taken together, are --O(CO)O--, R.sup.3 is H and R.sup.1
is methyl. In another preferred aspect of this embodiment, R.sup.4
and R.sup.2, taken together, are --O(CO)O--, R.sup.3 is H and
R.sup.1 is H. In another preferred aspect of this embodiment, one
of R.sup.4 or R.sup.2 is OR.sup.a and the other of R.sup.4 or
R.sup.2 is OH. In another preferred aspect of this embodiment, one
of R.sup.4 or R.sup.2 is OR.sup.a wherein R.sup.a is not H and the
other of R.sup.4 or R.sup.2 is OH, R.sup.3 is H, and R.sup.1 is
methyl. In another preferred aspect of this embodiment, one of
R.sup.4 or R.sup.2 is OR.sup.a wherein R.sup.a is not H and the
other of R.sup.4 or R.sup.2 is OH, R.sup.3 is H, and R.sup.1 is H.
In another preferred aspect of this embodiment, R.sup.4 and R.sup.2
are OH, R.sup.3 is H, and R.sup.1 is methyl. In another preferred
aspect of this embodiment, R.sup.4 and R.sup.2 are OH, R.sup.3 is
H, and R.sup.1 is H. In another preferred aspect of this
embodiment, R.sup.4 is OR.sup.a, R.sup.2 is OR.sup.a or F, and each
R.sup.1 and R.sup.3 is H. In another preferred aspect of this
embodiment, R.sup.4 and R.sup.2 are, independently, OR.sup.a and
R.sup.1 is H. In another preferred aspect of this embodiment,
R.sup.4 and R.sup.2 are, independently OR.sup.a and each R.sup.1
and R.sup.3 is H.
In one embodiment of Formula III, R.sup.5 is H, OR.sup.a,
N(R.sup.a).sub.2, N.sub.3, CN, SR.sup.a, halogen,
(C.sub.1-C.sub.8)alkyl, (C.sub.2-C.sub.8)alkenyl or
(C.sub.2-C.sub.8)alkynyl. In another aspect of this embodiment,
R.sup.6 is OR.sup.a, N(R.sup.a).sub.2, N.sub.3, CN, NO.sub.2,
S(O).sub.nR.sup.a, --C(.dbd.O)R.sup.11, --C(.dbd.O)OR.sup.11,
--C(.dbd.O)NR.sup.11R.sup.12, --C(.dbd.O)SR.sup.11, --S(O)R.sup.11,
--S(O).sub.2R.sup.11, --S(O)(OR.sup.11), --S(O).sub.2(OR.sup.11),
--SO.sub.2NR.sup.11R.sup.12, halogen, (C.sub.1-C.sub.8)alkyl,
(C.sub.4-C.sub.8)carbocyclylalkyl, (C.sub.1-C.sub.8)substituted
alkyl, (C.sub.2-C.sub.8)alkenyl, (C.sub.2-C.sub.8)substituted
alkenyl, (C.sub.2-C.sub.8)alkynyl, (C.sub.2-C.sub.8)substituted
alkynyl, or aryl(C.sub.1-C.sub.8)alkyl and R.sup.5 is H, OR.sup.a,
N(R.sup.a).sub.2, N.sub.3, CN, SR.sup.a, halogen,
(C.sub.1-C.sub.8)alkyl, (C.sub.2-C.sub.8)alkenyl or
(C.sub.2-C.sub.8)alkynyl. In another aspect of this embodiment,
R.sup.6 is OR.sup.a, N(R.sup.a).sub.2, N.sub.3, CN, NO.sub.2,
S(O).sub.nR.sup.a, --C(.dbd.O)R.sup.11, --C(.dbd.O)OR.sup.11,
--C(.dbd.O)NR.sup.11R.sup.12, --C(.dbd.O)SR.sup.11, --S(O)R.sup.11,
--S(O).sub.2R.sup.11, --S(O)(OR.sup.11), --S(O).sub.2(OR.sup.11),
--SO.sub.2NR.sup.11R.sup.12, halogen, (C.sub.1-C.sub.8)alkyl,
(C.sub.4-C.sub.8)carbocyclylalkyl, (C.sub.1-C.sub.8)substituted
alkyl, (C.sub.2-C.sub.8)alkenyl, (C.sub.2-C.sub.8)substituted
alkenyl, (C.sub.2-C.sub.8)alkynyl, (C.sub.2-C.sub.8)substituted
alkynyl, or aryl(C.sub.1-C.sub.8)alkyl and R.sup.5 is H, N.sub.3,
CN, (C.sub.1-C.sub.8)alkyl, (C.sub.2-C.sub.8)alkenyl or
(C.sub.2-C.sub.8)alkynyl. In another aspect of this embodiment,
R.sup.6 is OR.sup.a, N.sub.3, CN, S(O).sub.nR.sup.a,
--C(.dbd.O)R.sup.11, --C(.dbd.O)OR.sup.11,
--C(.dbd.O)NR.sup.11R.sup.12, --C(.dbd.O)SR.sup.11, --S(O)R.sup.11,
--S(O).sub.2R.sup.11, --S(O)(OR.sup.11), --S(O).sub.2(OR.sup.11),
--SO.sub.2NR.sup.11R.sup.12, halogen, (C.sub.1-C.sub.8)substituted
alkyl, (C.sub.2-C.sub.8)alkenyl, (C.sub.2-C.sub.8)substituted
alkenyl, (C.sub.2-C.sub.8)alkynyl, or (C.sub.2-C.sub.8)substituted
alkynyl; R.sup.5 is H, N.sub.3, CN, methyl, ethenyl or ethynyl;
R.sup.4 is OR.sup.a and R.sup.3 is H. In another aspect of this
embodiment, R.sup.6 is OR.sup.a, N.sub.3, CN, S(O)R.sup.a,
--C(.dbd.O)R.sup.11, --C(.dbd.O)OR.sup.11,
--C(.dbd.O)NR.sup.11R.sup.12, --C(.dbd.O)SR.sup.11, --S(O)R.sup.11,
--S(O).sub.2R.sup.11, --S(O)(OR.sup.11), --S(O).sub.2(OR.sup.11),
--SO.sub.2NR.sup.11R.sup.12, halogen, substituted methyl, ethenyl,
substituted ethenyl, ethynyl, or substituted ethynyl, R.sup.5 is H
or N.sub.3, R.sup.4 is OR.sup.a, R.sup.3 is H, and R.sup.2 is F or
OR.sup.a. In another aspect of this embodiment, R.sup.6 is
OR.sup.a, N.sub.3, CN, S(O).sub.nR.sup.a, --C(.dbd.O)R.sup.11,
--C(.dbd.O)OR.sup.11, --C(.dbd.O)NR.sup.11R.sup.12,
--C(.dbd.O)SR.sup.11, --S(O)R.sup.11, --S(O).sub.2R.sup.11,
--S(O)(OR.sup.11), --S(O).sub.2(OR.sup.11),
--SO.sub.2NR.sup.11R.sup.12, halogen, substituted methyl, ethenyl,
substituted ethenyl, ethynyl, or substituted ethynyl, R.sup.5 is H
or N.sub.3, R.sup.4 is OR.sup.a, R.sup.3 is H, R.sup.2 is OR.sup.a
and R.sup.1 is methyl. In another aspect of this embodiment,
R.sup.6 is OR.sup.a, N.sub.3, CN, S(O).sub.nR.sup.a,
--C(.dbd.O)R.sup.11, --C(.dbd.O)OR.sup.11,
--C(.dbd.O)NR.sup.11R.sup.12, --C(.dbd.O)SR.sup.11, --S(O)R.sup.11,
--S(O).sub.2R.sup.11, --S(O)(OR.sup.11), --S(O).sub.2(OR.sup.11),
--SO.sub.2NR.sup.11R.sup.12, halogen, substituted methyl, ethenyl,
substituted ethenyl, ethynyl, or substituted ethynyl, R.sup.3 and
R.sup.5 are H, R.sup.2 and R.sup.4 are, independently, OR.sup.a,
and R.sup.1 is methyl. In another aspect of this embodiment,
R.sup.6 is OR.sup.a, N.sub.3, CN, S(O).sub.nR.sup.a,
--C(.dbd.O)R.sup.11, --C(.dbd.O)OR.sup.11,
--C(.dbd.O)NR.sup.11R.sup.12, --C(.dbd.O)SR.sup.11, --S(O)R.sup.11,
--S(O).sub.2R.sup.11, --S(O)(OR.sup.11), --S(O).sub.2(OR.sup.11),
--SO.sub.2NR.sup.11R.sup.12, halogen, substituted methyl, ethenyl,
substituted ethenyl, ethynyl, or substituted ethynyl, R.sup.3 and
R.sup.5 are H, R.sup.2 and R.sup.4 are OH, and R.sup.1 is methyl.
In another aspect of this embodiment, R.sup.6 is OR.sup.a, N.sub.3,
CN, S(O).sub.nR.sup.a, --C(.dbd.O)R.sup.11, --C(.dbd.O)OR.sup.11,
--C(.dbd.O)NR.sup.11R.sup.12, --C(.dbd.O)SR.sup.11, --S(O)R.sup.11,
--S(O).sub.2R.sup.11, --S(O)(OR.sup.11), --S(O).sub.2(OR.sup.11),
--SO.sub.2NR.sup.11R.sup.12, halogen, substituted methyl, ethenyl,
substituted ethenyl, ethynyl, or substituted ethynyl, R.sup.1,
R.sup.3 and R.sup.5 are each H and R.sup.2 and R.sup.4 are OH. In
another aspect of this embodiment, R.sup.6 is OR.sup.a, N.sub.3,
CN, S(O).sub.nR.sup.a, --C(.dbd.O)R.sup.11, --C(.dbd.O)OR.sup.11,
--C(.dbd.O)NR.sup.11R.sup.12, --C(.dbd.O)SR.sup.11, --S(O)R.sup.11,
--S(O).sub.2R.sup.11, --S(O)(OR.sup.11), --S(O).sub.2(OR.sup.11),
--SO.sub.2NR.sup.11R.sup.12, halogen, substituted methyl, ethenyl,
substituted ethenyl, ethynyl, or substituted ethynyl, R.sup.3 and
R.sup.5 are H, R.sup.2 and R.sup.4, taken together, are --O(CO)O--,
and R.sup.1 is methyl. In another aspect of this embodiment,
R.sup.6 is OR.sup.a, N.sub.3, CN, S(O).sub.nR.sup.a,
--C(.dbd.O)R.sup.11, --C(.dbd.O)OR.sup.11,
--C(.dbd.O)NR.sup.11R.sup.12, --C(.dbd.O)SR.sup.11, --S(O)R.sup.11,
--S(O).sub.2R.sup.11, --S(O)(OR.sup.11), --S(O).sub.2(OR.sup.11),
--SO.sub.2NR.sup.11R.sup.12, halogen, substituted methyl, ethenyl,
substituted ethenyl, ethynyl, or substituted ethynyl, R.sup.1,
R.sup.3 and R.sup.5 are each H and R.sup.2 and R.sup.4, taken
together, are --O(CO)O--. In another aspect of this embodiment,
R.sup.6 is OR.sup.a, N.sub.3, CN, S(O).sub.nR.sup.a,
--C(.dbd.O)R.sup.11, --C(.dbd.O)OR.sup.11,
--C(.dbd.O)NR.sup.11R.sup.12, --C(.dbd.O)SR.sup.11, --S(O)R.sup.11,
--S(O).sub.2R.sup.11, --S(O)(OR.sup.11), --S(O).sub.2(OR.sup.11),
--SO.sub.2NR.sup.11R.sup.12 halogen, substituted methyl, ethenyl,
substituted ethenyl, ethynyl, or substituted ethynyl, R.sup.1 and
R.sup.3 are each H, R.sup.2 and R.sup.4 are independently OR.sup.a
and R.sup.5 is N.sub.3.
In one embodiment of Formula III, R.sup.2 and R.sup.4 are each
OR.sup.a and at least one of R.sup.1, R.sup.3, or R.sup.5 is not H.
In another aspect of this embodiment, R.sup.2 and R.sup.4 are each
OR.sup.a and R.sup.1 methyl. In another embodiment, R.sup.2 and
R.sup.4 are each OR.sup.a and R.sup.3 is (C.sub.1-C.sub.8)alkyl,
(C.sub.1-C.sub.8)substituted alkyl, (C.sub.2-C.sub.8)alkenyl,
(C.sub.2-C.sub.8)substituted alkenyl, (C.sub.2-C.sub.8)alkynyl,
(C.sub.2-C.sub.8)substituted alkynyl or aryl(C.sub.1-C.sub.8)alkyl.
In another aspect of this embodiment, R.sup.2 and R.sup.4 are each
OR.sup.a and R.sup.5 is OR.sup.a, N(R.sup.a).sub.2, N.sub.3, CN,
NO.sub.2, S(O).sub.nR.sup.a, halogen, (C.sub.1-C.sub.8)alkyl,
(C.sub.1-C.sub.8)substituted alkyl, (C.sub.2-C.sub.8)alkenyl,
(C.sub.2-C.sub.8)substituted alkenyl, (C.sub.2-C.sub.8)alkynyl,
(C.sub.2-C.sub.8)substituted alkynyl or aryl(C.sub.1-C.sub.8)alkyl.
In another aspect of this embodiment, R.sup.2 and R.sup.4 are each
OR.sup.a and R.sup.6 is OR.sup.a, N(R.sup.a).sub.2, N.sub.3, CN,
NO.sub.2, S(O).sub.nR.sup.a, --C(.dbd.O)R.sup.11,
--C(.dbd.O)OR.sup.11, --C(.dbd.O)NR.sup.11R.sup.12,
--C(.dbd.O)SR.sup.11, --S(O)R.sup.11, --S(O).sub.2R.sup.11,
--S(O)(OR.sup.11), --S(O).sub.2(OR.sup.11),
--SO.sub.2NR.sup.11R.sup.12, halogen, (C.sub.1-C.sub.8)alkyl,
(C.sub.1-C.sub.8)substituted alkyl, (C.sub.2-C.sub.8)alkenyl,
(C.sub.2-C.sub.8)substituted alkenyl, (C.sub.2-C.sub.8)alkynyl,
(C.sub.2-C.sub.8)substituted alkynyl or aryl
(C.sub.1-C.sub.8)alkyl. In another aspect of this embodiment,
R.sup.2 and R.sup.4 are both OH and R.sup.6 is OR.sup.a, N.sub.3,
CN, S(O).sub.nR.sup.a, --C(.dbd.O)R.sup.11, --C(.dbd.O)OR.sup.11,
--C(.dbd.O)NR.sup.11R.sup.12, --C(.dbd.O)SR.sup.11, --S(O)R.sup.11,
--S(O).sub.2R.sup.11, --S(O)(OR.sup.11), --S(O).sub.2(OR.sup.11),
--SO.sub.2NR.sup.11R.sup.12, halogen, (C.sub.1-C.sub.8)alkyl,
(C.sub.1-C.sub.8)substituted alkyl, (C.sub.2-C.sub.8)alkenyl,
(C.sub.2-C.sub.8)substituted alkenyl, (C.sub.2-C.sub.8)alkynyl, or
(C.sub.2-C.sub.8)substituted alkynyl.
In another embodiment of Formula III, each R.sup.1 and R.sup.2 is
H, one of R.sup.3 or R.sup.4 is OR.sup.a and the other of R.sup.3
or R.sup.4 is (C.sub.1-C.sub.8)alkyl, (C.sub.1-C.sub.8)substituted
alkyl, (C.sub.2-C.sub.8)alkenyl, (C.sub.2-C.sub.8)substituted
alkenyl, (C.sub.2-C.sub.8)alkynyl, (C.sub.2-C.sub.8)substituted
alkynyl or aryl(C.sub.1-C.sub.8)alkyl. In another aspect of this
embodiment, each R.sup.1 and R.sup.2 is H, one of R.sup.3 or
R.sup.4 is OR.sup.a and the other of R.sup.3 or R.sup.4 is
(C.sub.1-C.sub.8)alkyl, (C.sub.1-C.sub.8)substituted alkyl,
(C.sub.2-C.sub.8)alkenyl, (C.sub.2-C.sub.8)substituted alkenyl,
(C.sub.2-C.sub.8)alkynyl, (C.sub.2-C.sub.8)substituted alkynyl or
aryl(C.sub.1-C.sub.8)alkyl.
In another embodiment of Formula III, R.sup.6 is OR.sup.a,
N(R.sup.a).sub.2, N.sub.3, CN, NO.sub.2, S(O).sub.nR.sup.a,
--C(.dbd.O)R.sup.11, --C(.dbd.O)OR.sup.1I,
--C(.dbd.O)NR.sup.11R.sup.12, --C(.dbd.O)SR.sup.11, --S(O)R.sup.11,
--S(O).sub.2R.sup.11, --S(O)(OR.sup.11), --S(O).sub.2(OR.sup.11),
--SO.sub.2NR.sup.11R.sup.12, halogen, (C.sub.1-C.sub.8)alkyl,
(C.sub.4-C.sub.8)carbocyclylalkyl, (C.sub.1-C.sub.8)substituted
alkyl, (C.sub.2-C.sub.8)alkenyl, (C.sub.2-C.sub.8)substituted
alkenyl, (C.sub.2-C.sub.8)alkynyl, (C.sub.2-C.sub.8)substituted
alkynyl, or aryl(C.sub.1-C.sub.8)alkyl. In another aspect of this
embodiment, R.sup.5 is H, N.sub.3, CN, (C.sub.1-C.sub.8)alkyl,
(C.sub.2-C.sub.8)alkenyl or (C.sub.2-C.sub.8)alkynyl. In another
aspect of this embodiment, R.sup.1 is H. In another aspect of this
embodiment, R.sup.1 is methyl. In another aspect of this
embodiment, R.sup.1 is H and R.sup.2 and R.sup.4 are each OR.sup.a.
In another aspect of this embodiment, R.sup.1 is methyl and R.sup.2
and R.sup.4 are each OR.sup.a. In another aspect of this
embodiment, R.sup.1 is H; R.sup.2 and R.sup.4 are each OR.sup.a;
and R.sup.3 and R.sup.5 are each H. In another aspect of this
embodiment, R.sup.1 is methyl; R.sup.2 and R.sup.4 are each
OR.sup.a; and R.sup.3 and R.sup.5 are each H. In another aspect of
this embodiment, R.sup.5 is H, N.sub.3, CN, methyl, ethenyl or
ethynyl; R.sup.4 is OR.sup.a and R.sup.3 is H. In another aspect of
this embodiment, R.sup.6 is OR.sup.a, N.sub.3, halogen, CN, methyl,
substituted methyl, ethenyl, substituted ethenyl, ethynyl, or
substituted ethynyl; R.sup.5 is H or N.sub.3; R.sup.4 is OR.sup.a;
R.sup.3 is H; and R.sup.2 is OR.sup.a. In another aspect of this
embodiment, R.sup.6 is OR.sup.a, N.sub.3, halogen, CN, methyl,
substituted methyl, ethenyl, substituted ethenyl, ethynyl, or
substituted ethynyl; R.sup.3 and R.sup.5 are H and R.sup.2 and
R.sup.4 are, independently, OR.sup.a. In another aspect of this
embodiment, R.sup.6 is OR.sup.a, N.sub.3, halogen, CN, methyl,
substituted methyl, ethenyl, substituted ethenyl, ethynyl, or
substituted ethynyl; R.sup.3 and R.sup.5 are H; and R.sup.2 and
R.sup.4 are each OH. In another aspect of this embodiment, R.sup.6
is OR.sup.a, N.sub.3, halogen, CN, methyl, substituted methyl,
ethenyl, substituted ethenyl, ethynyl, or substituted ethynyl;
R.sup.3 and R.sup.5 are H; and R.sup.2 and R.sup.4, taken together,
are --O(CO)O--. In another aspect of this embodiment, R.sup.6 is
OR.sup.a, N.sub.3, halogen, CN, methyl, substituted methyl,
ethenyl, substituted ethenyl, ethynyl, or substituted ethynyl;
R.sup.3 is H; R.sup.2 and R.sup.4 are independently OR.sup.a and
R.sup.5 is N.sub.3. In another aspect of this of this embodiment,
R.sup.6 is N.sub.3, halogen, CN, methyl, hydroxymethyl, ethenyl or
ethynyl. In another aspect of this of this embodiment, R.sup.6 is
N.sub.3, halogen, CN, methyl, hydroxymethyl, ethenyl or ethynyl;
R.sup.1 is H; and R.sup.2 and R.sup.4 are each OR.sup.a. In another
aspect of this of this embodiment, R.sup.6 is N.sub.3, halogen, CN,
methyl, hydroxymethyl, ethenyl or ethynyl; R.sup.1 is methyl; and
R.sup.2 and R.sup.4 are each OR.sup.a. In another aspect of this of
this embodiment, R.sup.6 is N.sub.3, halogen, CN, methyl,
hydroxymethyl, ethenyl or ethynyl; R.sup.1 is H; R.sup.2 and
R.sup.4 are each OR.sup.a; and R.sup.3 and R.sup.5 are each H. In
another aspect of this of this embodiment, R.sup.6 is N.sub.3,
halogen, CN, methyl, hydroxymethyl, ethenyl or ethynyl; R.sup.1 is
methyl; R.sup.2 and R.sup.4 are each OR.sup.a; and R.sup.3 and
R.sup.5 are each H.
In one embodiment of Formula III, R.sup.7 is H,
--C(.dbd.O)R.sup.11, --C(.dbd.O)OR.sup.11, --C(.dbd.O)SR.sup.11
or
##STR00012## In a preferred aspect of this embodiment, R.sup.7 is
H. In another preferred aspect of this embodiment, R.sup.7 is H and
R.sup.1 is H. In another preferred aspect of this embodiment,
R.sup.7 is --C(.dbd.O)R.sup.11. In another preferred aspect of this
embodiment, R.sup.7 is --C(.dbd.O)R.sup.11 and R.sup.1 is H. In
another preferred aspect of this embodiment, R.sup.7 is
--C(.dbd.O)R.sup.11 wherein R.sup.11 is (C.sub.1-C.sub.8)alkyl. In
another preferred aspect of this embodiment, R.sup.7 is
--C(.dbd.O)R.sup.11 wherein R.sup.11 is (C.sub.1-C.sub.8)alkyl and
R.sup.1 is H. In another preferred aspect of this embodiment,
R.sup.7 is
##STR00013## In another preferred aspect of this embodiment,
R.sup.7 is
##STR00014## and R.sup.1 is H.
In another embodiment of Formula III, each R.sup.8 is independently
halogen, NR.sup.11R.sup.12, N(R.sup.11)OR.sup.11,
NR.sup.11NR.sup.11R.sup.12, N.sub.3, NO, NO.sub.2, CHO, CN,
--CH(.dbd.NR.sup.11), --CH.dbd.NHNR.sup.11, --CH.dbd.N(OR.sup.11),
--CH(OR.sup.11).sub.2, --C(.dbd.O)NR.sup.11R.sup.12,
--C(.dbd.S)NR.sup.11R.sup.12, --C(.dbd.O)OR.sup.11,
(C.sub.1-C.sub.8)alkyl, (C.sub.2-C.sub.8)alkenyl,
(C.sub.2-C.sub.8)alkynyl, (C.sub.4-C.sub.8)carbocyclylalkyl,
optionally substituted aryl, optionally substituted heteroaryl,
--C(.dbd.O)(C.sub.1-C.sub.8)alkyl,
--S(O).sub.n(C.sub.1-C.sub.8)alkyl, aryl(C.sub.1-C.sub.8)alkyl,
OR.sup.11 or SR.sup.11. In another aspect of this embodiment, each
R.sup.8 is, independently, halogen, NR.sup.11R.sup.12,
N(R.sup.11)OR.sup.11, NR.sup.11NR.sup.11R.sup.12, OR.sup.11 or
SR.sup.11. In another aspect of this embodiment, each R.sup.8 is,
independently, halogen, NR.sup.11R.sup.12, N(R.sup.11)OR.sup.11,
NR.sup.11NR.sup.11R.sup.12, OR.sup.11 or SR.sup.11 and R.sup.1 is
H. In another aspect of this embodiment, each R.sup.8 is,
independently, halogen, NR.sup.11R.sup.12, N(R.sup.11)OR.sup.11,
NR.sup.11NR.sup.11R.sup.12, OR.sup.11 or SR.sup.11 and R.sup.1 is
methyl. In another aspect of this embodiment, each R.sup.8 is,
independently, halogen, NR.sup.11R.sup.12, N(R.sup.11)OR.sup.11,
NR.sup.11NR.sup.11R.sup.12, OR.sup.11 or SR.sup.11 and R.sup.9 is
H, halogen, or NR.sup.11R.sup.12. In another aspect of this
embodiment, each R.sup.8 is, independently, halogen,
NR.sup.11R.sup.12, N(R.sup.11)OR.sup.11,
NR.sup.11NR.sup.11R.sup.12, OR.sup.11 or SR.sup.11 and R.sup.9 is
H, halogen, or NR.sup.11R.sup.12 and R.sup.1 is H. In another
aspect of this embodiment, each R.sup.8 is, independently, halogen,
NR.sup.11R.sup.12, N(R.sup.11)OR.sup.11,
NR.sup.11NR.sup.11R.sup.12, OR.sup.11 or SR.sup.11 and R.sup.9 is
H, halogen, or NR.sup.11R.sup.12 and R.sup.1 is methyl. In another
preferred aspect of this embodiment, R.sup.8 is NH.sub.2 and
R.sup.9 is H or halogen. In another preferred aspect of this
embodiment, R.sup.8 is NH.sub.2 and R.sup.9 is H or halogen and
R.sup.1 is H. In another preferred aspect of this embodiment,
R.sup.8 is NH.sub.2 and R.sup.9 is H or halogen and R.sup.1 is
methyl. In another preferred aspect of this embodiment, R.sup.8 and
R.sup.9 are each NH.sub.2. In another preferred aspect of this
embodiment, R.sup.8 and R.sup.9 are each NH.sub.2 and R.sup.1 is H.
In another preferred aspect of this embodiment, R.sup.8 and R.sup.9
are each NH.sub.2 and R.sup.1 is methyl. In another preferred
aspect of this embodiment, R.sup.8 is OH and R.sup.9 is NH.sub.2.
In another preferred aspect of this embodiment, R.sup.8 is OH and
R.sup.9 is NH.sub.2 and R.sup.1 is H. In another preferred aspect
of this embodiment, R.sup.8 is OH and R.sup.9 is NH.sub.2 and
R.sup.1 is methyl.
In another embodiment of Formula III, each R.sup.10 is,
independently, H, halogen, NR.sup.11R.sup.12, N(R.sup.11)OR.sup.11,
NR.sup.11NR.sup.11R.sup.12, N.sub.3, NO, NO.sub.2, CHO, CN,
--CH(.dbd.NR.sup.11), --CH.dbd.NHNR.sup.11, --CH.dbd.N(OR.sup.11),
--CH(OR.sup.11).sub.2, --C(.dbd.O)NR.sup.11R.sup.12,
--C(.dbd.S)NR.sup.11R.sup.12, --C(.dbd.O)OR.sup.11, R.sup.11,
OR.sup.11 or SR.sup.11. In another aspect of this embodiment,
R.sup.6 is OR.sup.a, N.sub.3, halogen, --C(.dbd.O)R.sup.11,
--C(.dbd.O)OR.sup.11, --C(.dbd.O)NR.sup.11R.sup.12,
--C(.dbd.O)SR.sup.11, --S(O)R.sup.11, --S(O).sub.2R.sup.11,
--S(O)(OR.sup.11), --S(O).sub.2(OR.sup.11),
--SO.sub.2NR.sup.11R.sup.12, CN, methyl, substituted methyl,
ethenyl, substituted ethenyl, ethynyl, or substituted ethynyl. In
another aspect of this embodiment, each R.sup.10 is H, halogen, CN
or optionally substituted heteroaryl and R.sup.6 is OR.sup.a,
N.sub.3, halogen, --C(.dbd.O)R.sup.11, --C(.dbd.O)OR.sup.11,
--C(.dbd.O)NR.sup.11R.sup.12, --C(.dbd.O)SR.sup.11, --S(O)R.sup.11,
--S(O).sub.2R.sup.11, --S(O)(OR.sup.11), --S(O).sub.2(OR.sup.11),
--SO.sub.2NR.sup.11R.sup.12, CN, methyl, substituted methyl,
ethenyl, substituted ethenyl, ethynyl, or substituted ethynyl. In
another aspect of this embodiment, R.sup.10 is H and R.sup.6 is
OR.sup.a, N.sub.3, halogen, CN, methyl, substituted methyl,
ethenyl, substituted ethenyl, ethynyl, or substituted ethynyl. In
another aspect of this embodiment, R.sup.3 is H; R.sup.2 and
R.sup.4 are each OR.sup.a; and R.sup.6 is OR.sup.a, N.sub.3,
halogen, CN, methyl, substituted methyl, ethenyl, substituted
ethenyl, ethynyl, or substituted ethynyl. In another aspect of this
embodiment, each R.sup.3 and R.sup.5 is H; R.sup.2 and R.sup.4 are
each OR.sup.a; and R.sup.6 is methyl, hydroxymethyl, N.sub.3,
halogen or CN.
In one embodiment of Formulas I-III, R.sup.11 or R.sup.12 is
independently H, (C.sub.1-C.sub.8)alkyl, (C.sub.2-C.sub.8)alkenyl,
(C.sub.2-C.sub.8)alkynyl, (C.sub.4-C.sub.8)carbocyclylalkyl,
optionally substituted aryl, optionally substituted heteroaryl,
--C(.dbd.O)(C.sub.1-C.sub.8)alkyl,
--S(O).sub.n(C.sub.1-C.sub.8)alkyl or aryl(C.sub.1-C.sub.8)alkyl.
In another embodiment, R.sup.11 and R.sup.12 taken together with a
nitrogen to which they are both attached, form a 3 to 7 membered
heterocyclic ring wherein any one carbon atom of said heterocyclic
ring can optionally be replaced with --O--, --S-- or --NR.sup.a--.
Therefore, by way of example and not limitation, the moiety
--NR.sup.11R.sup.12 can be represented by the heterocycles:
##STR00015## and the like.
In another embodiment of Formulas I-III, R.sup.2, R.sup.3, R.sup.4,
R.sup.5, R.sup.6, R.sup.11 or R.sup.12 is, independently,
(C.sub.1-C.sub.8)alkyl, (C.sub.2-C.sub.8)alkenyl,
(C.sub.2-C.sub.8)alkynyl or aryl(C.sub.1-C.sub.8)alkyl, wherein
said (C.sub.1-C.sub.8)alkyl, (C.sub.2-C.sub.8)alkenyl,
(C.sub.2-C.sub.8)alkynyl or aryl(C.sub.1-C.sub.8)alkyl are,
independently, optionally substituted with one or more halo,
hydroxy, CN, N.sub.3, N(R.sup.a).sub.2 or OR.sup.a. Therefore, by
way of example and not limitation, R.sup.2, R.sup.3, R.sup.4,
R.sup.5, R.sup.6, R.sup.11 or R.sup.12 could represent moieties
such as --CH(NH.sub.2)CH.sub.3, --CH(OH)CH2CH3,
--CH(NH.sub.2)CH(CH.sub.3).sub.2, --CH.sub.2CF.sub.3,
--(CH.sub.2).sub.2CH(N.sub.3)CH.sub.3, --(CH.sub.2).sub.6NH.sub.2
and the like.
In another embodiment of Formula I-III, R.sup.2, R.sup.3, R.sup.4,
R.sup.5, R.sup.6, R.sup.11 or R.sup.12 is (C.sub.1-C.sub.8)alkyl
wherein one or more of the non-terminal carbon atoms of each said
(C.sub.1-C.sub.8)alkyl may be optionally replaced with --O--, --S--
or --NR.sup.a--. Therefore, by way of example and not limitation,
R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.11 or R.sup.12
could represent moieties such as --CH.sub.2OCH.sub.3,
--CH.sub.2OCH.sub.2CH.sub.3, --CH.sub.2OCH(CH.sub.3).sub.2,
--CH.sub.2SCH.sub.3, --(CH.sub.2).sub.6OCH.sub.3,
--(CH.sub.2).sub.6N(CH.sub.3).sub.2 and the like.
In still another embodiment, the compounds of Formula I, Formula
II, or Formula III are named below in tabular format (Table 6) as
compounds of general Formula IV:
##STR00016## wherein X1 and X2, represent substituents attached to
the tetrahydrofuranyl ring as defined in Tables 1-2, below; B is a
purine defined in Table 4, below; and X3 represents a ring element
of the purine base B as described in Table 3, below.
The point of attachment of the core structure ribose is indicated
in each of the structures of X1, X2, and B. The point of attachment
of the core structure purine is indicated in each of the structures
X3. Each structure in Tables 1-4 is represented by an alphanumeric
"code". Each structure of a compound of Formula IV can thus be
designated in tabular form by combining the "code" representing
each structural moiety using the following syntax: X1.X2.X3.B.
Thus, for example, X1a.X2c.X3a.B1 represents the following
structure:
##STR00017##
TABLE-US-00001 TABLE 1 X1 Structures Code Structure X1a CN X1b
CH.sub.3 X1c N.sub.3 X1d CH.sub.2OH
TABLE-US-00002 TABLE 2 X2 Structures Code Structure X2a H X2b
CH.sub.3 X2c ##STR00018##
TABLE-US-00003 TABLE 3 X3 Structures Code Structure X3a --N.dbd.
X3b --CH.dbd. X3c --CF.dbd.
TABLE-US-00004 TABLE 4 B Structures Code Structure B1 ##STR00019##
B2 ##STR00020## B3 ##STR00021## B4 ##STR00022##
TABLE-US-00005 TABLE 6 List of Compounds of Formula IV
X1a.X2b.X3a.B1, X1a.X2b.X3a.B2, X1a.X2b.X3a.B3, X1a.X2b.X3a.B4,
X1a.X2b.X3b.B1, X1a.X2b.X3b.B2, X1a.X2b.X3b.B3, X1a.X2b.X3b.B4,
X1a.X2b.X3c.B1, X1a.X2b.X3c.B2, X1a.X2b.X3c.B3, X1a.X2b.X3c.B4,
X1a.X2c.X3a.B1, X1a.X2c.X3a.B2, X1a.X2c.X3a.B3, X1a.X2c.X3a.B4,
X1a.X2c.X3b.B1, X1a.X2c.X3b.B2, X1a.X2c.X3b.B3, X1a.X2c.X3b.B4,
X1a.X2c.X3c.B1, X1a.X2c.X3c.B2, X1a.X2c.X3c.B3, X1a.X2c.X3c.B4,
X1b.X2a.X3a.B1, X1b.X2a.X3a.B2, X1b.X2a.X3a.B3, X1b.X2a.X3a.B4,
X1b.X2a.X3b.B1, X1b.X2a.X3b.B2, X1b.X2a.X3b.B3, X1b.X2a.X3b.B4,
X1b.X2a.X3c.B1, X1b.X2a.X3c.B2, X1b.X2a.X3c.B3, X1b.X2a.X3c.B4,
X1b.X2b.X3a.B1, X1b.X2b.X3a.B2, X1b.X2b.X3a.B3, X1b.X2b.X3a.B4,
X1b.X2b.X3b.B1, X1b.X2b.X3b.B2, X1b.X2b.X3b.B3, X1b.X2b.X3b.B4,
X1b.X2b.X3c.B1, X1b.X2b.X3c.B2, X1b.X2b.X3c.B3, X1b.X2b.X3c.B4,
X1b.X2c.X3a.B1, X1b.X2c.X3a.B2, X1b.X2c.X3a.B3, X1b.X2c.X3a.B4,
X1b.X2c.X3b.B1, X1b.X2c.X3b.B2, X1b.X2c.X3b.B3, X1b.X2c.X3b.B4,
X1b.X2c.X3c.B1, X1b.X2c.X3c.B2, X1b.X2c.X3c.B3, X1b.X2c.X3c.B4,
X1c.X2a.X3a.B1, X1c.X2a.X3a.B2, X1c.X2a.X3a.B3, X1c.X2a.X3a.B4,
X1c.X2a.X3b.B1, X1c.X2a.X3b.B2, X1c.X2a.X3b.B3, X1c.X2a.X3b.B4,
X1c.X2a.X3c.B1, X1c.X2a.X3c.B2, X1c.X2a.X3c.B3, X1c.X2a.X3c.B4,
X1c.X2b.X3a.B1, X1c.X2b.X3a.B2, X1c.X2b.X3a.B3, X1c.X2b.X3a.B4,
X1c.X2b.X3b.B1, X1c.X2b.X3b.B2, X1c.X2b.X3b.B3, X1c.X2b.X3b.B4,
X1c.X2b.X3c.B1, X1c.X2b.X3c.B2, X1c.X2b.X3c.B3, X1c.X2b.X3c.B4,
X1c.X2c.X3a.B1, X1c.X2c.X3a.B2, X1c.X2c.X3a.B3, X1c.X2c.X3a.B4,
X1c.X2c.X3b.B1, X1c.X2c.X3b.B2, X1c.X2c.X3b.B3, X1c.X2c.X3b.B4,
X1c.X2c.X3c.B1, X1c.X2c.X3c.B2, X1c.X2c.X3c.B3, X1c.X2c.X3c.B4,
X1d.X2a.X3a.B1, X1d.X2a.X3a.B2, X1d.X2a.X3a.B3, X1d.X2a.X3a.B4,
X1d.X2a.X3b.B1, X1d.X2a.X3b.B2, X1d.X2a.X3b.B3, X1d.X2a.X3b.B4,
X1d.X2a.X3c.B1, X1d.X2a.X3c.B2, X1d.X2a.X3c.B3, X1d.X2a.X3c.B4.
In another embodiment, Formulas I-III is a compound selected from
the group consisting of
##STR00023## ##STR00024## ##STR00025## ##STR00026## ##STR00027##
##STR00028## ##STR00029## or a pharmaceutically acceptable salt
thereof.
DEFINITIONS
Unless stated otherwise, the following terms and phrases as used
herein are intended to have the following meanings:
When trade names are used herein, applicants intend to
independently include the tradename product and the active
pharmaceutical ingredient(s) of the tradename product.
As used herein, "a compound of the invention" or "a compound of
Formula I" means a compound of Formula I or a pharmaceutically
acceptable salt, thereof. Similarly, with respect to isolatable
intermediates, the phrase "a compound of Formula (number)" means a
compound of that formula and pharmaceutically acceptable salts,
thereof.
"Alkyl" is hydrocarbon containing normal, secondary, tertiary or
cyclic carbon atoms. For example, an alkyl group can have 1 to 20
carbon atoms (i.e, C.sub.1-C.sub.20 alkyl), 1 to 8 carbon atoms
(i.e., C.sub.1-C.sub.8 alkyl), or 1 to 6 carbon atoms (i.e.,
C.sub.1-C.sub.6 alkyl). Examples of suitable alkyl groups include,
but are not limited to, methyl (Me, --CH.sub.3), ethyl (Et,
--CH.sub.2CH.sub.3), 1-propyl (n-Pr, n-propyl,
--CH.sub.2CH.sub.2CH.sub.3), 2-propyl (i-Pr, i-propyl,
--CH(CH.sub.3).sub.2), 1-butyl (n-Bu, n-butyl,
--CH.sub.2CH.sub.2CH.sub.2CH.sub.3), 2-methyl-1-propyl (i-Bu,
i-butyl, --CH.sub.2CH(CH.sub.3).sub.2), 2-butyl (s-Bu, s-butyl,
--CH(CH.sub.3)CH.sub.2CH.sub.3), 2-methyl-2-propyl (t-Bu, t-butyl,
--C(CH.sub.3).sub.3), 1-pentyl (n-pentyl,
--CH.sub.2CH.sub.2CH.sub.2CH.sub.2CH.sub.3), 2-pentyl
(--CH(CH.sub.3)CH.sub.2CH.sub.2CH.sub.3), 3-pentyl
(--CH(CH.sub.2CH.sub.3).sub.2), 2-methyl-2-butyl
(--C(CH.sub.3).sub.2CH.sub.2CH.sub.3), 3-methyl-2-butyl
(--CH(CH.sub.3)CH(CH.sub.3).sub.2), 3-methyl-1-butyl
(--CH.sub.2CH.sub.2CH(CH.sub.3).sub.2), 2-methyl-1-butyl
(--CH.sub.2CH(CH.sub.3)CH.sub.2CH.sub.3), 1-hexyl
(--CH.sub.2CH.sub.2CH.sub.2CH.sub.2CH.sub.2CH.sub.3), 2-hexyl
(--CH(CH.sub.3)CH.sub.2CH.sub.2CH.sub.2CH.sub.3), 3-hexyl
(--CH(CH.sub.2CH.sub.3)(CH.sub.2CH.sub.2CH.sub.3)),
2-methyl-2-pentyl (--C(CH.sub.3).sub.2CH.sub.2CH.sub.2CH.sub.3),
3-methyl-2-pentyl (--CH(CH.sub.3)CH(CH.sub.3)CH.sub.2CH.sub.3),
4-methyl-2-pentyl (--CH(CH.sub.3)CH.sub.2CH(CH.sub.3).sub.2),
3-methyl-3-pentyl (--C(CH.sub.3)(CH.sub.2CH.sub.3).sub.2),
2-methyl-3-pentyl (--CH(CH.sub.2CH.sub.3)CH(CH.sub.3).sub.2),
2,3-dimethyl-2-butyl (--C(CH.sub.3).sub.2CH(CH.sub.3).sub.2),
3,3-dimethyl-2-butyl (--CH(CH.sub.3)C(CH.sub.3).sub.3, and octyl
((--CH.sub.2).sub.7CH.sub.3).
"Alkoxy" means a group having the formula --O-alkyl, in which an
alkyl group, as defined above, is attached to the parent molecule
via an oxygen atom. The alkyl portion of an alkoxy group can have 1
to 20 carbon atoms (i.e., C.sub.1-C.sub.20 alkoxy), 1 to 12 carbon
atoms (i.e., C.sub.1-C.sub.12 alkoxy), or 1 to 6 carbon atoms
(i.e., C.sub.1-C.sub.6 alkoxy). Examples of suitable alkoxy groups
include, but are not limited to, methoxy (--O--CH.sub.3 or -OMe),
ethoxy (--OCH.sub.2CH.sub.3 or -OEt), t-butoxy
(--O--C(CH.sub.3).sub.3 or -OtBu) and the like.
"Haloalkyl" is an alkyl group, as defined above, in which one or
more hydrogen atoms of the alkyl group is replaced with a halogen
atom. The alkyl portion of a haloalkyl group can have 1 to 20
carbon atoms (i.e., C.sub.1-C.sub.20 haloalkyl), 1 to 12 carbon
atoms (i.e., C.sub.1-C.sub.12 haloalkyl), or 1 to 6 carbon atoms
(i.e., C.sub.1-C.sub.6 alkyl). Examples of suitable haloalkyl
groups include, but are not limited to, --CF.sub.3, --CHF.sub.2,
--CFH.sub.2, --CH.sub.2CF.sub.3, and the like.
"Alkenyl" is a hydrocarbon containing normal, secondary, tertiary
or cyclic carbon atoms with at least one site of unsaturation, i.e.
a carbon-carbon, sp.sup.2 double bond. For example, an alkenyl
group can have 2 to 20 carbon atoms (i.e., C.sub.2-C.sub.20
alkenyl), 2 to 8 carbon atoms (i.e., C.sub.2-C.sub.8 alkenyl), or 2
to 6 carbon atoms (i.e., C.sub.2-C.sub.6 alkenyl). Examples of
suitable alkenyl groups include, but are not limited to, ethylene
or vinyl (--CH.dbd.CH.sub.2), allyl (--CH.sub.2CH.dbd.CH.sub.2),
cyclopentenyl (--C.sub.5H.sub.7), and 5-hexenyl
(--CH.sub.2CH.sub.2CH.sub.2CH.sub.2CH.dbd.CH.sub.2).
"Alkynyl" is a hydrocarbon containing normal, secondary, tertiary
or cyclic carbon atoms with at least one site of unsaturation, i.e.
a carbon-carbon, sp triple bond. For example, an alkynyl group can
have 2 to 20 carbon atoms (i.e., C.sub.2-C.sub.20 alkynyl), 2 to 8
carbon atoms (i.e., C.sub.2-C.sub.8 alkyne,), or 2 to 6 carbon
atoms (i.e., C.sub.2-C.sub.6 alkynyl). Examples of suitable alkynyl
groups include, but are not limited to, acetylenic (--CH.ident.CH),
propargyl (--CH.sub.2C.ident.CH), and the like.
"Alkylene" refers to a saturated, branched or straight chain or
cyclic hydrocarbon radical having two monovalent radical centers
derived by the removal of two hydrogen atoms from the same or two
different carbon atoms of a parent alkane. For example, an alkylene
group can have 1 to 20 carbon atoms, 1 to 10 carbon atoms, or 1 to
6 carbon atoms. Typical alkylene radicals include, but are not
limited to, methylene (--CH.sub.2--), 1,1-ethyl (--CH(CH.sub.3)--),
1,2-ethyl (--CH.sub.2CH.sub.2--), 1,1-propyl
(--CH(CH.sub.2CH.sub.3)--), 1,2-propyl (--CH.sub.2CH(CH.sub.3)--),
1,3-propyl (--CH.sub.2CH.sub.2CH.sub.2--), 1,4-butyl
(--CH.sub.2CH.sub.2CH.sub.2CH.sub.2--), and the like.
"Alkenylene" refers to an unsaturated, branched or straight chain
or cyclic hydrocarbon radical having two monovalent radical centers
derived by the removal of two hydrogen atoms from the same or two
different carbon atoms of a parent alkene. For example, and
alkenylene group can have 1 to 20 carbon atoms, 1 to 10 carbon
atoms, or 1 to 6 carbon atoms. Typical alkenylene radicals include,
but are not limited to, 1,2-ethylene (--CH.dbd.CH--).
"Alkynylene" refers to an unsaturated, branched or straight chain
or cyclic hydrocarbon radical having two monovalent radical centers
derived by the removal of two hydrogen atoms from the same or two
different carbon atoms of a parent alkyne. For example, an
alkynylene group can have 1 to 20 carbon atoms, 1 to 10 carbon
atoms, or 1 to 6 carbon atoms. Typical alkynylene radicals include,
but are not limited to, acetylene (--C.ident.C--), propargyl
(--CH.sub.2C.ident.C--), and 4-pentynyl
(--CH.sub.2CH.sub.2CH.sub.2C.ident.C--).
"Amino" refers generally to a nitrogen radical which can be
considered a derivative of ammonia, having the formula
--N(X).sub.2, where each "X" is independently H, substituted or
unsubstituted alkyl, substituted or unsubstituted carbocyclyl,
substituted or unsubstituted heterocyclyl, etc. The hybridization
of the nitrogen is approximately sp.sup.3. Nonlimiting types of
amino include --NH.sub.2, --N(alkyl).sub.2, --NH(alkyl),
--N(carbocyclyl).sub.2, --NH(carbocyclyl), --N(heterocyclyl).sub.2,
--NH(heterocyclyl), --N(aryl).sub.2, --NH(aryl), --N(alkyl)(aryl),
--N(alkyl)(heterocyclyl), --N(carbocyclyl)(heterocyclyl),
--N(aryl)(heteroaryl), --N(alkyl)(heteroaryl), etc. The term
"alkylamino" refers to an amino group substituted with at least one
alkyl group. Nonlimiting examples of amino groups include NH.sub.2,
--NH(CH.sub.3), --N(CH.sub.3).sub.2, --NH(CH.sub.2CH.sub.3),
--N(CH.sub.2CH.sub.3).sub.2, --NH(phenyl), --N(phenyl).sub.2,
--NH(benzyl), --N(benzyl).sub.2, etc. Substituted alkylamino refers
generally to alkylamino groups, as defined above, in which at least
one substituted alkyl, as defined herein, is attached to the amino
nitrogen atom. Non-limiting examples of substituted alkylamino
includes --NH(alkylene-C(O)--OH), --NH(alkylene-C(O)--O-alkyl),
--N(alkylene-C(O)--OH).sub.2, --N(alkylene-C(O)--O-alkyl).sub.2,
etc.
"Aryl" means an aromatic hydrocarbon radical derived by the removal
of one hydrogen atom from a single carbon atom of a parent aromatic
ring system. For example, an aryl group can have 6 to 20 carbon
atoms, 6 to 14 carbon atoms, or 6 to 10 carbon atoms. Typical aryl
groups include, but are not limited to, radicals derived from
benzene (e.g., phenyl), substituted benzene, naphthalene,
anthracene, biphenyl, and the like.
"Arylalkyl" refers to an acyclic alkyl radical in which one of the
hydrogen atoms bonded to a carbon atom, typically a terminal or
sp.sup.3 carbon atom, is replaced with an aryl radical. Typical
arylalkyl groups include, but are not limited to, benzyl,
2-phenylethan-1-yl, naphthylmethyl, 2-naphthylethan-1-yl,
naphthobenzyl, 2-naphthophenylethan-1-yl and the like. The
arylalkyl group can comprise 7 to 20 carbon atoms, e.g., the alkyl
moiety is 1 to 6 carbon atoms and the aryl moiety is 6 to 14 carbon
atoms.
"Arylalkenyl" refers to an acyclic alkenyl radical in which one of
the hydrogen atoms bonded to a carbon atom, typically a terminal or
sp.sup.3 carbon atom, but also an sp.sup.2 carbon atom, is replaced
with an aryl radical. The aryl portion of the arylalkenyl can
include, for example, any of the aryl groups disclosed herein, and
the alkenyl portion of the arylalkenyl can include, for example,
any of the alkenyl groups disclosed herein. The arylalkenyl group
can comprise 8 to 20 carbon atoms, e.g., the alkenyl moiety is 2 to
6 carbon atoms and the aryl moiety is 6 to 14 carbon atoms.
"Arylalkynyl" refers to an acyclic alkynyl radical in which one of
the hydrogen atoms bonded to a carbon atom, typically a terminal or
sp.sup.3 carbon atom, but also an sp carbon atom, is replaced with
an aryl radical. The aryl portion of the arylalkynyl can include,
for example, any of the aryl groups disclosed herein, and the
alkynyl portion of the arylalkynyl can include, for example, any of
the alkynyl groups disclosed herein. The arylalkynyl group can
comprise 8 to 20 carbon atoms, e.g., the alkynyl moiety is 2 to 6
carbon atoms and the aryl moiety is 6 to 14 carbon atoms.
The term "substituted" in reference to alkyl, alkylene, aryl,
arylalkyl, alkoxy, heterocyclyl, heteroaryl, carbocyclyl, etc., for
example, "substituted alkyl", "substituted alkylene", "substituted
aryl", "substituted arylalkyl", "substituted heterocyclyl", and
"substituted carbocyclyl" means alkyl, alkylene, aryl, arylalkyl,
heterocyclyl, carbocyclyl respectively, in which one or more
hydrogen atoms are each independently replaced with a non-hydrogen
substituent. Typical substituents include, but are not limited to,
--X, --R.sup.b, --O.sup.-, .dbd.O, --OR.sup.b, --SR.sup.b,
--S.sup.-, --NR.sup.b.sub.2, --N.sup.+R.sup.b.sub.3, .dbd.NR.sup.b,
--CX.sub.3, --CN, --OCN, --SCN, --N.dbd.C.dbd.O, --NCS, --NO,
--NO.sub.2, .dbd.N.sub.2, --N.sub.3, --NHC(.dbd.O)R.sup.b,
--OC(.dbd.O)R.sup.b, --NHC(.dbd.O)NR.sup.b.sub.2,
--S(.dbd.O).sub.2--, --S(O).sub.2OH, --S(.dbd.O).sub.2 R.sup.b,
--OS(.dbd.O).sub.2OR.sup.b, --S(O).sub.2NR.sup.b.sub.2,
--S(.dbd.O)R.sup.b, --OP(.dbd.O)(OR.sup.b).sub.2,
--P(.dbd.O)(OR.sup.b).sub.2, --P(.dbd.O)(O.sup.-).sub.2,
--P(.dbd.O)(OH).sub.2, --P(O)(OR.sup.b)(O.sup.-),
--C(.dbd.O)R.sup.b, --C(.dbd.O)X, --C(S)R.sup.b, --C(O)OR.sup.b,
--C(O)O.sup.-, --C(S)OR.sup.b, --C(O)SR.sup.b, --C(S)SR.sup.b,
--C(O)NR.sup.b.sub.2, --C(S)NR.sup.b.sub.2,
--C(.dbd.NR.sup.b)NR.sup.b.sub.2, where each X is independently a
halogen: F, Cl, Br, or I; and each R.sup.b is independently H,
alkyl, aryl, arylalkyl, a heterocycle, or a protecting group or
prodrug moiety. Alkylene, alkenylene, and alkynylene groups may
also be similarly substituted. Unless otherwise indicated, when the
term "substituted" is used in conjunction with groups such as
arylalkyl, which have two or more moieties capable of substitution,
the substituents can be attached to the aryl moiety, the alkyl
moiety, or both.
The term "prodrug" as used herein refers to any compound that when
administered to a biological system generates the drug substance,
i.e., active ingredient, as a result of spontaneous chemical
reaction(s), enzyme catalyzed chemical reaction(s), photolysis,
and/or metabolic chemical reaction(s). A prodrug is thus a
covalently modified analog or latent form of a therapeutically
active compound.
One skilled in the art will recognize that substituents and other
moieties of the compounds of Formula I-III should be selected in
order to provide a compound which is sufficiently stable to provide
a pharmaceutically useful compound which can be formulated into an
acceptably stable pharmaceutical composition. Compounds of Formula
I-III which have such stability are contemplated as falling within
the scope of the present invention.
"Heteroalkyl" refers to an alkyl group where one or more carbon
atoms have been replaced with a heteroatom, such as, O, N, or S.
For example, if the carbon atom of the alkyl group which is
attached to the parent molecule is replaced with a heteroatom
(e.g., O, N, or S) the resulting heteroalkyl groups are,
respectively, an alkoxy group (e.g., --OCH.sub.3, etc.), an amine
(e.g., --NHCH.sub.3, --N(CH.sub.3).sub.2, etc.), or a thioalkyl
group (e.g., --SCH.sub.3). If a non-terminal carbon atom of the
alkyl group which is not attached to the parent molecule is
replaced with a heteroatom (e.g., O, N, or S) the resulting
heteroalkyl groups are, respectively, an alkyl ether (e.g.,
--CH.sub.2CH.sub.2--O--CH.sub.3, etc.), an alkyl amine (e.g.,
--CH.sub.2NHCH.sub.3, --CH.sub.2N(CH.sub.3).sub.2, etc.), or a
thioalkyl ether (e.g., --CH.sub.2--S--CH.sub.3). If a terminal
carbon atom of the alkyl group is replaced with a heteroatom (e.g.,
O, N, or S), the resulting heteroalkyl groups are, respectively, a
hydroxyalkyl group (e.g., --CH.sub.2CH.sub.2--OH), an aminoalkyl
group (e.g., --CH.sub.2NH.sub.2), or an alkyl thiol group (e.g.,
--CH.sub.2CH.sub.2--SH). A heteroalkyl group can have, for example,
1 to 20 carbon atoms, 1 to 10 carbon atoms, or 1 to 6 carbon atoms.
A C.sub.1-C.sub.6 heteroalkyl group means a heteroalkyl group
having 1 to 6 carbon atoms.
"Heterocycle" or "heterocyclyl" as used herein includes by way of
example and not limitation those heterocycles described in
Paquette, Leo A.; Principles of Modern Heterocyclic Chemistry (W.
A. Benjamin, NewYork, 1968), particularly Chapters 1, 3, 4, 6, 7,
and 9; The Chemistry of Heterocyclic Compounds, A Series of
Monographs" (John Wiley & Sons, New York, 1950 to present), in
particular Volumes 13, 14, 16, 19, and 28; and J. Am. Chem. Soc.
(1960) 82:5566. In one specific embodiment of the invention
"heterocycle" includes a "carbocycle" as defined herein, wherein
one or more (e.g. 1, 2, 3, or 4) carbon atoms have been replaced
with a heteroatom (e.g. O, N, or S). The terms "heterocycle" or
"heterocyclyl" includes saturated rings, partially unsaturated
rings, and aromatic rings (i.e., heteroaromatic rings). Substituted
heterocyclyls include, for example, heterocyclic rings substituted
with any of the substituents disclosed herein including carbonyl
groups. A non-limiting example of a carbonyl substituted
heterocyclyl is:
##STR00030##
Examples of heterocycles include by way of example and not
limitation pyridyl, dihydroypyridyl, tetrahydropyridyl (piperidyl),
thiazolyl, tetrahydrothiophenyl, sulfur oxidized
tetrahydrothiophenyl, pyrimidinyl, furanyl, thienyl, pyrrolyl,
pyrazolyl, imidazolyl, tetrazolyl, benzofuranyl, thianaphthalenyl,
indolyl, indolenyl, quinolinyl, isoquinolinyl, benzimidazolyl,
piperidinyl, 4-piperidonyl, pyrrolidinyl, 2-pyrrolidonyl,
pyrrolinyl, tetrahydrofuranyl, tetrahydroquinolinyl,
tetrahydroisoquinolinyl, decahydroquinolinyl,
octahydroisoquinolinyl, azocinyl, triazinyl, 6H-1,2,5-thiadiazinyl,
2H,6H-1,5,2-dithiazinyl, thienyl, thianthrenyl, pyranyl,
isobenzofuranyl, chromenyl, xanthenyl, phenoxathinyl, 2H-pyrrolyl,
isothiazolyl, isoxazolyl, pyrazinyl, pyridazinyl, indolizinyl,
isoindolyl, 3H-indolyl, 1H-indazoly, purinyl, 4H-quinolizinyl,
phthalazinyl, naphthyridinyl, quinoxalinyl, quinazolinyl,
cinnolinyl, pteridinyl, 4aH-carbazolyl, carbazolyl,
.beta.-carbolinyl, phenanthridinyl, acridinyl, pyrimidinyl,
phenanthrolinyl, phenazinyl, phenothiazinyl, furazanyl,
phenoxazinyl, isochromanyl, chromanyl, imidazolidinyl,
imidazolinyl, pyrazolidinyl, pyrazolinyl, piperazinyl, indolinyl,
isoindolinyl, quinuclidinyl, morpholinyl, oxazolidinyl,
benzotriazolyl, benzisoxazolyl, oxindolyl, benzoxazolinyl,
isatinoyl, and bis-tetrahydrofuranyl:
##STR00031##
By way of example and not limitation, carbon bonded heterocycles
are bonded at position 2, 3, 4, 5, or 6 of a pyridine, position 3,
4, 5, or 6 of a pyridazine, position 2, 4, 5, or 6 of a pyrimidine,
position 2, 3, 5, or 6 of a pyrazine, position 2, 3, 4, or 5 of a
furan, tetrahydrofuran, thiofuran, thiophene, pyrrole or
tetrahydropyrrole, position 2, 4, or 5 of an oxazole, imidazole or
thiazole, position 3, 4, or 5 of an isoxazole, pyrazole, or
isothiazole, position 2 or 3 of an aziridine, position 2, 3, or 4
of an azetidine, position 2, 3, 4, 5, 6, 7, or 8 of a quinoline or
position 1, 3, 4, 5, 6, 7, or 8 of an isoquinoline. Still more
typically, carbon bonded heterocycles include 2-pyridyl, 3-pyridyl,
4-pyridyl, 5-pyridyl, 6-pyridyl, 3-pyridazinyl, 4-pyridazinyl,
5-pyridazinyl, 6-pyridazinyl, 2-pyrimidinyl, 4-pyrimidinyl,
5-pyrimidinyl, 6-pyrimidinyl, 2-pyrazinyl, 3-pyrazinyl,
5-pyrazinyl, 6-pyrazinyl, 2-thiazolyl, 4-thiazolyl, or
5-thiazolyl.
By way of example and not limitation, nitrogen bonded heterocycles
are bonded at position 1 of an aziridine, azetidine, pyrrole,
pyrrolidine, 2-pyrroline, 3-pyrroline, imidazole, imidazolidine,
2-imidazoline, 3-imidazoline, pyrazole, pyrazoline, 2-pyrazoline,
3-pyrazoline, piperidine, piperazine, indole, indoline,
1H-indazole, position 2 of a isoindole, or isoindoline, position 4
of a morpholine, and position 9 of a carbazole, or
.beta.-carboline. Still more typically, nitrogen bonded
heterocycles include 1-aziridyl, 1-azetedyl, 1-pyrrolyl,
1-imidazolyl, 1-pyrazolyl, and 1-piperidinyl.
"Heterocyclylalkyl" refers to an acyclic alkyl radical in which one
of the hydrogen atoms bonded to a carbon atom, typically a terminal
or sp.sup.3 carbon atom, is replaced with a heterocyclyl radical
(i.e., a heterocyclyl-alkylene- moiety). Typical heterocyclyl alkyl
groups include, but are not limited to heterocyclyl-CH.sub.2--,
2-(heterocyclyl)ethan-1-yl, and the like, wherein the
"heterocyclyl" portion includes any of the heterocyclyl groups
described above, including those described in Principles of Modern
Heterocyclic Chemistry. One skilled in the art will also understand
that the heterocyclyl group can be attached to the alkyl portion of
the heterocyclyl alkyl by means of a carbon-carbon bond or a
carbon-heteroatom bond, with the proviso that the resulting group
is chemically stable. The heterocyclyl alkyl group comprises 3 to
20 carbon atoms, e.g., the alkyl portion of the arylalkyl group is
1 to 6 carbon atoms and the heterocyclyl moiety is 2 to 14 carbon
atoms. Examples of heterocyclylalkyls include by way of example and
not limitation 5-membered sulfur, oxygen, and/or nitrogen
containing heterocycles such as thiazolylmethyl,
2-thiazolylethan-1-yl, imidazolylmethyl, oxazolylmethyl,
thiadiazolylmethyl, etc., 6-membered sulfur, oxygen, and/or
nitrogen containing heterocycles such as piperidinylmethyl,
piperazinylmethyl, morpholinylmethyl, pyridinylmethyl,
pyridizylmethyl, pyrimidylmethyl, pyrazinylmethyl, etc.
"Heterocyclylalkenyl" refers to an acyclic alkenyl radical in which
one of the hydrogen atoms bonded to a carbon atom, typically a
terminal or sp.sup.3 carbon atom, but also a sp.sup.2 carbon atom,
is replaced with a heterocyclyl radical (i.e., a
heterocyclyl-alkenylene-moiety). The heterocyclyl portion of the
heterocyclyl alkenyl group includes any of the heterocyclyl groups
described herein, including those described in Principles of Modern
Heterocyclic Chemistry, and the alkenyl portion of the heterocyclyl
alkenyl group includes any of the alkenyl groups disclosed herein.
One skilled in the art will also understand that the heterocyclyl
group can be attached to the alkenyl portion of the heterocyclyl
alkenyl by means of a carbon-carbon bond or a carbon-heteroatom
bond, with the proviso that the resulting group is chemically
stable. The heterocyclyl alkenyl group comprises 4 to 20 carbon
atoms, e.g., the alkenyl portion of the heterocyclyl alkenyl group
is 2 to 6 carbon atoms and the heterocyclyl moiety is 2 to 14
carbon atoms.
"Heterocyclylalkynyl" refers to an acyclic alkynyl radical in which
one of the hydrogen atoms bonded to a carbon atom, typically a
terminal or sp.sup.3 carbon atom, but also an sp carbon atom, is
replaced with a heterocyclyl radical (i.e., a
heterocyclyl-alkynylene-moiety). The heterocyclyl portion of the
heterocyclyl alkynyl group includes any of the heterocyclyl groups
described herein, including those described in Principles of Modern
Heterocyclic Chemistry, and the alkynyl portion of the heterocyclyl
alkynyl group includes any of the alkynyl groups disclosed herein.
One skilled in the art will also understand that the heterocyclyl
group can be attached to the alkynyl portion of the heterocyclyl
alkynyl by means of a carbon-carbon bond or a carbon-heteroatom
bond, with the proviso that the resulting group is chemically
stable. The heterocyclyl alkynyl group comprises 4 to 20 carbon
atoms, e.g., the alkynyl portion of the heterocyclyl alkynyl group
is 2 to 6 carbon atoms and the heterocyclyl moiety is 2 to 14
carbon atoms.
"Heteroaryl" refers to an aromatic heterocyclyl having at least one
heteroatom in the ring. Non-limiting examples of suitable
heteroatoms which can be included in the aromatic ring include
oxygen, sulfur, and nitrogen. Non-limiting examples of heteroaryl
rings include all of those aromatic rings listed in the definition
of "heterocyclyl", including pyridinyl, pyrrolyl, oxazolyl,
indolyl, isoindolyl, purinyl, furanyl, thienyl, benzofuranyl,
benzothiophenyl, carbazolyl, imidazolyl, thiazolyl, isoxazolyl,
pyrazolyl, isothiazolyl, quinolyl, isoquinolyl, pyridazyl,
pyrimidyl, pyrazyl, etc.
"Carbocycle" or "carbocyclyl" refers to a saturated (i.e.,
cycloalkyl), partially unsaturated (e.g., cycloakenyl,
cycloalkadienyl, etc.) or aromatic ring having 3 to 7 carbon atoms
as a monocycle, 7 to 12 carbon atoms as a bicycle, and up to about
20 carbon atoms as a polycycle. Monocyclic carbocycles have 3 to 7
ring atoms, still more typically 5 or 6 ring atoms. Bicyclic
carbocycles have 7 to 12 ring atoms, e.g., arranged as a
bicyclo[4,5], [5,5], [5,6] or [6,6] system, or 9 or 10 ring atoms
arranged as a bicyclo[5,6] or [6,6] system, or spiro-fused rings.
Non-limiting examples of monocyclic carbocycles include
cyclopropyl, cyclobutyl, cyclopentyl, 1-cyclopent-1-enyl,
1-cyclopent-2-enyl, 1-cyclopent-3-enyl, cyclohexyl,
1-cyclohex-1-enyl, 1-cyclohex-2-enyl, 1-cyclohex-3-enyl, and
phenyl. Non-limiting examples of bicyclo carbocycles includes
naphthyl, tetrahydronapthalene, and decaline.
"Carbocyclylalkyl" refers to to an acyclic alkyl radical in which
one of the hydrogen atoms bonded to a carbon atom is replaced with
a carbocyclyl radical as described herein. Typical, but
non-limiting, examples of carbocyclylalkyl groups include
cyclopropylmethyl, cyclopropylethyl, cyclobutylmethyl,
cyclopentylmethyl and cyclohexylmethyl.
"Arylheteroalkyl" refers to a heteroalkyl as defined herein, in
which a hydrogen atom (which may be attached either to a carbon
atom or a heteroatom) has been replaced with an aryl group as
defined herein. The aryl groups may be bonded to a carbon atom of
the heteroalkyl group, or to a heteroatom of the heteroalkyl group,
provided that the resulting arylheteroalkyl group provides a
chemically stable moiety. For example, an arylheteroalkyl group can
have the general formulae -alkylene-O-aryl,
-alkylene-O-alkylene-aryl, -alkylene-NH-aryl,
-alkylene-NH-alkylene-aryl, -alkylene-S-aryl,
-alkylene-S-alkylene-aryl, etc. In addition, any of the alkylene
moieties in the general formulae above can be further substituted
with any of the substituents defined or exemplified herein.
"Heteroarylalkyl" refers to an alkyl group, as defined herein, in
which a hydrogen atom has been replaced with a heteroaryl group as
defined herein. Non-limiting examples of heteroaryl alkyl include
--CH.sub.2-pyridinyl, --CH.sub.2-pyrrolyl, --CH.sub.2-oxazolyl,
--CH.sub.2-indolyl, --CH.sub.2-isoindolyl, --CH.sub.2-purinyl,
--CH.sub.2-furanyl, --CH.sub.2-thienyl, --CH.sub.2-benzofuranyl,
--CH.sub.2-benzothiophenyl, --CH.sub.2-carbazolyl,
--CH.sub.2-imidazolyl, --CH.sub.2-thiazolyl, --CH.sub.2-isoxazolyl,
--CH.sub.2-pyrazolyl, --CH.sub.2-isothiazolyl, --CH.sub.2-quinolyl,
--CH.sub.2-isoquinolyl, --CH.sub.2-pyridazyl, --CH.sub.2-pyrimidyl,
--CH.sub.2-pyrazyl, --CH(CH.sub.3)-pyridinyl,
--CH(CH.sub.3)-pyrrolyl, --CH(CH.sub.3)-oxazolyl,
--CH(CH.sub.3)-indolyl, --CH(CH.sub.3)-isoindolyl,
--CH(CH.sub.3)-purinyl, --CH(CH.sub.3)-furanyl,
--CH(CH.sub.3)-thienyl, --CH(CH.sub.3)-benzofuranyl,
--CH(CH.sub.3)-benzothiophenyl, --CH(CH.sub.3)-carbazolyl,
--CH(CH.sub.3)-imidazolyl, --CH(CH.sub.3)-thiazolyl,
--CH(CH.sub.3)-isoxazolyl, --CH(CH.sub.3)-pyrazolyl,
--CH(CH.sub.3)-isothiazolyl, --CH(CH.sub.3)-quinolyl,
--CH(CH.sub.3)-isoquinolyl, --CH(CH.sub.3)-pyridazyl,
--CH(CH.sub.3)-pyrimidyl, --CH(CH.sub.3)-pyrazyl, etc.
The term "optionally substituted" in reference to a particular
moiety of the compound of Formula I-III (e.g., an optionally
substituted aryl group) refers to a moiety wherein all substituents
are hydrogen or wherein one or more of the hydrogens of the moiety
may be replaced by substituents such as those listed under the
definition of "substituted".
The term "optionally replaced" in reference to a particular moiety
of the compound of Formula I-III (e.g., the carbon atoms of said
(C.sub.1-C.sub.8)alkyl may be optionally replaced by --O--, --S--,
or --NR.sup.a--) means that one or more of the methylene groups of
the (C.sub.1-C.sub.8)alkyl may be replaced by 0, 1, 2, or more of
the groups specified (e.g., --O--, --S--, or --NR.sup.a--).
The term "non-terminal carbon atom(s)" in reference to an alkyl,
alkenyl, alkynyl, alkylene, alkenylene, or alkynylene moiety refers
to the carbon atoms in the moiety that intervene between the first
carbon atom of the moiety and the last carbon atom in the moiety.
Therefore, by way of example and not limitation, in the alkyl
moiety --CH.sub.2(C*)H.sub.2(C*)H.sub.2CH.sub.3 or alkylene moiety
--CH.sub.2(C*)H.sub.2(C*)H.sub.2CH.sub.2-- the C* atoms would be
considered to be the non-terminal carbon atoms.
Certain Y and Y.sup.1 alternatives are nitrogen oxides such as
.sup.+N(O)(R) or .sup.+N(O)(OR). These nitrogen oxides, as shown
here attached to a carbon atom, can also be represented by charge
separated groups such as
##STR00032## respectively, and are intended to be equivalent to the
aforementioned representations for the purposes of describing this
invention.
"Linker" or "link" means a chemical moiety comprising a covalent
bond or a chain of atoms. Linkers include repeating units of
alkyloxy (e.g. polyethyleneoxy, PEG, polymethyleneoxy) and
alkylamino (e.g. polyethyleneamino, Jeffamine.TM.); and diacid
ester and amides including succinate, succinamide, diglycolate,
malonate, and caproamide.
The terms such as "oxygen-linked", "nitrogen-linked",
"carbon-linked", "sulfur-linked", or "phosphorous-linked" mean that
if a bond between two moieties can be formed by using more than one
type of atom in a moiety, then the bond formed between the moieties
is through the atom specified. For example, a nitrogen-linked amino
acid would be bonded through a nitrogen atom of the amino acid
rather than through an oxygen or carbon atom of the amino acid.
Unless otherwise specified, the carbon atoms of the compounds of
Formula I-III are intended to have a valence of four. In some
chemical structure representations where carbon atoms do not have a
sufficient number of variables attached to produce a valence of
four, the remaining carbon substitutents needed to provide a
valence of four should be assumed to be hydrogen. For example,
##STR00033## has the same meaning as
##STR00034##
"Protecting group" refers to a moiety of a compound that masks or
alters the properties of a functional group or the properties of
the compound as a whole. The chemical substructure of a protecting
group varies widely. One function of a protecting group is to serve
as an intermediate in the synthesis of the parental drug substance.
Chemical protecting groups and strategies for
protection/deprotection are well known in the art. See: "Protective
Groups in Organic Chemistry", Theodora W. Greene (John Wiley &
Sons, Inc., New York, 1991. Protecting groups are often utilized to
mask the reactivity of certain functional groups, to assist in the
efficiency of desired chemical reactions, e.g. making and breaking
chemical bonds in an ordered and planned fashion. Protection of
functional groups of a compound alters other physical properties
besides the reactivity of the protected functional group, such as
the polarity, lipophilicity (hydrophobicity), and other properties
which can be measured by common analytical tools. Chemically
protected intermediates may themselves be biologically active or
inactive.
Protected compounds may also exhibit altered, and in some cases,
optimized properties in vitro and in vivo, such as passage through
cellular membranes and resistance to enzymatic degradation or
sequestration. In this role, protected compounds with intended
therapeutic effects may be referred to as prodrugs. Another
function of a protecting group is to convert the parental drug into
a prodrug, whereby the parental drug is released upon conversion of
the prodrug in vivo. Because active prodrugs may be absorbed more
effectively than the parental drug, prodrugs may possess greater
potency in vivo than the parental drug. Protecting groups are
removed either in vitro, in the instance of chemical intermediates,
or in vivo, in the case of prodrugs. With chemical intermediates,
it is not particularly important that the resulting products after
deprotection, e.g. alcohols, be physiologically acceptable,
although in general it is more desirable if the products are
pharmacologically innocuous.
"Prodrug moiety" means a labile functional group which separates
from the active inhibitory compound during metabolism,
systemically, inside a cell, by hydrolysis, enzymatic cleavage, or
by some other process (Bundgaard, Hans, "Design and Application of
Prodrugs" in Textbook of Drug Design and Development (1991), P.
Krogsgaard-Larsen and H. Bundgaard, Eds. Harwood Academic
Publishers, pp. 113-191). Enzymes which are capable of an enzymatic
activation mechanism with the phosphonate prodrug compounds of the
invention include, but are not limited to, amidases, esterases,
microbial enzymes, phospholipases, cholinesterases, and phosphases.
Prodrug moieties can serve to enhance solubility, absorption and
lipophilicity to optimize drug delivery, bioavailability and
efficacy.
A prodrug moiety may include an active metabolite or drug
itself.
Exemplary prodrug moieties include the hydrolytically sensitive or
labile acyloxymethyl esters --CH.sub.2OC(.dbd.O)R.sup.30 and
acyloxymethyl carbonates CH.sub.2C(.dbd.O)OR.sup.30 where R.sup.30
is C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 substituted alkyl,
C.sub.6-C.sub.20 aryl or C.sub.6-C.sub.20 substituted aryl. The
acyloxyalkyl ester was used as a prodrug strategy for carboxylic
acids and then applied to phosphates and phosphonates by Farquhar
et al (1983) J. Pharm. Sci. 72: 324; also U.S. Pat. Nos. 4,816,570,
4,968,788, 5663159 and 5792756. In certain compounds of the
invention, a prodrug moiety is part of a phosphate group. The
acyloxyalkyl ester may be used to deliver phosphoric acids across
cell membranes and to enhance oral bioavailability. A close variant
of the acyloxyalkyl ester, the alkoxycarbonyloxyalkyl ester
(carbonate), may also enhance oral bioavailability as a prodrug
moiety in the compounds of the combinations of the invention. An
exemplary acyloxymethyl ester is pivaloyloxymethoxy, (POM)
--CH.sub.2C(.dbd.O)C(CH.sub.3).sub.3. An exemplary acyloxymethyl
carbonate prodrug moiety is pivaloyloxymethylcarbonate (POC)
--CH.sub.2C(.dbd.O)OC(CH.sub.3).sub.3.
The phosphate group may be a phosphate prodrug moiety. The prodrug
moiety may be sensitive to hydrolysis, such as, but not limited to
those comprising a pivaloyloxymethyl carbonate (POC) or POM group.
Alternatively, the prodrug moiety may be sensitive to enzymatic
potentiated cleavage, such as a lactate ester or a
phosphonamidate-ester group.
Aryl esters of phosphorus groups, especially phenyl esters, are
reported to enhance oral bioavailability (DeLambert et al (1994) J.
Med. Chem. 37: 498). Phenyl esters containing a carboxylic ester
ortho to the phosphate have also been described (Khamnei and
Torrence, (1996) J. Med. Chem. 39:4109-4115). Benzyl esters are
reported to generate the parent phosphonic acid. In some cases,
substituents at the ortho- or para-position may accelerate the
hydrolysis. Benzyl analogs with an acylated phenol or an alkylated
phenol may generate the phenolic compound through the action of
enzymes, e.g. esterases, oxidases, etc., which in turn undergoes
cleavage at the benzylic C--O bond to generate the phosphoric acid
and the quinone methide intermediate. Examples of this class of
prodrugs are described by Mitchell et al (1992) J. Chem. Soc.
Perkin Trans. I2345; Brook et al WO 91/19721. Still other benzylic
prodrugs have been described containing a carboxylic
ester-containing group attached to the benzylic methylene (Glazier
et al WO 91/19721). Thio-containing prodrugs are reported to be
useful for the intracellular delivery of phosphonate drugs. These
proesters contain an ethylthio group in which the thiol group is
either esterified with an acyl group or combined with another thiol
group to form a disulfide. Deesterification or reduction of the
disulfide generates the free thio intermediate which subsequently
breaks down to the phosphoric acid and episulfide (Puech et al
(1993) Antiviral Res., 22: 155-174; Benzaria et al (1996) J. Med.
Chem. 39: 4958). Cyclic phosphonate esters have also been described
as prodrugs of phosphorus-containing compounds (Erion et al, U.S.
Pat. No. 6,312,662).
It is to be noted that all enantiomers, diastereomers, and racemic
mixtures, tautomers, polymorphs, pseudopolymorphs of compounds
within the scope of Formula I, Formula II, or Formula III and
pharmaceutically acceptable salts thereof are embraced by the
present invention. All mixtures of such enantiomers and
diastereomers are within the scope of the present invention.
A compound of Formula I-III and its pharmaceutically acceptable
salts may exist as different polymorphs or pseudopolymorphs. As
used herein, crystalline polymorphism means the ability of a
crystalline compound to exist in different crystal structures. The
crystalline polymorphism may result from differences in crystal
packing (packing polymorphism) or differences in packing between
different conformers of the same molecule (conformational
polymorphism). As used herein, crystalline pseudopolymorphism means
the ability of a hydrate or solvate of a compound to exist in
different crystal structures. The pseudopolymorphs of the instant
invention may exist due to differences in crystal packing (packing
pseudopolymorphism) or due to differences in packing between
different conformers of the same molecule (conformational
pseudopolymorphism). The instant invention comprises all polymorphs
and pseudopolymorphs of the compounds of Formula I-III and their
pharmaceutically acceptable salts.
A compound of Formula I-III and its pharmaceutically acceptable
salts may also exist as an amorphous solid. As used herein, an
amorphous solid is a solid in which there is no long-range order of
the positions of the atoms in the solid. This definition applies as
well when the crystal size is two nanometers or less. Additives,
including solvents, may be used to create the amorphous forms of
the instant invention. The instant invention comprises all
amorphous forms of the compounds of Formula I-III and their
pharmaceutically acceptable salts.
Selected substituents comprising the compounds of Formula I-III are
present to a recursive degree. In this context, "recursive
substituent" means that a substituent may recite another instance
of itself. Because of the recursive nature of such substituents,
theoretically, a large number of compounds may be present in any
given embodiment. For example, R.sup.x comprises a R.sup.y
substituent. R.sup.y can be R. R can be W.sup.3. W.sup.3 can be
W.sup.4 and W.sup.4 can be R or comprise substituents comprising
R.sup.y. One of ordinary skill in the art of medicinal chemistry
understands that the total number of such substituents is
reasonably limited by the desired properties of the compound
intended. Such properties include, by way of example and not
limitation, physical properties such as molecular weight,
solubility or log P, application properties such as activity
against the intended target, and practical properties such as ease
of synthesis.
By way of example and not limitation, W.sup.3 and R.sup.y are
recursive substituents in certain embodiments. Typically, each
recursive substituent can independently occur 20, 19, 18, 17, 16,
15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, 1, or 0, times in a
given embodiment. More typically, each recursive substituent can
independently occur 12 or fewer times in a given embodiment. Even
more typically, each recursive substituent can independently occur
3 or fewer times in a given embodiment. For example, W.sup.3 will
occur 0 to 8 times, R.sup.y will occur 0 to 6 times in a given
embodiment. Even more typically, W.sup.3 will occur 0 to 6 times
and R.sup.y will occur 0 to 4 times in a given embodiment.
Recursive substituents are an intended aspect of the invention. One
of ordinary skill in the art of medicinal chemistry understands the
versatility of such substituents. To the degree that recursive
substituents are present in an embodiment of the invention, the
total number will be determined as set forth above.
The modifier "about" used in connection with a quantity is
inclusive of the stated value and has the meaning dictated by the
context (e.g., includes the degree of error associated with
measurement of the particular quantity).
The compounds of the Formula I-III may comprise a phosphate group
as R.sup.7, which may be a prodrug moiety
##STR00035## wherein each Y or Y.sup.1 is, independently, O, S, NR,
.sup.+N(O)(R), N(OR), .sup.+N(O)(OR), or N--NR.sub.2; W.sup.1 and
W.sup.2, when taken together, are
--Y.sup.3(C(R.sup.y).sub.2).sub.3Y.sup.3--; or one of W.sup.1 or
W.sup.2 together with either R.sup.3 or R.sup.4 is --Y.sup.3-- and
the other of W.sup.1 or W.sup.2 is Formula Ia; or W.sup.1 and
W.sup.2 are each, independently, a group of Formula Ia:
##STR00036##
wherein:
each Y.sup.2 is independently a bond, O, CR.sub.2, NR,
.sup.+N(O)(R), N(OR), .sup.+N(O)(OR), N--NR.sub.2, S, S--S, S(O),
or S(O).sub.2;
each Y.sup.3 is independently O, S, or NR;
M2 is 0, 1 or 2;
each R.sup.y is independently H, F, Cl, Br, I, OH, R,
--C(Y.sup.1)R, --C(.dbd.Y.sup.1)OR, --C(.dbd.Y.sup.1)N(R).sub.2,
--N(R).sub.2, --.sup.+N(R).sub.3, --SR, --S(O)R, --S(O).sub.2R,
--S(O)(OR), --S(O).sub.2(OR), --OC(.dbd.Y.sup.1)R,
--OC(.dbd.Y.sup.1)OR, --OC(.dbd.Y.sup.1)(N(R).sub.2),
--SC(.dbd.Y.sup.1)R, --SC(.dbd.Y.sup.1)OR,
--SC(.dbd.Y.sup.1)(N(R).sub.2), --N(R)C(.dbd.Y.sup.1)R,
--N(R)C(.dbd.Y.sup.1)OR, or --N(R)C(.dbd.Y.sup.1)N(R).sub.2,
--SO.sub.2--NR.sub.2, --CN, --N.sub.3, --NO.sub.2, --OR, a
protecting group or W.sup.3; or when taken together, two R.sup.y on
the same carbon atom form a carbocyclic ring of 3 to 7 carbon
atoms;
each R.sup.x is independently R.sup.y, a protecting group, or the
formula:
##STR00037##
wherein:
M1a, M1c, and M1d are independently 0 or 1;
M12c is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12;
each R is H, halogen, (C.sub.1-C.sub.8) alkyl, (C.sub.1-C.sub.8)
substituted alkyl, (C.sub.2-C.sub.8) alkenyl, (C.sub.2-C.sub.8)
substituted alkenyl, (C.sub.2-C.sub.8) alkynyl, (C.sub.2-C.sub.8)
substituted alkynyl, C.sub.6-C.sub.20 aryl, C.sub.6-C.sub.20
substituted aryl, C.sub.2-C.sub.20 heterocycle, C.sub.2-C.sub.20
substituted heterocyclyl, arylalkyl, substituted arylalkyl or a
protecting group;
W.sup.3 is W.sup.4 or W.sup.5; W.sup.4 is R, --C(Y.sup.1)R.sup.y,
--C(Y.sup.1)W.sup.5, --SO.sub.2R.sup.y, or --SO.sub.2W.sup.5; and
W.sup.5 is a carbocycle or a heterocycle wherein W.sup.5 is
independently substituted with 0 to 3 R.sup.y groups.
W.sup.5 carbocycles and W.sup.5 heterocycles may be independently
substituted with 0 to 3 R.sup.y groups. W.sup.5 may be a saturated,
unsaturated or aromatic ring comprising a mono- or bicyclic
carbocycle or heterocycle. W.sup.5 may have 3 to 10 ring atoms,
e.g., 3 to 7 ring atoms. The W.sup.5 rings are saturated when
containing 3 ring atoms, saturated or mono-unsaturated when
containing 4 ring atoms, saturated, or mono- or di-unsaturated when
containing 5 ring atoms, and saturated, mono- or di-unsaturated, or
aromatic when containing 6 ring atoms.
A W.sup.5 heterocycle may be a monocycle having 3 to 7 ring members
(2 to 6 carbon atoms and 1 to 3 heteroatoms selected from N, O, P,
and S) or a bicycle having 7 to 10 ring members (4 to 9 carbon
atoms and 1 to 3 heteroatoms selected from N, O, P, and S). W.sup.5
heterocyclic monocycles may have 3 to 6 ring atoms (2 to 5 carbon
atoms and 1 to 2 heteroatoms selected from N, O, and S); or 5 or 6
ring atoms (3 to 5 carbon atoms and 1 to 2 heteroatoms selected
from N and S). W.sup.5 heterocyclic bicycles have 7 to 10 ring
atoms (6 to 9 carbon atoms and 1 to 2 heteroatoms selected from N,
O, and S) arranged as a bicyclo[4,5], [5,5], [5,6], or [6,6]
system; or 9 to 10 ring atoms (8 to 9 carbon atoms and 1 to 2
hetero atoms selected from N and S) arranged as a bicyclo[5,6] or
[6,6] system. The W.sup.5 heterocycle may be bonded to Y.sup.2
through a carbon, nitrogen, sulfur or other atom by a stable
covalent bond.
W.sup.5 heterocycles include for example, pyridyl, dihydropyridyl
isomers, piperidine, pyridazinyl, pyrimidinyl, pyrazinyl,
s-triazinyl, oxazolyl, imidazolyl, thiazolyl, isoxazolyl,
pyrazolyl, isothiazolyl, furanyl, thiofuranyl, thienyl, and
pyrrolyl. W.sup.5 also includes, but is not limited to, examples
such as:
##STR00038##
W.sup.5 carbocycles and heterocycles may be independently
substituted with 0 to 3 R groups, as defined above. For example,
substituted W.sup.5 carbocycles include:
##STR00039##
Examples of substituted phenyl carbocycles include:
##STR00040##
Embodiments of
##STR00041## of Formula I-III compounds include substructures such
as:
##STR00042## wherein each Y.sup.2b is, independently, O or N(R). In
a preferred aspect of this embodiment, each Y.sup.2b is O and each
R.sup.x is independently:
##STR00043## wherein M12c is 1, 2 or 3 and each Y.sup.2 is
independently a bond, O, CR.sub.2, or S. In another preferred
aspect of this embodiment, one Y.sup.2b--R.sup.x is NH(R) and the
other Y.sup.2b--R.sup.x is O--R.sup.x wherein R.sup.x is:
##STR00044## wherein M12c is 2. In another preferred aspect of this
embodiment, each Y.sup.2b is O and each R.sup.x is
independently:
##STR00045## wherein M12c is 2. In another preferred aspect of this
embodiment, each Y.sup.2b is O and each R.sup.x is
independently:
##STR00046## wherein M12c is 1 and Y.sup.2 is a bond, O, or
CR.sub.2.
Other embodiments of
##STR00047## Formulas I-III compounds include substructures such
as:
##STR00048## wherein each Y.sup.3 is, independently, O or N(R). In
a preferred aspect of this embodiment, each Y.sup.3 is O. In
another preferred aspect of this embodiment, the substructure
is:
##STR00049## wherein R.sup.y is W.sup.5 as defined herein.
Another embodiment of
##STR00050## of Formula I-III includes the substructures:
##STR00051## wherein each Y.sup.2c is, independently, O, N(R.sup.y)
or S.
Another embodiment of
##STR00052## of Formula I-III compounds includes the substructures
wherein one of W.sup.1 or W.sup.2 together with either R.sup.3 or
R.sup.4 is --Y.sup.3-- and the other of W.sup.1 or W.sup.2 is
Formula Ia. Such an embodiment is represented by a compound of
Formula Ib selected from:
##STR00053## In a preferred aspect of the embodiment of Formula Ib,
each Y and Y.sup.3 is O. In another preferred aspect of the
embodiment of Formula Ib, W.sup.1 or W.sup.2 is Y.sup.2b--R.sup.x;
each Y, Y.sup.3 and Y.sup.2b is O and R.sup.x is:
##STR00054## wherein M12c is 1, 2 or 3 and each Y.sup.2 is
independently a bond, O, CR.sub.2, or S. In another preferred
aspect of the embodiment of Formula Ib, W.sup.1 or W.sup.2 is
Y.sup.2b--R.sup.x; each Y, Y.sup.3 and Y.sup.2b is O and R.sup.x
is:
##STR00055## wherein M12c is 2. In another preferred aspect of the
embodiment of Formula Ib, W.sup.1 or W.sup.2 is Y.sup.2b--R.sup.X;
R.sup.x; each Y, Y.sup.3 and Y.sup.2b is O and R.sup.x is:
##STR00056## wherein M12c is 1 and Y.sup.2 is a bond, O, or
CR.sub.2.
Another embodiment of
##STR00057## of Formula I-III compounds includes a
substructure:
##STR00058## wherein W.sup.5 is a carbocycle such as phenyl or
substituted phenyl. In another aspect of this embodiment, the
substructure is:
##STR00059## wherein Y.sup.2b is O or N(R) and the phenyl
carbocycle is substituted with 0 to 3 R groups. In another aspect
of this embodiment of the substructure, R.sup.x is:
##STR00060## wherein M12c is 1, 2 or 3 and each Y.sup.2 is
independently a bond, O, CR.sub.2, or S.
Another embodiment of
##STR00061## of Formula I-III includes substructures:
##STR00062## The chiral carbon of the amino acid and lactate
moieties may be either the R or S configuration or the racemic
mixture.
Another embodiment of
##STR00063## Formula I-III is substructure
##STR00064## wherein each Y.sup.2 is, independently, --O-- or
--NH--. In another preferred aspect of this embodiment, R.sup.y is
(C.sub.1-C.sub.8) alkyl, (C.sub.1-C.sub.8) substituted alkyl,
(C.sub.2-C.sub.8) alkenyl, (C.sub.2-C.sub.8) substituted alkenyl,
(C.sub.2-C.sub.3) alkynyl or (C.sub.2-C.sub.8) substituted alkynyl.
In another preferred aspect of this embodiment, R.sup.y is
(C.sub.1-C.sub.8) alkyl, (C.sub.1-C.sub.8) substituted alkyl,
(C.sub.2-C.sub.8) alkenyl, (C.sub.2-C.sub.8) substituted alkenyl,
(C.sub.2-C.sub.8) alkynyl or (C.sub.2-C.sub.8) substituted alkynyl;
and R is CH.sub.3. In another preferred aspect of this embodiment,
R.sup.y is (C.sub.1-C.sub.8) alkyl, (C.sub.1-C.sub.8) substituted
alkyl, (C.sub.2-C.sub.8) alkenyl, (C.sub.2-C.sub.8) substituted
alkenyl, (C.sub.2-C.sub.8) alkynyl or (C.sub.2-C.sub.8) substituted
alkynyl; R is CH.sub.3; and each Y.sup.2 is NH--. In a preferred
aspect of this embodiment, W.sup.1 and W.sup.2 are, independently,
nitrogen-linked, naturally occurring amino acids or naturally
occurring amino acid esters. In another preferred aspect of this
embodiment, W.sup.1 and W.sup.2 are, independently,
naturally-occurring 2-hydroxy carboxylic acids or
naturally-occurring 2-hydroxy carboxylic acid esters wherein the
acid or ester is linked to P through the 2-hydroxy group.
Another embodiment of
##STR00065## of Formula I, Formula II, or Formula III is
substructure:
##STR00066## In one preferred aspect of this embodiment, each
R.sup.x is, independently, (C.sub.1-C.sub.8) alkyl. In another
preferred aspect of this embodiment, each R.sup.x is,
independently, C.sub.6-C.sub.20 aryl or C.sub.6-C.sub.20
substituted aryl.
Another embodiment of
##STR00067## of Formulas I-III is substructure
##STR00068## wherein W.sup.1 and W.sup.2 are independently selected
from one of the formulas in Tables 20.1-20.37 and Table 30.1 below.
The variables used in Tables 20.1-20.37 (e.g., W.sup.23, R.sup.21,
etc.) pertain only to Tables 20.1-20.37, unless otherwise
indicated.
The variables used in Tables 20.1 to 20.37 have the following
definitions:
each R.sup.21 is independently H or (C.sub.1-C.sub.8)alkyl;
each R.sup.22 is independently H, R.sup.21, R.sup.23 or R.sup.24
wherein each R.sup.24 is independently substituted with 0 to 3
R.sup.23;
each R.sup.23 is independently R.sup.23a, R.sup.23b, R.sup.23c or
R.sup.23d, provided that when R.sup.23 is bound to a heteroatom,
then R.sup.23 is R.sup.23c or R.sup.23d;
each R.sup.23a is independently F, Cl, Br, I, --CN, N.sub.3 or
--NO.sub.2;
each R.sup.23b is independently Y.sup.21;
each R.sup.23c is independently --R.sup.2x,
--N(R.sup.2x)(R.sup.2x), --SR.sup.2x, --S(O)R.sup.2x,
--S(O).sub.2R.sup.2x, --S(O)(OR.sup.2x), --S(O).sub.2(OR.sup.2x),
--OC(.dbd.Y.sup.21)R.sup.2x, --OC(.dbd.Y.sup.21)OR.sup.2x,
--OC(.dbd.Y.sup.21)(N(R.sup.2x)(R.sup.2x)),
--SC(.dbd.Y.sup.21)R.sup.2x, --SC(.dbd.Y.sup.21)OR.sup.2x,
--SC(.dbd.Y.sup.21)(N(R.sup.2x)(R.sup.2x)),
--N(R.sup.2x)C(.dbd.Y.sup.21)R.sup.2x,
--N(R.sup.2x)C(.dbd.Y.sup.21)OR.sup.2x, or
--N(R.sup.2x)C(.dbd.Y.sup.21)(N(R.sup.2x)(R.sup.2x));
each R.sup.23d is independently --C(.dbd.Y.sup.21)R.sup.2x,
--C(.dbd.Y.sup.21)OR.sup.2x or
--C(.dbd.Y.sup.21)(N(R.sup.2x)(R.sup.2x));
each R.sup.2x is independently H, (C.sub.1-C.sub.8)alkyl,
(C.sub.2-C.sub.8)alkenyl, (C.sub.2-C.sub.8)alkynyl, aryl,
heteroaryl; or two R.sup.2x taken together with a nitrogen to which
they are both attached form a 3 to 7 membered heterocyclic ring
wherein any one carbon atom of said heterocyclic ring can
optionally be replaced with --O--, --S-- or NR.sup.21--; and
wherein one or more of the non-terminal carbon atoms of each said
(C.sub.1-C.sub.8)alkyl may be optionally replaced with --O--, --S--
or NR.sup.21--;
each R.sup.24 is independently (C.sub.1-C.sub.8)alkyl,
(C.sub.2-C.sub.8)alkenyl, or (C.sub.2-C.sub.8)alkynyl;
each R.sup.25 is independently R.sup.24 wherein each R.sup.24 is
substituted with 0 to 3 R.sup.23 groups;
each R.sup.25a is independently (C.sub.1-C.sub.8)alkylene,
(C.sub.2-C.sub.8)alkenylene, or (C.sub.2-C.sub.8)alkynylene any one
of which said (C.sub.1-C.sub.8)alkylene,
(C.sub.2-C.sub.8)alkenylene, or (C.sub.2-C.sub.8)alkynylene is
substituted with 0-3 R.sup.23 groups;
each W.sup.23 is independently W.sup.24 or W.sup.25;
each W.sup.24 is independently R.sup.25,
--C(.dbd.Y.sup.21)R.sup.25, --C(.dbd.Y.sup.21)W.sup.25,
--SO.sub.2R.sup.25, or --SO.sub.2W.sup.25;
each W.sup.25 is independently carbocycle or heterocycle wherein
W.sup.25 is independently substituted with 0 to 3 R.sup.22 groups;
and
each Y.sup.21 is independently O or S.
TABLE-US-00006 TABLE 20.1 ##STR00069## 1 ##STR00070## 2
##STR00071## 3 ##STR00072## 4 ##STR00073## 5 ##STR00074## 6
##STR00075## 7 ##STR00076## 8
TABLE-US-00007 TABLE 20.2 ##STR00077## 9 ##STR00078## 10
##STR00079## 11
TABLE-US-00008 TABLE 20.3 ##STR00080## 12 ##STR00081## 13
##STR00082## 14 ##STR00083## 15 ##STR00084## 16 ##STR00085## 17
##STR00086## 18 ##STR00087## 19
TABLE-US-00009 TABLE 20.4 ##STR00088## 20 ##STR00089## 21
##STR00090## 22
TABLE-US-00010 TABLE 20.5 ##STR00091## 23 ##STR00092## 24
##STR00093## 25 ##STR00094## 26 ##STR00095## 27 ##STR00096## 28
##STR00097## 29 ##STR00098## 30
TABLE-US-00011 TABLE 20.6 ##STR00099## 31 ##STR00100## 32
##STR00101## 33
TABLE-US-00012 TABLE 20.7 ##STR00102## 34 ##STR00103## 35
##STR00104## 36 ##STR00105## 37 ##STR00106## 38 ##STR00107## 39
##STR00108## 40 ##STR00109## 41
TABLE-US-00013 TABLE 20.8 ##STR00110## 42 ##STR00111## 43
##STR00112## 44 ##STR00113## 45 ##STR00114## 46 ##STR00115## 47
##STR00116## 48 ##STR00117## 49
TABLE-US-00014 TABLE 20.9 ##STR00118## 50 ##STR00119## 51
##STR00120## 52 ##STR00121## 53 ##STR00122## 54 ##STR00123## 55
##STR00124## 56 ##STR00125## 57
TABLE-US-00015 TABLE 20.10 ##STR00126## 58 ##STR00127## 59
##STR00128## 60
TABLE-US-00016 TABLE 20.11 ##STR00129## 61 ##STR00130## 62
##STR00131## 63 ##STR00132## 64 ##STR00133## 65 ##STR00134## 66
##STR00135## 67 ##STR00136## 68
TABLE-US-00017 TABLE 20.12 ##STR00137## 69 ##STR00138## 70
##STR00139## 71
TABLE-US-00018 TABLE 20.13 ##STR00140## 72 ##STR00141## 73
##STR00142## 74 ##STR00143## 75 ##STR00144## 76 ##STR00145## 77
##STR00146## 78 ##STR00147## 79
TABLE-US-00019 TABLE 20.14 ##STR00148## 80 ##STR00149## 81
##STR00150## 82
TABLE-US-00020 TABLE 20.15 ##STR00151## 83 ##STR00152## 84
##STR00153## 85 ##STR00154## 86 ##STR00155## 87 ##STR00156## 88
##STR00157## 89 ##STR00158## 90
TABLE-US-00021 TABLE 20.16 ##STR00159## 91 ##STR00160## 92
##STR00161## 93 ##STR00162## 94 ##STR00163## 95 ##STR00164## 96
##STR00165## 97 ##STR00166## 98
TABLE-US-00022 TABLE 20.17 ##STR00167## 99 ##STR00168## 100
##STR00169## 101 ##STR00170## 102 ##STR00171## 103 ##STR00172## 104
##STR00173## 105 ##STR00174## 106
TABLE-US-00023 TABLE 20.18 ##STR00175## 107 ##STR00176## 108
##STR00177## 109
TABLE-US-00024 TABLE 20.19 ##STR00178## 110 ##STR00179## 111
##STR00180## 112 ##STR00181## 113 ##STR00182## 114 ##STR00183## 115
##STR00184## 116 ##STR00185## 117
TABLE-US-00025 TABLE 20.20 ##STR00186## 118 ##STR00187## 119
##STR00188## 120
TABLE-US-00026 TABLE 20.21 ##STR00189## 121 ##STR00190## 122
##STR00191## 123 ##STR00192## 124 ##STR00193## 125 ##STR00194## 126
##STR00195## 127 ##STR00196## 128
TABLE-US-00027 TABLE 20.22 ##STR00197## 129 ##STR00198## 130
##STR00199## 131
TABLE-US-00028 TABLE 20.23 ##STR00200## 132 ##STR00201## 133
##STR00202## 134 ##STR00203## 135 ##STR00204## 136 ##STR00205## 137
##STR00206## 138 ##STR00207## 139
TABLE-US-00029 TABLE 20.24 ##STR00208## 140 ##STR00209## 141
##STR00210## 142 ##STR00211## 143 ##STR00212## 144 ##STR00213## 145
##STR00214## 146 ##STR00215## 147
TABLE-US-00030 TABLE 20.25 ##STR00216## 148 ##STR00217## 149
##STR00218## 150 ##STR00219## 151 ##STR00220## 152 ##STR00221## 153
##STR00222## 154 ##STR00223## 155 ##STR00224## 156 ##STR00225## 157
##STR00226## 158 ##STR00227## 159
TABLE-US-00031 TABLE 20.26 ##STR00228## 160 ##STR00229## 161
##STR00230## 162 ##STR00231## 163 ##STR00232## 164 ##STR00233## 165
##STR00234## 166 ##STR00235## 167 ##STR00236## 168 ##STR00237## 169
##STR00238## 170 ##STR00239## 171
TABLE-US-00032 TABLE 20.27 ##STR00240## 172 ##STR00241## 173
##STR00242## 174 ##STR00243## 175 ##STR00244## 176 ##STR00245## 177
##STR00246## 178 ##STR00247## 179
TABLE-US-00033 TABLE 20.28 ##STR00248## 180 ##STR00249## 181
##STR00250## 182 ##STR00251## 183 ##STR00252## 184 ##STR00253##
185
TABLE-US-00034 TABLE 20.29 ##STR00254## 186 ##STR00255## 187
##STR00256## 188 ##STR00257## 189 ##STR00258## 190 ##STR00259## 191
##STR00260## 192 ##STR00261## 193
TABLE-US-00035 TABLE 20.30 ##STR00262## 194 ##STR00263## 195
##STR00264## 196 ##STR00265## 197 ##STR00266## 198 ##STR00267##
199
TABLE-US-00036 TABLE 20.31 ##STR00268## 200 ##STR00269## 201
##STR00270## 202 ##STR00271## 203 ##STR00272## 204 ##STR00273## 205
##STR00274## 206 ##STR00275## 207
TABLE-US-00037 TABLE 20.32 ##STR00276## 208 ##STR00277## 209
##STR00278## 210 ##STR00279## 211 ##STR00280## 212 ##STR00281##
213
TABLE-US-00038 TABLE 20.33 ##STR00282## 214 ##STR00283## 215
##STR00284## 216 ##STR00285## 217 ##STR00286## 218 ##STR00287## 219
##STR00288## 220 ##STR00289## 221
TABLE-US-00039 TABLE 20.34 ##STR00290## 222 ##STR00291## 223
##STR00292## 224 ##STR00293## 225 ##STR00294## 226 ##STR00295##
227
TABLE-US-00040 TABLE 20.35 ##STR00296## 228 ##STR00297## 229
##STR00298## 230 ##STR00299## 231 ##STR00300## 232 ##STR00301## 233
##STR00302## 234 ##STR00303## 235
TABLE-US-00041 TABLE 20.36 ##STR00304## 236 ##STR00305## 237
##STR00306## 238 ##STR00307## 239 ##STR00308## 240 ##STR00309## 241
##STR00310## 242 ##STR00311## 243
TABLE-US-00042 TABLE 20.37 ##STR00312## 244 ##STR00313## 245
##STR00314## 246 ##STR00315## 247
TABLE-US-00043 TABLE 30.1 ##STR00316## 67 ##STR00317## 68
##STR00318## 69 ##STR00319## 70 ##STR00320## 71 ##STR00321## 258
##STR00322## 248 ##STR00323## 249 ##STR00324## 250 ##STR00325## 251
##STR00326## 252 ##STR00327## 253 ##STR00328## 254 ##STR00329## 255
##STR00330## 256 ##STR00331## 257
Phosphate Embodiments of Compounds of Formula I-IV
By way of example and not limitation, the phosphate embodiments of
Formula I-IV may be represented by the general formula "MBF":
##STR00332## Each embodiment of MBF is depicted as a substituted
nucleus (Sc). Sc is described in formulae A-G of Table 1.1 below,
wherein Sc is a generic formula for a compound of Formula I,
Formula II, or Formula III and the point of attachment to
--P(O)Pd.sup.1Pd.sup.2 is indicated with a wavy line.
TABLE-US-00044 TABLE 1.1 ##STR00333## A ##STR00334## B ##STR00335##
C ##STR00336## D ##STR00337## E ##STR00338## F ##STR00339## G
Combinations of "Sc" and Pd.sup.1 and Pd.sup.2, independently
selected from Table 30.1, can be expressed in the form of
Sc.Pd.sup.1.Pd.sup.2, where Sc is represented by the respective
letter A-G from Table 1.1 and Pd.sup.1 and Pd.sup.2 are represented
by the respective number from Table 30.1. Thus, A.256.256
represents the following compound:
##STR00340## Thereby, Table 7 lists many specific examples of
phosphate prodrugs of Formula I-IV. Table 7: List of Compounds of
MBF A.254.67, A.254.68, A.254.69, A.254.70, A.254.71, A.254.258,
A.254.248, A.254.249, A.254.250, A.254.251, A.254.252, A.254.253,
B.254.67, B.254.68, B.254.69, B.254.70, B.254.71, B.254.258,
B.254.248, B.254.249, B.254.250, B.254.251, B.254.252, B.254.253,
C.254.67, C.254.68, C.254.69, C.254.70, C.254.71, C.254.258,
C.254.248, C.254.249, C.254.250, C.254.251, C.254.252, C.254.253,
D.254.67, D.254.68, D.254.69, D.254.70, D.254.71, D.254.258,
D.254.248, D.254.249, D.254.250, D.254.251, D.254.252, D.254.253,
E.254.67, E.254.68, E.254.69, E.254.70, E.254.71, E.254.258,
E.254.248, E.254.249, E.254.250, E.254.251, E.254.252, E.254.253,
F.254.67, F.254.68, F.254.69, F.254.70, F.254.71, F.254.258,
F.254.248, F.254.249, F.254.250, F.254.251, F.254.252, F.254.253,
G.254.67, G.254.68, G.254.69, G.254.70, G.254.71, G.254.258,
G.254.248, G.254.249, G.254.250, G.254.251, G.254.252, G.254.253,
A.255.67, A.255.68, A.255.69, A.255.70, A.255.71, A.255.258,
A.255.248, A.255.249, A.255.250, A.255.251, A.255.252, A.255.253,
B.255.67, B.255.68, B.255.69, B.255.70, B.255.71, B.255.258,
B.255.248, B.255.249, B.255.250, B.255.251, B.255.252, B.255.253,
C.255.67, C.255.68, C.255.69, C.255.70, C.255.71, C.255.258,
C.255.248, C.255.249, C.255.250, C.255.251, C.255.252, C.255.253,
D.255.67, D.255.68, D.255.69, D.255.70, D.255.71, D.255.258,
D.255.248, D.255.249, D.255.250, D.255.251, D.255.252, D.255.253,
E.255.67, E.255.68, E.255.69, E.255.70, E.255.71, E.255.258,
E.255.248, E.255.249, E.255.250, E255.251, E.255.252, E.255.253,
F.255.67, F.255.68, F.255.69, F.255.70, F.255.71, F.255.258,
F.255.248, F.255.249, F.255.250, F.255.251, F.255.252, F.255.253,
G.255.67, G.255.68, G.255.69, G.255.70, G.255.71, G.255.258,
G.255.248, G.255.249, G.255.250, G.255.251, G.255.252, G.255.253,
A.67.67, A.68.68, A.69.69, A.70.70, A.71.71, A.258.258, A.248.248,
A.249.249, A.250.250, A.251.251, A252.252, A.253.253, B.67.67,
B.68.68, B.69.69, B.70.70, B.71.71, B.258.258, B.248.248,
B.249.249, B.250.250, B.251.251, B252.252, B.253.253, C.67.67,
C.68.68, C.69.69, C.70.70, C.71.71, C.258.258, C.248.248,
C.249.249, C.250.250, C.251.251, C252.252, C.253.253, D.67.67,
D.68.68, D.69.69, D.70.70, D.71.71, D.258.258, D.248.248,
D.249.249, D.250.250, D.251.251, D252.252, D.253.253, E.67.67,
E.68.68, E.69.69, E.70.70, E.71.71, E.258.258, E.248.248,
E.249.249, E.250.250, E.251.251, E252.252, E.253.253, F.67.67,
F.68.68, F.69.69, F.70.70, F.71.71, F.258.258, F.248.248,
F.249.249, F.250.250, F.251.251, F252.252, F.253.253, G.67.67,
G.68.68, G.69.69, G.70.70, G.71.71, G.258.258, G.248.248,
G.249.249, G.250.250, G.251.251, G252.252, G.253.253, A.256.257,
B.256.257, C.256.257, D.256.257, E.256.257, F.256.257, G.256.257,
A.256.254, B.256.254, C.256.254, D.256.254, E.256.254, F.256.254,
G.256.254, A.256.250, B.256.250, C.256.250, D.256.250, E.256.250,
F.256.250, G.256.250, A.256.69, B.256.69, C.256.69, D.256.69,
E.256.69, F.256.69, G.256.69, A.256.71, B.256.71, C.256.71,
D.256.71, E.256.71, F.256.71, G.256.71, A.256.255, B.256.255,
C.256.255, D.256.255, E.256.255, F.256.255, G.256.255.
Embodiments of R.sup.x include esters, carbamates, carbonates,
thioesters, amides, thioamides, and urea groups:
##STR00341##
Any reference to the compounds of the invention described herein
also includes a reference to a physiologically acceptable salt
thereof. Examples of physiologically acceptable salts of the
compounds of the invention include salts derived from an
appropriate base, such as an alkali metal or an alkaline earth (for
example, Na.sup.+, Li.sup.+, K.sup.+, Ca.sup.+2 and Mg.sup.+2),
ammonium and NR.sub.4.sup.+ (wherein R is defined herein).
Physiologically acceptable salts of a nitrogen atom or an amino
group include (a) acid addition salts formed with inorganic acids,
for example, hydrochloric acid, hydrobromic acid, sulfuric acid,
sulfamic acids, phosphoric acid, nitric acid and the like; (b)
salts formed with organic acids such as, for example, acetic acid,
oxalic acid, tartaric acid, succinic acid, maleic acid, fumaric
acid, gluconic acid, citric acid, malic acid, ascorbic acid,
benzoic acid, isethionic acid, lactobionic acid, tannic acid,
palmitic acid, alginic acid, polyglutamic acid, naphthalenesulfonic
acid, methanesulfonic acid, p-toluenesulfonic acid, benzenesulfonic
acid, naphthalenedisulfonic acid, polygalacturonic acid, malonic
acid, sulfosalicylic acid, glycolic acid, 2-hydroxy-3-naphthoate,
pamoate, salicylic acid, stearic acid, phthalic acid, mandelic
acid, lactic acid, ethanesulfonic acid, lysine, arginine, glutamic
acid, glycine, serine, threonine, alanine, isoleucine, leucine and
the like; and (c) salts formed from elemental anions for example,
chlorine, bromine, and iodine. Physiologically acceptable salts of
a compound of a hydroxy group include the anion of said compound in
combination with a suitable cation such as Na.sup.+ and
NR.sub.4.sup.+.
For therapeutic use, salts of active ingredients of the compounds
of the invention will be physiologically acceptable, i.e. they will
be salts derived from a physiologically acceptable acid or base.
However, salts of acids or bases which are not physiologically
acceptable may also find use, for example, in the preparation or
purification of a physiologically acceptable compound. All salts,
whether or not derived form a physiologically acceptable acid or
base, are within the scope of the present invention.
Finally, it is to be understood that the compositions herein
comprise compounds of the invention in their un-ionized, as well as
zwitterionic form, and combinations with stoichiometric amounts of
water as in hydrates.
The compounds of the invention, exemplified by Formula I-III may
have chiral centers, e.g. chiral carbon or phosphorus atoms. The
compounds of the invention thus include racemic mixtures of all
stereoisomers, including enantiomers, diastereomers, and
atropisomers. In addition, the compounds of the invention include
enriched or resolved optical isomers at any or all asymmetric,
chiral atoms. In other words, the chiral centers apparent from the
depictions are provided as the chiral isomers or racemic mixtures.
Both racemic and diastereomeric mixtures, as well as the individual
optical isomers isolated or synthesized, substantially free of
their enantiomeric or diastereomeric partners, are all within the
scope of the invention. The racemic mixtures are separated into
their individual, substantially optically pure isomers through
well-known techniques such as, for example, the separation of
diastereomeric salts formed with optically active adjuncts, e.g.,
acids or bases followed by conversion back to the optically active
substances. In most instances, the desired optical isomer is
synthesized by means of stereospecific reactions, beginning with
the appropriate stereoisomer of the desired starting material.
The term "chiral" refers to molecules which have the property of
non-superimposability of the mirror image partner, while the term
"achiral" refers to molecules which are superimposable on their
mirror image partner.
The term "stereoisomers" refers to compounds which have identical
chemical constitution, but differ with regard to the arrangement of
the atoms or groups in space.
"Diastereomer" refers to a stereoisomer with two or more centers of
chirality and whose molecules are not mirror images of one another.
Diastereomers have different physical properties, e.g. melting
points, boiling points, spectral properties, and reactivities.
Mixtures of diastereomers may separate under high resolution
analytical procedures such as electrophoresis and
chromatography.
"Enantiomers" refer to two stereoisomers of a compound which are
non-superimposable mirror images of one another.
Stereochemical definitions and conventions used herein generally
follow S. P. Parker, Ed., McGraw-Hill Dictionary of Chemical Terms
(1984) McGraw-Hill Book Company, New York; and Eliel, E. and Wilen,
S., Stereochemistry of Organic Compounds (1994) John Wiley &
Sons, Inc., New York. Many organic compounds exist in optically
active forms, i.e., they have the ability to rotate the plane of
plane-polarized light. In describing an optically active compound,
the prefixes D and L or R and S are used to denote the absolute
configuration of the molecule about its chiral center(s). The
prefixes d and 1, D and L, or (+) and (-) are employed to designate
the sign of rotation of plane-polarized light by the compound, with
S, (-), or 1 meaning that the compound is levorotatory while a
compound prefixed with R, (+), or d is dextrorotatory. For a given
chemical structure, these stereoisomers are identical except that
they are mirror images of one another. A specific stereoisomer may
also be referred to as an enantiomer, and a mixture of such isomers
is often called an enantiomeric mixture. A 50:50 mixture of
enantiomers is referred to as a racemic mixture ora racemate, which
may occur where there has been no stereoselection or
stereospecificity in a chemical reaction or process. The terms
"racemic mixture" and "racemate" refer to an equimolar mixture of
two enantiomeric species, devoid of optical activity.
Whenever a compound described herein is substituted with more than
one of the same designated group, e.g., "R" or "R.sup.1", then it
will be understood that the groups may be the same or different,
i.e., each group is independently selected. Wavy lines, , indicate
the site of covalent bond attachments to the adjoining
substructures, groups, moieties, or atoms.
The compounds of the invention can also exist as tautomeric isomers
in certain cases. Although only one delocalized resonance structure
may be depicted, all such forms are contemplated within the scope
of the invention. For example, ene-amine tautomers can exist for
purine, pyrimidine, imidazole, guanidine, amidine, and tetrazole
systems and all their possible tautomeric forms are within the
scope of the invention.
One skilled in the art will recognize that the
pyrrolo[1,2-f][1,2,4]triazine, imidazo[1,5-f][1,2,4]triazine,
imidazo[1,2-f][1,2,4]triazine, and
[1,2,4]triazolo[4,3-f][1,2,4]triazine nucleosides can exist in
tautomeric forms. For example, but not by way of limitation,
structures (a) and (b) can have equivalent tautomeric forms as
shown below:
##STR00342## All possible tautomeric forms of the heterocycles in
all of the embodiments disclosed herein are within the scope of the
invention. Methods of Inhibition of HCV Polymerase
Another aspect of the invention relates to methods of inhibiting
the activity of HCV polymerase comprising the step of treating a
sample suspected of containing HCV with a composition of the
invention.
Compositions of the invention may act as inhibitors of HCV
polymerase, as intermediates for such inhibitors or have other
utilities as described below. The inhibitors will bind to locations
on the surface or in a cavity of HCV polymerase having a geometry
unique to HCV polymerase. Compositions binding HCV polymerase may
bind with varying degrees of reversibility. Those compounds binding
substantially irreversibly are ideal candidates for use in this
method of the invention. Once labeled, the substantially
irreversibly binding compositions are useful as probes for the
detection of HCV polymerase. Accordingly, the invention relates to
methods of detecting HCV polymerase in a sample suspected of
containing HCV polymerase comprising the steps of: treating a
sample suspected of containing HCV polymerase with a composition
comprising a compound of the invention bound to a label; and
observing the effect of the sample on the activity of the label.
Suitable labels are well known in the diagnostics field and include
stable free radicals, fluorophores, radioisotopes, enzymes,
chemiluminescent groups and chromogens. The compounds herein are
labeled in conventional fashion using functional groups such as
hydroxyl, carboxyl, sulfhydryl or amino.
Within the context of the invention, samples suspected of
containing HCV polymerase include natural or man-made materials
such as living organisms; tissue or cell cultures; biological
samples such as biological material samples (blood, serum, urine,
cerebrospinal fluid, tears, sputum, saliva, tissue samples, and the
like); laboratory samples; food, water, or air samples; bioproduct
samples such as extracts of cells, particularly recombinant cells
synthesizing a desired glycoprotein; and the like. Typically the
sample will be suspected of containing an organism which produces
HCV polymerase, frequently a pathogenic organism such as HCV.
Samples can be contained in any medium including water and organic
solvent\water mixtures. Samples include living organisms such as
humans, and man made materials such as cell cultures.
The treating step of the invention comprises adding the composition
of the invention to the sample or it comprises adding a precursor
of the composition to the sample. The addition step comprises any
method of administration as described above.
If desired, the activity of HCV polymerase after application of the
composition can be observed by any method including direct and
indirect methods of detecting HCV polymerase activity.
Quantitative, qualitative, and semiquantitative methods of
determining HCV polymerase activity are all contemplated. Typically
one of the screening methods described above are applied, however,
any other method such as observation of the physiological
properties of a living organism are also applicable.
Organisms that contain HCV polymerase include the HCV virus. The
compounds of this invention are useful in the treatment or
prophylaxis of HCV infections in animals or in man.
However, in screening compounds capable of inhibiting human
immunodeficiency viruses, it should be kept in mind that the
results of enzyme assays may not correlate with cell culture
assays. Thus, a cell based assay should be the primary screening
tool.
Screens for HCV Polymerase Inhibitors.
Compositions of the invention are screened for inhibitory activity
against HCV polymerase by any of the conventional techniques for
evaluating enzyme activity. Within the context of the invention,
typically compositions are first screened for inhibition of HCV
polymerase in vitro and compositions showing inhibitory activity
are then screened for activity in vivo. Compositions having in
vitro Ki (inhibitory constants) of less then about
5.times.10.sup.-6 M, typically less than about 1.times.10.sup.-7 M
and preferably less than about 5.times.10.sup.-8 M are preferred
for in vivo use.
Useful in vitro screens have been described in detail and will not
be elaborated here. However, the examples describe suitable in
vitro assays.
Pharmaceutical Formulations
The compounds of this invention are formulated with conventional
carriers and excipients, which will be selected in accord with
ordinary practice. Tablets will contain excipients, glidants,
fillers, binders and the like. Aqueous formulations are prepared in
sterile form, and when intended for delivery by other than oral
administration generally will be isotonic. All formulations will
optionally contain excipients such as those set forth in the
"Handbook of Pharmaceutical Excipients" (1986). Excipients include
ascorbic acid and other antioxidants, chelating agents such as
EDTA, carbohydrates such as dextran, hydroxyalkylcellulose,
hydroxyalkylmethylcellulose, stearic acid and the like. The pH of
the formulations ranges from about 3 to about 11, but is ordinarily
about 7 to 10.
While it is possible for the active ingredients to be administered
alone it may be preferable to present them as pharmaceutical
formulations. The formulations, both for veterinary and for human
use, of the invention comprise at least one active ingredient, as
above defined, together with one or more acceptable carriers
therefor and optionally other therapeutic ingredients. The
carrier(s) must be "acceptable" in the sense of being compatible
with the other ingredients of the formulation and physiologically
innocuous to the recipient thereof.
The formulations include those suitable for the foregoing
administration routes. The formulations may conveniently be
presented in unit dosage form and may be prepared by any of the
methods well known in the art of pharmacy. Techniques and
formulations generally are found in Remington's Pharmaceutical
Sciences (Mack Publishing Co., Easton, Pa.). Such methods include
the step of bringing into association the active ingredient with
the carrier which constitutes one or more accessory ingredients. In
general the formulations are prepared by uniformly and intimately
bringing into association the active ingredient with liquid
carriers or finely divided solid carriers or both, and then, if
necessary, shaping the product.
Formulations of the present invention suitable for oral
administration may be presented as discrete units such as capsules,
cachets or tablets each containing a predetermined amount of the
active ingredient; as a powder or granules; as a solution or a
suspension in an aqueous or non-aqueous liquid; or as an
oil-in-water liquid emulsion or a water-in-oil liquid emulsion. The
active ingredient may also be administered as a bolus, electuary or
paste.
A tablet is made by compression or molding, optionally with one or
more accessory ingredients. Compressed tablets may be prepared by
compressing in a suitable machine the active ingredient in a
free-flowing form such as a powder or granules, optionally mixed
with a binder, lubricant, inert diluent, preservative, surface
active or dispersing agent. Molded tablets may be made by molding
in a suitable machine a mixture of the powdered active ingredient
moistened with an inert liquid diluent. The tablets may optionally
be coated or scored and optionally are formulated so as to provide
slow or controlled release of the active ingredient therefrom.
For infections of the eye or other external tissues e.g. mouth and
skin, the formulations are preferably applied as a topical ointment
or cream containing the active ingredient(s) in an amount of, for
example, 0.075 to 20% w/w (including active ingredient(s) in a
range between 0.1% and 20% in increments of 0.1% w/w such as 0.6%
w/w, 0.7% w/w, etc.), preferably 0.2 to 15% w/w and most preferably
0.5 to 10% w/w. When formulated in an ointment, the active
ingredients may be employed with either a paraffinic or a
water-miscible ointment base. Alternatively, the active ingredients
may be formulated in a cream with an oil-in-water cream base.
If desired, the aqueous phase of the cream base may include, for
example, at least 30% w/w of a polyhydric alcohol, i.e. an alcohol
having two or more hydroxyl groups such as propylene glycol, butane
1,3-diol, mannitol, sorbitol, glycerol and polyethylene glycol
(including PEG 400) and mixtures thereof. The topical formulations
may desirably include a compound which enhances absorption or
penetration of the active ingredient through the skin or other
affected areas. Examples of such dermal penetration enhancers
include dimethyl sulphoxide and related analogs.
The oily phase of the emulsions of this invention may be
constituted from known ingredients in a known manner. While the
phase may comprise merely an emulsifier (otherwise known as an
emulgent), it desirably comprises a mixture of at least one
emulsifier with a fat or an oil or with both a fat and an oil.
Preferably, a hydrophilic emulsifier is included together with a
lipophilic emulsifier which acts as a stabilizer. It is also
preferred to include both an oil and a fat. Together, the
emulsifier(s) with or without stabilizer(s) make up the so-called
emulsifying wax, and the wax together with the oil and fat make up
the so-called emulsifying ointment base which forms the oily
dispersed phase of the cream formulations.
Emulgents and emulsion stabilizers suitable for use in the
formulation of the invention include Tween.RTM. 60, Span.RTM. 80,
cetostearyl alcohol, benzyl alcohol, myristyl alcohol, glyceryl
mono-stearate and sodium lauryl sulfate.
The choice of suitable oils or fats for the formulation is based on
achieving the desired cosmetic properties. The cream should
preferably be a non-greasy, non-staining and washable product with
suitable consistency to avoid leakage from tubes or other
containers. Straight or branched chain, mono- or dibasic alkyl
esters such as di-isoadipate, isocetyl stearate, propylene glycol
diester of coconut fatty acids, isopropyl myristate, decyl oleate,
isopropyl palmitate, butyl stearate, 2-ethylhexyl palmitate or a
blend of branched chain esters known as Crodamol CAP may be used,
the last three being preferred esters. These may be used alone or
in combination depending on the properties required. Alternatively,
high melting point lipids such as white soft paraffin and/or liquid
paraffin or other mineral oils are used.
Pharmaceutical formulations according to the present invention
comprise a combination according to the invention together with one
or more pharmaceutically acceptable carriers or excipients and
optionally other therapeutic agents. Pharmaceutical formulations
containing the active ingredient may be in any form suitable for
the intended method of administration. When used for oral use for
example, tablets, troches, lozenges, aqueous or oil suspensions,
dispersible powders or granules, emulsions, hard or soft capsules,
syrups or elixirs may be prepared. Compositions intended for oral
use may be prepared according to any method known to the art for
the manufacture of pharmaceutical compositions and such
compositions may contain one or more agents including sweetening
agents, flavoring agents, coloring agents and preserving agents, in
order to provide a palatable preparation. Tablets containing the
active ingredient in admixture with non-toxic pharmaceutically
acceptable excipient which are suitable for manufacture of tablets
are acceptable. These excipients may be, for example, inert
diluents, such as calcium or sodium carbonate, lactose, calcium or
sodium phosphate; granulating and disintegrating agents, such as
maize starch, or alginic acid; binding agents, such as starch,
gelatin or acacia; and lubricating agents, such as magnesium
stearate, stearic acid or talc. Tablets may be uncoated or may be
coated by known techniques including microencapsulation to delay
disintegration and adsorption in the gastrointestinal tract and
thereby provide a sustained action over a longer period. For
example, a time delay material such as glyceryl monostearate or
glyceryl distearate alone or with a wax may be employed.
Formulations for oral use may be also presented as hard gelatin
capsules where the active ingredient is mixed with an inert solid
diluent, for example calcium phosphate or kaolin, or as soft
gelatin capsules wherein the active ingredient is mixed with water
or an oil medium, such as peanut oil, liquid paraffin or olive
oil.
Aqueous suspensions of the invention contain the active materials
in admixture with excipients suitable for the manufacture of
aqueous suspensions. Such excipients include a suspending agent,
such as sodium carboxymethylcellulose, methylcellulose,
hydroxypropyl methylcelluose, sodium alginate,
polyvinylpyrrolidone, gum tragacanth and gum acacia, and dispersing
or wetting agents such as a naturally-occurring phosphatide (e.g.,
lecithin), a condensation product of an alkylene oxide with a fatty
acid (e.g., polyoxyethylene stearate), a condensation product of
ethylene oxide with a long chain aliphatic alcohol (e.g.,
heptadecaethyleneoxycetanol), a condensation product of ethylene
oxide with a partial ester derived from a fatty acid and a hexitol
anhydride (e.g., polyoxyethylene sorbitan monooleate). The aqueous
suspension may also contain one or more preservatives such as ethyl
or n-propyl p-hydroxy-benzoate, one or more coloring agents, one or
more flavoring agents and one or more sweetening agents, such as
sucrose or saccharin.
Oil suspensions may be formulated by suspending the active
ingredient in a vegetable oil, such as arachis oil, olive oil,
sesame oil or coconut oil, or in a mineral oil such as liquid
paraffin. The oral suspensions may contain a thickening agent, such
as beeswax, hard paraffin or cetyl alcohol. Sweetening agents, such
as those set forth above, and flavoring agents may be added to
provide a palatable oral preparation. These compositions may be
preserved by the addition of an antioxidant such as ascorbic
acid.
Dispersible powders and granules of the invention suitable for
preparation of an aqueous suspension by the addition of water
provide the active ingredient in admixture with a dispersing or
wetting agent, a suspending agent, and one or more preservatives.
Suitable dispersing or wetting agents and suspending agents are
exemplified by those disclosed above. Additional excipients, for
example sweetening, flavoring and coloring agents, may also be
present.
The pharmaceutical compositions of the invention may also be in the
form of oil-in-water emulsions. The oily phase may be a vegetable
oil, such as olive oil or arachis oil, a mineral oil, such as
liquid paraffin, or a mixture of these. Suitable emulsifying agents
include naturally-occurring gums, such as gum acacia and gum
tragacanth, naturally-occurring phosphatides, such as soybean
lecithin, esters or partial esters derived from fatty acids and
hexitol anhydrides, such as sorbitan monooleate, and condensation
products of these partial esters with ethylene oxide, such as
polyoxyethylene sorbitan monooleate. The emulsion may also contain
sweetening and flavoring agents. Syrups and elixirs may be
formulated with sweetening agents, such as glycerol, sorbitol or
sucrose. Such formulations may also contain a demulcent, a
preservative, a flavoring or a coloring agent.
The pharmaceutical compositions of the invention may be in the form
of a sterile injectable preparation, such as a sterile injectable
aqueous or oleaginous suspension. This suspension may be formulated
according to the known art using those suitable dispersing or
wetting agents and suspending agents which have been mentioned
above. The sterile injectable preparation may also be a sterile
injectable solution or suspension in a non-toxic parenterally
acceptable diluent or solvent, such as a solution in
1,3-butane-diol or prepared as a lyophilized powder. Among the
acceptable vehicles and solvents that may be employed are water,
Ringer's solution and isotonic sodium chloride solution. In
addition, sterile fixed oils may conventionally be employed as a
solvent or suspending medium. For this purpose any bland fixed oil
may be employed including synthetic mono- or diglycerides. In
addition, fatty acids such as oleic acid may likewise be used in
the preparation of injectables.
The amount of active ingredient that may be combined with the
carrier material to produce a single dosage form will vary
depending upon the host treated and the particular mode of
administration. For example, a time-release formulation intended
for oral administration to humans may contain approximately 1 to
1000 mg of active material compounded with an appropriate and
convenient amount of carrier material which may vary from about 5
to about 95% of the total compositions (weight:weight). The
pharmaceutical composition can be prepared to provide easily
measurable amounts for administration. For example, an aqueous
solution intended for intravenous infusion may contain from about 3
to 500 .mu.g of the active ingredient per milliliter of solution in
order that infusion of a suitable volume at a rate of about 30
mL/hr can occur.
Formulations suitable for topical administration to the eye also
include eye drops wherein the active ingredient is dissolved or
suspended in a suitable carrier, especially an aqueous solvent for
the active ingredient. The active ingredient is preferably present
in such formulations in a concentration of 0.5 to 20%,
advantageously 0.5 to 10%, and particularly about 1.5% w/w.
Formulations suitable for topical administration in the mouth
include lozenges comprising the active ingredient in a flavored
basis, usually sucrose and acacia or tragacanth; pastilles
comprising the active ingredient in an inert basis such as gelatin
and glycerin, or sucrose and acacia; and mouthwashes comprising the
active ingredient in a suitable liquid carrier.
Formulations for rectal administration may be presented as a
suppository with a suitable base comprising for example cocoa
butter or a salicylate.
Formulations suitable for intrapulmonary or nasal administration
have a particle size for example in the range of 0.1 to 500
microns, such as 0.5, 1, 30, 35 etc., which is administered by
rapid inhalation through the nasal passage or by inhalation through
the mouth so as to reach the alveolar sacs. Suitable formulations
include aqueous or oily solutions of the active ingredient.
Formulations suitable for aerosol or dry powder administration may
be prepared according to conventional methods and may be delivered
with other therapeutic agents such as compounds heretofore used in
the treatment or prophylaxis of HCV infections as described
below.
Formulations suitable for vaginal administration may be presented
as pessaries, tampons, creams, gels, pastes, foams or spray
formulations containing in addition to the active ingredient such
carriers as are known in the art to be appropriate.
Formulations suitable for parenteral administration include aqueous
and non-aqueous sterile injection solutions which may contain
anti-oxidants, buffers, bacteriostats and solutes which render the
formulation isotonic with the blood of the intended recipient; and
aqueous and non-aqueous sterile suspensions which may include
suspending agents and thickening agents.
The formulations are presented in unit-dose or multi-dose
containers, for example sealed ampoules and vials, and may be
stored in a freeze-dried (lyophilized) condition requiring only the
addition of the sterile liquid carrier, for example water for
injection, immediately prior to use. Extemporaneous injection
solutions and suspensions are prepared from sterile powders,
granules and tablets of the kind previously described. Preferred
unit dosage formulations are those containing a daily dose or unit
daily sub-dose, as herein above recited, or an appropriate fraction
thereof, of the active ingredient.
It should be understood that in addition to the ingredients
particularly mentioned above the formulations of this invention may
include other agents conventional in the art having regard to the
type of formulation in question, for example those suitable for
oral administration may include flavoring agents.
The invention further provides veterinary compositions comprising
at least one active ingredient as above defined together with a
veterinary carrier therefor.
Veterinary carriers are materials useful for the purpose of
administering the composition and may be solid, liquid or gaseous
materials which are otherwise inert or acceptable in the veterinary
art and are compatible with the active ingredient. These veterinary
compositions may be administered orally, parenterally or by any
other desired route.
Compounds of the invention are used to provide controlled release
pharmaceutical formulations containing as active ingredient one or
more compounds of the invention ("controlled release formulations")
in which the release of the active ingredient are controlled and
regulated to allow less frequency dosing or to improve the
pharmacokinetic or toxicity profile of a given active
ingredient.
Effective dose of active ingredient depends at least on the nature
of the condition being treated, toxicity, whether the compound is
being used prophylactically (lower doses) or against an active
viral infection, the method of delivery, and the pharmaceutical
formulation, and will be determined by the clinician using
conventional dose escalation studies. It can be expected to be from
about 0.0001 to about 100 mg/kg body weight per day; typically,
from about 0.01 to about 10 mg/kg body weight per day; more
typically, from about 0.01 to about 5 mg/kg body weight per day;
most typically, from about 0.05 to about 0.5 mg/kg body weight per
day. For example, the daily candidate dose for an adult human of
approximately 70 kg body weight will range from 1 mg to 1000 mg,
preferably between 5 mg and 500 mg, and may take the form of single
or multiple doses.
Routes of Administration
One or more compounds of the invention (herein referred to as the
active ingredients) are administered by any route appropriate to
the condition to be treated. Suitable routes include oral, rectal,
nasal, topical (including buccal and sublingual), vaginal and
parenteral (including subcutaneous, intramuscular, intravenous,
intradermal, intrathecal and epidural), and the like. It will be
appreciated that the preferred route may vary with for example the
condition of the recipient. An advantage of the compounds of this
invention is that they are orally bioavailable and can be dosed
orally.
Combination Therapy
Compositions of the invention are also used in combination with
other active ingredients. Preferably, the other active therapeutic
ingredients or agents are interferons, ribavirin analogs, NS3
protease inhibitors, NS5a inhibitors, alpha-glucosidase 1
inhibitors, cyclophilin inhibitors, hepatoprotectants,
non-nucleoside inhibitors of HCV, and other drugs for treating
HCV.
Combinations of the compounds of Formula I-III are typically
selected based on the condition to be treated, cross-reactivities
of ingredients and pharmaco-properties of the combination. For
example, when treating an infection (e.g., HCV), the compositions
of the invention are combined with other active therapeutic agents
(such as those described herein).
Suitable active therapeutic agents or ingredients which can be
combined with the compounds of Formula I-III can include
interferons, e.g., pegylated rIFN-alpha 2b, pegylated rIFN-alpha
2a, rIFN-alpha 2b, IFN alpha-2b XL, rIFN-alpha 2a, consensus IFN
alpha, infergen, rebif, locteron, AVI-005, PEG-infergen, pegylated
IFN-beta, oral interferon alpha, feron, reaferon, intermax alpha,
r-IFN-beta, infergen+actimmune, IFN-omega with DUROS, and
albuferon; ribavirin analogs, e.g., rebetol, copegus, VX-497, and
viramidine (taribavirin); NS5a inhibitors, e.g., A-831, A-689 and
BMS-790052; NS5b polymerase inhibitors, e.g., NM-283,
valopicitabine, R1626, PSI-6130 (R1656), HCV-796, BILB 1941,
MK-0608, NM-107, R7128, VCH-759, PF-868554, GSK625433, and
XTL-2125; NS3 protease inhibitors, e.g., SCH-503034 (SCH-7), VX-950
(Telaprevir), ITMN-191, and BILN-2065; alpha-glucosidase 1
inhibitors, e.g., MX-3253 (celgosivir) and UT-231B;
hepatoprotectants, e.g., IDN-6556, ME 3738, MitoQ, and LB-84451;
non-nucleoside inhibitors of HCV, e.g., benzimidazole derivatives,
benzo-1,2,4-thiadiazine derivatives, and phenylalanine derivatives;
and other drugs for treating HCV, e.g., zadaxin, nitazoxanide
(alinea), BIVN-401 (virostat), DEBIO-025, VGX-410C, EMZ-702, AVI
4065, bavituximab, oglufanide, PYN-17, KPE02003002, actilon
(CPG-10101), KRN-7000, civacir, GI-5005, ANA-975, XTL-6865, ANA
971, NOV-205, tarvacin, EHC-18, and NIM811.
In yet another embodiment, the present application discloses
pharmaceutical compositions comprising a compound of the present
invention, or a pharmaceutically acceptable salt, solvate, and/or
ester thereof, in combination with at least one additional
therapeutic agent, and a pharmaceutically acceptable carrier or
excipient.
According to the present invention, the therapeutic agent used in
combination with the compound of the present invention can be any
agent having a therapeutic effect when used in combination with the
compound of the present invention. For example, the therapeutic
agent used in combination with the compound of the present
invention can be interferons, ribavirin analogs, NS3 protease
inhibitors, NS5a inhibitors, alpha-glucosidase 1 inhibitors,
cyclophilin inhibitors, hepatoprotectants, non-nucleoside
inhibitors of HCV, and other drugs for treating HCV.
In another embodiment, the present application provides
pharmaceutical compositions comprising a compound of the present
invention, or a pharmaceutically acceptable salt, solvate, and/or
ester thereof, in combination with at least one additional
therapeutic agent selected from the group consisting of pegylated
rIFN-alpha 2b, pegylated rIFN-alpha 2a, rIFN-alpha 2b, IFN alpha-2b
XL, rIFN-alpha 2a, consensus IFN alpha, infergen, rebif, locteron,
AVI-005, PEG-infergen, pegylated IFN-beta, oral interferon alpha,
feron, reaferon, intermax alpha, r-IFN-beta, infergen+actimmune,
IFN-omega with DUROS, albuferon, rebetol, copegus, VX-497,
viramidine (taribavirin), A-831, A-689, NM-283, valopicitabine,
R1626, PSI-6130 (R1656), HCV-796, BILB 1941, MK-0608, NM-107,
R7128, VCH-759, PF-868554, GSK625433, XTL-2125, SCH-503034 (SCH-7),
VX-950 (Telaprevir), ITMN-191, and BILN-2065, MX-3253 (celgosivir),
UT-231B, IDN-6556, ME 3738, MitoQ, and LB-84451, benzimidazole
derivatives, benzo-1,2,4-thiadiazine derivatives, and phenylalanine
derivatives, zadaxin, nitazoxanide (alinea), BIVN-401 (virostat),
DEBIO-025, VGX-410C, EMZ-702, AVI 4065, bavituximab, oglufanide,
PYN-17, KPE02003002, actilon (CPG-10101), KRN-7000, civacir,
GI-5005, ANA-975, XTL-6865, ANA 971, NOV-205, tarvacin, EHC-18, and
NIM811 and a pharmaceutically acceptable carrier or excipient.
In yet another embodiment, the present application provides a
combination pharmaceutical agent comprising:
a) a first pharmaceutical composition comprising a compound of the
present invention, or a pharmaceutically acceptable salt, solvate,
or ester thereof; and
b) a second pharmaceutical composition comprising at least one
additional therapeutic agent selected from the group consisting of
HIV protease inhibiting compounds, HIV non-nucleoside inhibitors of
reverse transcriptase, HIV nucleoside inhibitors of reverse
transcriptase, HIV nucleotide inhibitors of reverse transcriptase,
HIV integrase inhibitors, gp41 inhibitors, CXCR4 inhibitors, gp120
inhibitors, CCR5 inhibitors, interferons, ribavirin analogs, NS3
protease inhibitors, NS5a inhibitors, alpha-glucosidase 1
inhibitors, cyclophilin inhibitors, hepatoprotectants,
non-nucleoside inhibitors of HCV, and other drugs for treating HCV,
and combinations thereof.
Combinations of the compounds of Formula I-III and additional
active therapeutic agents may be selected to treat patients
infected with HCV and other conditions such as HIV infections.
Accordingly, the compounds of Formula I-III may be combined with
one or more compounds useful in treating HIV, for example HIV
protease inhibiting compounds, HIV non-nucleoside inhibitors of
reverse transcriptase, HIV nucleoside inhibitors of reverse
transcriptase, HIV nucleotide inhibitors of reverse transcriptase,
HIV integrase inhibitors, gp41 inhibitors, CXCR4 inhibitors, gp120
inhibitors, CCR5 inhibitors, interferons, ribavirin analogs, NS3
protease inhibitors, NS5a inhibitors, alpha-glucosidase 1
inhibitors, cyclophilin inhibitors, hepatoprotectants,
non-nucleoside inhibitors of HCV, and other drugs for treating
HCV.
More specifically, one or more compounds of the present invention
may be combined with one or more compounds selected from the group
consisting of 1) HIV protease inhibitors, e.g., amprenavir,
atazanavir, fosamprenavir, indinavir, lopinavir, ritonavir,
lopinavir+ritonavir, nelfinavir, saquinavir, tipranavir,
brecanavir, darunavir, TMC-126, TMC-114, mozenavir (DMP-450),
JE-2147 (AG1776), AG1859, DG35, L-756423, RO0334649, KNI-272,
DPC-681, DPC-684, and GW640385X, DG17, PPL-100, 2) a HIV
non-nucleoside inhibitor of reverse transcriptase, e.g.,
capravirine, emivirine, delaviridine, efavirenz, nevirapine, (+)
calanolide A, etravirine, GW5634, DPC-083, DPC-961, DPC-963,
MIV-150, and TMC-120, TMC-278 (rilpivirine), efavirenz, BILR 355
BS, VRX 840773, UK-453,061, RDEA806, 3) a HIV nucleoside inhibitor
of reverse transcriptase, e.g., zidovudine, emtricitabine,
didanosine, stavudine, zalcitabine, lamivudine, abacavir,
amdoxovir, elvucitabine, alovudine, MIV-210, racivir (.+-.-FTC),
D-d4FC, emtricitabine, phosphazide, fozivudine tidoxil, fosalvudine
tidoxil, apricitibine (AVX754), amdoxovir, KP-1461,
abacavir+lamivudine, abacavir+lamivudine+zidovudine,
zidovudine+lamivudine, 4) a HIV nucleotide inhibitor of reverse
transcriptase, e.g., tenofovir, tenofovir disoproxil
fumarate+emtricitabine, tenofovir disoproxil
fumarate+emtricitabine+efavirenz, and adefovir, 5) a HIV integrase
inhibitor, e.g., curcumin, derivatives of curcumin, chicoric acid,
derivatives of chicoric acid, 3,5-dicaffeoylquinic acid,
derivatives of 3,5-dicaffeoylquinic acid, aurintricarboxylic acid,
derivatives of aurintricarboxylic acid, caffeic acid phenethyl
ester, derivatives of caffeic acid phenethyl ester, tyrphostin,
derivatives of tyrphostin, quercetin, derivatives of quercetin,
S-1360, zintevir (AR-177), L-870812, and L-870810, MK-0518
(raltegravir), BMS-707035, MK-2048, BA-011, BMS-538158, GSK364735C,
6) a gp41 inhibitor, e.g., enfuvirtide, sifuvirtide, FB006M,
TRI-1144, SPC3, DES6, Locus gp41, CovX, and REP 9, 7) a CXCR4
inhibitor, e.g., AMD-070, 8) an entry inhibitor, e.g., SP01A,
TNX-355, 9) a gp120 inhibitor, e.g., BMS-488043 and BlockAide/CR,
10) a G6PD and NADH-oxidase inhibitor, e.g., immunitin, 10) a CCR5
inhibitor, e.g., aplaviroc, vicriviroc, INCB9471, PRO-140,
INCB15050, PF-232798, CCR5 mAb004, and maraviroc, 11) an
interferon, e.g., pegylated rIFN-alpha 2b, pegylated rIFN-alpha 2a,
rIFN-alpha 2b, IFN alpha-2b XL, rIFN-alpha 2a, consensus IFN alpha,
infergen, rebif, locteron, AVI-005, PEG-infergen, pegylated
IFN-beta, oral interferon alpha, feron, reaferon, intermax alpha,
r-IFN-beta, infergen+actimmune, IFN-omega with DUROS, and
albuferon, 12) ribavirin analogs, e.g., rebetol, copegus, VX-497,
and viramidine (taribavirin) 13) NS5a inhibitors, e.g., A-831,
A-689 and BMS-790052, 14) NS5b polymerase inhibitors, e.g., NM-283,
valopicitabine, R1626, PSI-6130 (R1656), HCV-796, BILB 1941,
MK-0608, NM-107, R7128, VCH-759, PF-868554, GSK625433, and
XTL-2125, 15) NS3 protease inhibitors, e.g., SCH-503034 (SCH-7),
VX-950 (Telaprevir), ITMN-191, and BILN-2065, 16) alpha-glucosidase
1 inhibitors, e.g., MX-3253 (celgosivir) and UT-231B, 17)
hepatoprotectants, e.g., IDN-6556, ME 3738, MitoQ, and LB-84451,
18) non-nucleoside inhibitors of HCV, e.g., benzimidazole
derivatives, benzo-1,2,4-thiadiazine derivatives, and phenylalanine
derivatives, 19) other drugs for treating HCV, e.g., zadaxin,
nitazoxanide (alinea), BIVN-401 (virostat), DEBIO-025, VGX-410C,
EMZ-702, AVI 4065, bavituximab, oglufanide, PYN-17, KPE02003002,
actilon (CPG-10101), KRN-7000, civacir, GI-5005, ANA-975, XTL-6865,
ANA 971, NOV-205, tarvacin, EHC-18, and NIM811, 19) pharmacokinetic
enhancers, e.g., BAS-100 and SPI452, 20)RNAse H inhibitors, e.g.,
ODN-93 and ODN-112, 21) other anti-HIV agents, e.g., VGV-1, PA-457
(bevirimat), ampligen, HRG214, cytolin, polymun, VGX-410, KD247,
AMZ 0026, CYT 99007, A-221 HIV, BAY 50-4798, MDX010 (iplimumab),
PBS119, ALG889, and PA-1050040.
It is also possible to combine any compound of the invention with
one or more other active therapeutic agents in a unitary dosage
form for simultaneous or sequential administration to a patient.
The combination therapy may be administered as a simultaneous or
sequential regimen. When administered sequentially, the combination
may be administered in two or more administrations.
Co-administration of a compound of the invention with one or more
other active therapeutic agents generally refers to simultaneous or
sequential administration of a compound of the invention and one or
more other active therapeutic agents, such that therapeutically
effective amounts of the compound of the invention and one or more
other active therapeutic agents are both present in the body of the
patient.
Co-administration includes administration of unit dosages of the
compounds of the invention before or after administration of unit
dosages of one or more other active therapeutic agents, for
example, administration of the compounds of the invention within
seconds, minutes, or hours of the administration of one or more
other active therapeutic agents. For example, a unit dose of a
compound of the invention can be administered first, followed
within seconds or minutes by administration of a unit dose of one
or more other active therapeutic agents. Alternatively, a unit dose
of one or more other therapeutic agents can be administered first,
followed by administration of a unit dose of a compound of the
invention within seconds or minutes. In some cases, it may be
desirable to administer a unit dose of a compound of the invention
first, followed, after a period of hours (e.g., 1-12 hours), by
administration of a unit dose of one or more other active
therapeutic agents. In other cases, it may be desirable to
administer a unit dose of one or more other active therapeutic
agents first, followed, after a period of hours (e.g., 1-12 hours),
by administration of a unit dose of a compound of the
invention.
The combination therapy may provide "synergy" and "synergistic",
i.e. the effect achieved when the active ingredients used together
is greater than the sum of the effects that results from using the
compounds separately. A synergistic effect may be attained when the
active ingredients are: (1) co-formulated and administered or
delivered simultaneously in a combined formulation; (2) delivered
by alternation or in parallel as separate formulations; or (3) by
some other regimen. When delivered in alternation therapy, a
synergistic effect may be attained when the compounds are
administered or delivered sequentially, e.g. in separate tablets,
pills or capsules, or by different injections in separate syringes.
In general, during alternation therapy, an effective dosage of each
active ingredient is administered sequentially, i.e. serially,
whereas in combination therapy, effective dosages of two or more
active ingredients are administered together. A synergistic
anti-viral effect denotes an antiviral effect which is greater than
the predicted purely additive effects of the individual compounds
of the combination.
In still yet another embodiment, the present application provides
for methods of inhibiting HCV polymerase in a cell, comprising:
contacting a cell infected with HCV with an effective amount of a
compound of Formula I-III, or a pharmaceutically acceptable salt,
solvate, and/or ester thereof, whereby HCV polymerase is
inhibited.
In still yet another embodiment, the present application provides
for methods of inhibiting HCV polymerase in a cell, comprising:
contacting a cell infected with HCV with an effective amount of a
compound of Formula I-III, or a pharmaceutically acceptable salt,
solvate, and/or ester thereof, and at least one additional active
therapeutic agent, whereby HCV polymerase is inhibited.
In still yet another embodiment, the present application provides
for methods of inhibiting HCV polymerase in a cell, comprising:
contacting a cell infected with HCV with an effective amount of a
compound of Formula I-III, or a pharmaceutically acceptable salt,
solvate, and/or ester thereof, and least one additional active
therapeutic agent selected from the group consisting of
interferons, ribavirin analogs, NS3 protease inhibitors, NS5a
inhibitors, alpha-glucosidase 1 inhibitors, cyclophilin inhibitors,
hepatoprotectants, non-nucleoside inhibitors of HCV, and other
drugs for treating HCV.
In still yet another embodiment, the present application provides
for methods of treating HCV in a patient, comprising: administering
to the patient a therapeutically effective amount of a compound of
Formula I-III, or a pharmaceutically acceptable salt, solvate,
and/or ester thereof.
In still yet another embodiment, the present application provides
for methods of treating HCV in a patient, comprising: administering
to the patient a therapeutically effective amount of a compound of
Formula I-III, or a pharmaceutically acceptable salt, solvate,
and/or ester thereof, and at least one additional active
therapeutic agent, whereby HCV polymerase is inhibited.
In still yet another embodiment, the present application provides
for methods of treating HCV in a patient, comprising: administering
to the patient a therapeutically effective amount of a compound of
Formula I-III, or a pharmaceutically acceptable salt, solvate,
and/or ester thereof, and at least one additional active
therapeutic agent selected from the group consisting of
interferons, ribavirin analogs, NS3 protease inhibitors, NS5a
inhibitors, alpha-glucosidase 1 inhibitors, cyclophilin inhibitors,
hepatoprotectants, non-nucleoside inhibitors of HCV, and other
drugs for treating HCV.
In still yet another embodiment, the present application provides
for the use of a compound of the present invention, or a
pharmaceutically acceptable salt, solvate, and/or ester thereof,
for the preparation of a medicament for treating an HCV infection
in a patient.
Metabolites of the Compounds of the Invention
Also falling within the scope of this invention are the in vivo
metabolic products of the compounds described herein, to the extent
such products are novel and unobvious over the prior art. Such
products may result for example from the oxidation, reduction,
hydrolysis, amidation, esterification and the like of the
administered compound, primarily due to enzymatic processes.
Accordingly, the invention includes novel and unobvious compounds
produced by a process comprising contacting a compound of this
invention with a mammal for a period of time sufficient to yield a
metabolic product thereof. Such products typically are identified
by preparing a radiolabelled (e.g. .sup.14C or .sup.3H) compound of
the invention, administering it parenterally in a detectable dose
(e.g. greater than about 0.5 mg/kg) to an animal such as rat,
mouse, guinea pig, monkey, or to man, allowing sufficient time for
metabolism to occur (typically about 30 seconds to 30 hours) and
isolating its conversion products from the urine, blood or other
biological samples. These products are easily isolated since they
are labeled (others are isolated by the use of antibodies capable
of binding epitopes surviving in the metabolite). The metabolite
structures are determined in conventional fashion, e.g. by MS or
NMR analysis. In general, analysis of metabolites is done in the
same way as conventional drug metabolism studies well-known to
those skilled in the art. The conversion products, so long as they
are not otherwise found in vivo, are useful in diagnostic assays
for therapeutic dosing of the compounds of the invention even if
they possess no HCV polymerase inhibitory activity of their
own.
Recipes and methods for determining stability of compounds in
surrogate gastrointestinal secretions are known. Compounds are
defined herein as stable in the gastrointestinal tract where less
than about 50 mole percent of the protected groups are deprotected
in surrogate intestinal or gastric juice upon incubation for 1 hour
at 37.degree. C. Simply because the compounds are stable to the
gastrointestinal tract does not mean that they cannot be hydrolyzed
in vivo. The prodrugs of the invention typically will be stable in
the digestive system but may be substantially hydrolyzed to the
parental drug in the digestive lumen, liver or other metabolic
organ, or within cells in general.
EXAMPLES
Certain abbreviations and acronyms are used in describing the
experimental details. Although most of these would be understood by
one skilled in the art, Table 1 contains a list of many of these
abbreviations and acronyms.
TABLE-US-00045 TABLE 1 List of abbreviations and acronyms.
Abbreviation Meaning Ac.sub.2O acetic anhydride AIBN
2,2'-azobis(2-methylpropionitrile) Bn benzyl BnBr benzylbromide BSA
bis(trimethylsilyl)acetamide BzCl benzoyl chloride CDI carbonyl
diimidazole DABCO 1,4-diazabicyclo[2.2.2]octane DBN
1,5-diazabicyclo[4.3.0]nonene-5 DDQ
2,3-dichloro-5,6-dicyano-1,4-benzoquinone DBU
1,5-diazabicyclo[5.4.0]undecene-5 DCA dichloroacetamide DCC
dicyclohexylcarbodiimide DCM dichloromethane DMAP
4-dimethylaminopyridine DME 1,2-dimethoxy ethane DMTCl
dimethoxytrityl chloride DMSO dimethylsulfoxide DMTr
4,4'-dimethoxytrityl DMF dimethylformamide EtOAc ethyl acetate ESI
electrospray ionization HMDS hexamethyldisilazane HPLC High
pressure liquid chromatography LDA lithium diisopropylamide LRMS
low resolution mass spectrum MCPBA meta-chloroperbenzoic acid MeCN
acetonitrile MeOH methanol MMTC mono methoxytrityl chloride m/z or
m/e mass to charge ratio MH.sup.+ mass plus 1 MH.sup.- mass minus 1
MsOH methanesulfonic acid MS or ms mass spectrum NBS N-bromo
succinimide rt or r.t. room temperature TBAF tetrabutylammonium
fluoride TMSCl chlorotrimethylsilane TMSBr bromotrimethylsilane
TMSI iodotrimethylsilane TEA triethylamine TBA tributylamine TBAP
tributylammonium pyrophosphate TBSCl t-butyldimethylsilyl chloride
TEAB triethylammonium bicarbonate TFA trifluoroacetic acid TLC or
tlc thin layer chromatography Tr triphenylmethyl Tol
4-methylbenzoyl .delta. parts per million down field from
tetramethylsilane
Preparation of Compounds
##STR00343##
To a solution of 1a (22.0 g, 54.9 mmol, prepared according to the
procedures described in J. O. C., 2004, 6257) in methanol (300 mL)
was dropwise added acetyl chloride (22 mL) at 0.degree. C. using a
dropping funnel over a period of 30 min. and then stirred at room
temperature for 16 h. The mixture was concentrated, re-dissolved in
ethyl acetate (400 mL), washed with ice-cold 2 N NaOH, and
concentrated to dryness, affording the crude methyl ether 1b as an
oil. MS=437.2 (M+Na.sup.+).
##STR00344##
To a solution of 1b (obtained from the previous step) in methanol
(300 mL) was added 0.5 M sodium methoxide solution in methanol (20
mL, 10 mmol), and stirred for 16 h at room temperature. The
reaction was quenched with 4.0 N HCl solution in dioxane (2.5 mL,
10 mmol). The mixture was then concentrated, affording the crude
1c. MS=201.0 (M+Na.sup.+).
##STR00345##
A mixture of 1c (obtained from the previous step), Tritron X-405
(70% in water, 6.0 g), 50% KOH (in water, 85 g) in toluene (500 mL)
was heated to reflux with a Dean-Stark trap attached. After 1 h
collecting .about.25 mL of water, benzyl chloride (33 g, 260 mmol)
was added and continued to reflux with stirring for 16 h. The
mixture was then cooled and partitioned between ethyl acetate (400
mL) and water (300 mL). The organic layer was washed with water
(300 mL), and concentrated. The residue was purified by silica gel
column chromatography (.about.20% EtOAc/hexanes), affording the
methyl ether 1d as an oil (22.0 g, 89% in three steps). .sup.1H NMR
(300 MHz, CDCl.sub.3): .delta. 7.3 (m, 15H), 4.5-4.9 (m, 7H), 4.37
(m, 1H), 3.87 (d, 1H), 3.56 (m, 2H), 3.52 (s, 3H), 1.40 (s,
3H).
##STR00346##
To a solution of 1d (22.0 g, 49.0 mmol) in acetic acid (110 mL) was
added .about.3 M sulfuric acid (prepared by mixing 4.8 g of
concentrated sulfuric acid with 24 mL of water) and stirred at
70.degree. C. for 8 h. The mixture was concentrated to a volume of
.about.20 mL, and partitioned between ethyl acetate and ice-cold 2N
NaOH. The ethyl acetate layer was concentrated, and purified by
silica gel column chromatography (.about.35% EtOAc/hexanes),
affording 1e as an oil (17.0 g, 80%). MS=457.2 (M+Na.sup.+).
##STR00347##
To a solution of 1e (45 g, 104 mmol) in DMSO (135 mL) was dropwise
added acetic anhydride (90 mL, 815 mmol) at room temperature under
argon. The mixture was stirred for 16 h at room temperature, and
then poured into ice-water (1 L) while stirring. After ice was
completely melted (.about.30 min), ethyl acetate (.about.500 mL)
was added. The organic layer was separated. This extraction process
was repeated three times (3.times.500 mL). The organic extracts
were combined and concentrated. The residue was purified by silica
gel column chromatography (.about.20% EtOAc/hexanes), affording if
as an oil (39 g, 88%). .sup.1H NMR (300 MHz, DMSO-d.sub.6): .delta.
7.3 (m, 15H), 4.4-4.8 (m, 7H), 4.08 (d, J=7.5 Hz, 1H), 3.75 (dd,
J=2.4, 11.4 Hz, 1H), 3.64 (dd, J=5.4, 11.4 Hz, 1H), 1.51 (s,
3H).
##STR00348##
To a dry, argon purged round bottom flask (100 mL) were added
7-bromo-pyrrolo[2,1-f][1,2,4]triazin-4-ylamine (234 mg, 1.10 mmol)
(prepared according to WO2007056170) and anhydrous THF (1.5 mL).
TMSCl (276 .mu.L, 2.2 mmol) was then added and the reaction mixture
stirred for 2 h. The flask was placed into a dry ice/acetone bath
(.about.-78.degree. C.) and BuLi (2.5 mL, 4.0 mmol, 1.6M in
hexanes) was added dropwise. After 1 h, a solution of 1f (432.5 mg,
1.0 mmol) in THF was cooled to 0.degree. C. and then added to the
reaction flask dropwise. After 1 h of stirring at -78.degree. C.,
the flask was warmed to 0.degree. C. and sat. NH.sub.4Cl (5 mL) was
added to quench the reaction. The organics were extracted using
EtOAc (3.times.10 L) and the combined organic layers were dried
using MgSO.sub.4. The solvent was removed under reduced pressure
and the crude material was purified using flash chromatography
(hexanes/EtOAc). 560 mg (99%) of 2a was isolated as a mixture of
two anomers. LC/MS=567.2 (M+H.sup.+). .sup.1H NMR (300 MHz,
CDCl.sub.3): .delta. 7.85 (m, 1H), 7.27 (m, 15H), 7.01 (m, 1H),
6.51 (m, 1H), 4.66 (m, 8H), 4.40 (m, 2H), 3.79 (m, 3H), 1.62 (s,
2'-CH.sub.3 from the one anomer), 1.18 (s, 2'-CH.sub.3 from the
other anomer).
##STR00349##
To a dry, argon purged round bottom flask (50 mL) were added
compound 2a (185 mg, 0.33 mmol) and anhydrous dichloromethane (10
mL). The flask was placed into a dry ice/acetone bath
(.about.-78.degree. C.) and the solution stirred for 10 min.
BBr.sub.3 (0.25 mL, 0.25 mmol, 1.0 M in DCM) was then added and the
reaction continued to stir at -78.degree. C. until complete
disappearance of the starting material. After 1 h, a solution of
pyridine (2 mL) in MeOH (10 mL) was added and the flask was warmed
to room temperature. The solvent was removed under reduced pressure
and the crude material was re-dissolved in MeOH. After this process
was repeated two more times, the crude material was then dissolved
in water and purified using a Gilson Preparatory HPLC system
(acetonitrile/H.sub.2O). 49 mg (50%) of Compound 2 was isolated as
an isomeric mixture. LC/MS=297.1 (M+H.sup.+). .sup.1H NMR (300 MHz,
D.sub.2O): .delta. 7.68 (m, 1H), 6.80 (m, 2H), 4.04 (m, 2H), 3.78
(m, 2H), 3.65 (m, 1H), 1.30 (s, 2'-CH.sub.3), 0.80 (s,
2'-CH.sub.3).
##STR00350##
To a dry, argon purged round bottom flask (100 mL) were added
Compound 2 (12 mg, 0.04 mmol) (2) and anhydrous MeOH (5 mL). Acetic
acid (5 mL) was then added and the reaction stirred overnight at
room temperature. Saturated NaHCO.sub.3 was added to neutralize the
reaction mixture and the crude material was purified using a Gilson
Preparatory HPLC system (acetonitrile-H.sub.2O). 2 mg (16%) of the
desired material Compound 3 was isolated. LC/MS=311.2 (M+H.sup.+).
.sup.1H NMR (300 MHz, D.sub.2O): .delta. 7.71 (s, 1H), 6.78 (s,
2H), 3.98 (m, 1H), 3.83 (dd, 1H), 3.74 (dd, 1H), 3.62 (d, 1H), 2.94
(s, 3H), 0.76 (s, 3H). The other alpha-isomer was also isolated;
.sup.1H NMR (300 MHz, D.sub.2O): .delta. 7.65 (s, 1H), 6.78 (d,
1H), 6.75 (d, 1H), 4.03 (m, 2H), 3.77 (dd, 1H), 3.59 (d, 1H), 2.95
(s, 3H), 1.31 (s, 3H).
##STR00351##
To a dry, argon purged round bottom flask (50 mL) were added
compound 2a (220 mg, 0.39 mmol) and anhydrous dichloromethane (10
mL). The flask was placed into a dry ice/acetone bath
(.about.-78.degree. C.) and the solution stirred for 10 min.
BF.sub.3-Et.sub.2O (0.10 mL) was added dropwise and the reaction
stirred for 10 min. AlMe.sub.3 (0.58 mL, 1.16 mmol, 2.0 M in
toluene) was then added. After a few minutes, the dry ice/acetone
bath was removed and the reaction mixture warmed to room
temperature over 4 h. A solution of pyridine (2 mL) in MeOH (10 mL)
was added and the solvent was removed under reduced pressure. The
crude material was purified using flash chromatography
(hexanes/EtOAc). 164 mg (74%) of the desired material 4a was
isolated. LC/MS=565.2 (M+H.sup.+). .sup.1H NMR (300 MHz,
CD.sub.3OD): .delta. 7.71 (s, 1H), 7.32 (m, 15H), 7.02 (m, 1H),
6.78 (m, 1H), 4.62 (m, 8H), 4.21 (m, 1H), 4.04 (m, 1H), 3.84 (m,
1H), 1.95 (s, 3H), 1.10 (s, 3H).
##STR00352##
To a dry, argon purged round bottom flask (50 mL) were added
compound 4a (164 mg, 0.29 mmol) and glacial acetic acid (10 mL).
Pd/C (100 mg, 10% by wt.) was then added and the flask was equipped
with a balloon containing hydrogen gas. The flask was purged two
times to ensure all of the argon had been replaced with hydrogen.
The reaction was allowed to stir at room temperature overnight. The
reaction mixture was then neutralized using NaHCO.sub.3 and
filtered to remove the catalyst. The crude material was purified
using a Gilson Preparatory HPLC system (acetonitrile/H.sub.2O). 6
mg (7%) of the desired material Compound 4 was isolated.
LC/MS=295.1 (M+H.sup.+). .sup.1H NMR (300 MHz, D.sub.2O): .delta.
7.66 (s, 1H), 6.72 (m, 1H), 6.64 (m, 1H), 3.93 (m, 1H), 3.76 (m,
3H), 1.63 (s, 3H), 0.76 (s, 3H).
##STR00353##
To a solution of compound 2a (1 g, 1.77 mmol) in CH.sub.2Cl.sub.2
(20 mL) at 0.degree. C. was added TMSCN (1.4 mL, 10.5 mmol) and
BF.sub.3-Et.sub.2O (1 mL, 8.1 mmol). The reaction mixture was
stirred at 0.degree. C. for 0.5 h, then at room temperature for
additional 0.5 h. The reaction was quenched with NaHCO.sub.3 at
0.degree. C., and diluted with CH.sub.3CO.sub.2Et. The organic
phase was separated, washed with brine, dried over
Na.sub.2SO.sub.4, filtered and concentrated. The residue was
purified by chromatography on silica gel, eluted with
CH.sub.3CO.sub.2Et-hexanes (1:1 to 2:1), to give the desired
compound 5a (620 mg, 61%) as an isomeric mixture. MS=576.1
(M+H.sup.+).
##STR00354##
To a solution of compound 5a (150 mg, 0.26 mmol) in
CH.sub.2Cl.sub.2 (4 mL) at -78.degree. C. was added BCl.sub.3 (2
mL, 1M in CH.sub.2Cl.sub.2). The reaction mixture was stirred at
-78.degree. C. for 1 h. The reaction was quenched at -78.degree. C.
by dropwise addition of TEA (2 mL) and MeOH (5 mL). The mixture was
allowed to warm up to room temperature, evaporated, and
co-evaporated with MeOH several times. The residue was treated with
NaHCO.sub.3 (1 g in 10 mL H.sub.2O), concentrated and purified by
HPLC to give the desired product Compound 5 (48 mg, 60%). .sup.1H
NMR (300 MHz, D.sub.2O): .delta. 7.74 (s 1H), 6.76 (d, J=5 Hz, 1H),
6.73 (d, J=5 Hz, 1H), 4.1 (m, 1H), 3.9 (m, 1H), 3.8 (m, 2H), 0.84
(s, 3H). MS=305.9 (M+H.sup.+). The other alpha-anomer was also
obtained (9 mg, 11%): .sup.1H NMR (300 MHz, D.sub.2O): .delta. 7.70
(s 1H), 6.8 (d, J=5 Hz, 1H), 6.7 (d, J=5 Hz, 1H), 4.25 (d, J=9 Hz,
1H), 4.07 (m, 1H), 3.85 (m, 1H), 3.7 (m, 1H), 1.6 (s, 3H). MS=306.1
(M+H.sup.+).
##STR00355##
To a solution of compound 5 (30 mg, 0.098 mmol) and 1H-tetrazole
(30 mg, 0.43 mmol) in anhydrous CH.sub.3CN (1 mL) at 0.degree. C.
was added 2,2-dimethyl-thiopropionic acid
S-(2-{diisopropylamino-[2-(2,2-dimethyl-propionyl
sulfanyl)-ethoxy]-phosphanyloxy}-ethyl)ester (90 mg, 0.2 mmol)
(described in J. Med. Chem., 1995, 3941). The reaction mixture was
stirred at 0.degree. C. for 1 h, then H.sub.2O.sub.2 (30%, 80 uL)
was added and stirred for 0.5 hat 0.degree. C. The reaction was
quenched with sodium thiosulfate (1 M, 1 mL) and NaHCO.sub.3,
diluted with CH.sub.3CO.sub.2Et. The organic phase was separated,
washed with brine, dried over Na.sub.2SO.sub.4, filtered and
concentrated. The residue was purified by HPLC to give the desired
Compound 6 (28 mg, 42%). .sup.1H NMR (300 MHz, CDCl.sub.3): .delta.
8.04 (s, 1H), 6.85 (d, J=4.5 Hz, 1H), 6.73 (d, J=4.5 Hz, 1H), 6.0
(brs, 2H), 4.6 (m, 1H), 4.4 (m, 2H), 4.1 (m, 4H), 4.0 (d, J=4 Hz,
1H), 3.15 (m, 4H), 1.24 (s, 18H), 0.99 (s, 3H). .sup.31P NMR (300
MHz, CDCl.sub.3): .delta. -1.825. MS=673.9 (M+H.sup.+), 672.1
(M-H.sup.-)
General Procedure for Preparation of a Nucleoside Triphosphate:
To a pear-shaped flask (5-15 mL) is charged with a nucleoside
(.about.20 mg). Trimethyl phosphate (0.5-1.0 mL) is added. The
solution is cooled with ice-water bath. POCl.sub.3 (40-45 mg) is
added and stirred at 0.degree. C. until the reaction is complete (1
to 4 h; the reaction progress is monitored by ion-exchange
HPLC; analytical samples are prepared by taking .about.3 uL of the
reaction mixture and diluting it with 1.0 M
Et.sub.3NH.sub.2CO.sub.3 (30-50 uL)). A solution of
pyrophosphate-Bu.sub.3N (250 mg) and Bu.sub.3N (90-105 mg) in
acetonitrile or DMF (1-1.5 mL) is then added. The mixture is
stirred at 0.degree. C. for 0.3 to 2.5 h, and then the reaction is
quenched with 1.0 M Et.sub.3NH.sub.2CO.sub.3 (.about.5 mL). The
resulting mixture is stirred for additional 0.5-1 h while warming
up to room temperature. The mixture is concentrated to dryness,
re-dissolved in water (4 mL), and purified by ion exchange HPLC.
The fractions containing the desired product is concentrated to
dryness, dissolved in water (.about.5 mL), concentrated to dryness,
and again dissolved in water (.about.5 mL). NaHCO.sub.3 (30-50 mg)
is added and concentrated to dryness. The residue is dissolved in
water and concentrated to dryness again. This process is repeated
2-5 times. The residue is then subjected to C-18 HPLC purification,
affording the desired product as a sodium salt.
##STR00356##
Compound 7 was prepared by the general method using Compound 5 as
starting material. .sup.1H NMR (300 MHz, D.sub.2O): .delta. 7.76
(s, 1H), 6.95 (d, J=4.5 Hz, 1H), 6.8 (d, J=4.5 Hz, 1H), 4.25 (m,
3H), 4.0 (d, J=6 Hz, 1H), 0.92 (s, 3H). .sup.31P NMR (300 MHz,
D.sub.2O): .delta. -5.6, -10.7, -21.4. MS=545.8 (M+H.sup.+), 544.0
(M-H.sup.-).
##STR00357##
Compound 8 may be obtained from 2a in a manner similar to that
described in preparation of Compound 5 except using TMSN.sub.3
instead of TMSCN.
##STR00358##
Compound 9 may be obtained from 2a in a manner similar to that
described in preparation of Compound 5 except using TMS-acetylene
instead of TMSCN.
##STR00359##
To a suspension of
7-bromo-2,4-bis-methylsulfanyl-imidazo[2,1-f][1,2,4]triazine
(prepared according to WO2008116064, 600 mg, 2.06 mmol) in
anhydrous THF (6 mL) was dropwise added BuLi (1.6 M in hexanes,
1.75 mL, 2.81 mmol) at -78.degree. C. The suspension became red
brown solution after 5 min, and then if in THF (0.6 mL) was added
dropwise to the mixture. The mixture was then allowed to warm up to
room temperature. After 30 min, saturated NH.sub.4Cl was added to
quench the reaction. The mixture was diluted with ethyl acetate;
the organic layer was washed with brine and concentrated in vacuo.
The residue was purified by silica gel column chromatography
(.about.40% EtOAc/hexanes), affording 10a as an isomeric mixture
(0.77 g, 64%). MS=645.2 (M+H.sup.+).
##STR00360##
Compound 10a (2.0 g, 3.10 mmol) was transferred to a steel bomb
reactor, and cooled at -78.degree. C. Liquid ammonia (.about.20 mL)
was collected at -78.degree. C. and added to the bomb reactor. The
bomb reactor was tightly sealed and warmed up to room temperature.
The mixture was then heated at 50.degree. C. for 20 h. Complete
conversion occurred. After the gas was vented, the residue was
purified by silica gel column chromatography (EtOAc/hexanes),
affording the product 10b as a pale yellow solid (1.78 g, 94%).
MS=614.3 (M+H.sup.+).
##STR00361##
A solution of 10b (100 mg) in ethanol (about 10 ml) is treated with
Raney Ni (about 500 mg) that is neutralized by washing with
H.sub.2O. The mixture is then heated to about 35 to about
80.degree. C. until the reaction is complete. The catalyst is
removed by filtration and the solution is concentrated in vacuo.
The residue is purified by chromatography to give 10c.
##STR00362##
Compound 10c may be treated with BBr.sub.3 in a manner similar to
that described in preparation of compound 2 to give Compound
10.
##STR00363##
10a is treated with about one to ten mole equivalents of an alkali
metal salt of methanol in a suitable solvent such as dioxane for
about one to 48 hours. The mixture may also be heated from about 60
to about 110.degree. C. for about one to 24 hours to complete the
reaction. The mixture is neutralized with a strong acid and the
intermediate is isolated by extraction and chromatography. The
intermediate is dissolved in DCM and treated with about two to
about four mole equivalents of MCPBA for about one to about 24
hours. The mixture is treated with saturated NaHCO.sub.3 and the
solution is extracted with EtOAc. The organic layer is washed with
saturated NaHCO.sub.3 and brine and dried over MgSO.sub.4. The
solvent is removed in vacuo and the mixture is purified by
chromatography to give 11a.
##STR00364##
A solution of 11a in a suitable solvent such as methanol or THF is
treated with about five to ten mole equivalents of NH.sub.3 in
methanol or THF. The reaction is followed by TLC. After about one
to 48 hours, the solvent is evaporated and 11b is isolated by
chromatography. Alternatively, the mixture of 11a and NH.sub.3 is
heated in a sealed glass tube or Parr bomb to about 60 to about
120.degree. C. for about one to about 48 hours and subsequently
isolated in the same manner as described.
##STR00365##
11b in DCM is cooled to about -78.degree. C. and treated with about
four to 10 mole equivalents of BBr.sub.3 for about one to about 24
hours. The mixture is treated with about 4:1 MeOH-pyridine and the
solution was warmed to room temperature. The solvent is removed in
vacuo and the mixture is treated with concentrated NH.sub.4OH
followed by removal of solvent (.times.3). The mixture is purified
by reverse phase HPLC to give 11.
##STR00366##
Compound 12a (prepared according to J. Org. Chem., 1961, 26, 4605;
10.0 g, 23.8 mmol) was dissolved in anhydrous DMSO (30 mL) and
placed under nitrogen. Acetic anhydride (20 mL) was added, and the
mixture was stirred for 48 hat room temperature. When the reaction
was complete by LC/MS, it was poured onto 500 mL ice water and
stirred for 20 min. The aqueous layer was extracted with ethyl
acetate (3.times.200 mL). The organic extracts were combined and
washed with water (3.times.200 mL). The aqueous layers were
discarded and the organic was dried over anhydrous MgSO.sub.4 and
evaporated to dryness. The residue was taken up in DCM and loaded
onto a silica gel column. The final product 12b was purified by
elution with 25% EtOAc/hexanes; 96% yield. .sup.1H-NMR
(CD.sub.3CN): .delta. 3.63-3.75 (m, 2H), 4.27 (d, 1H), 4.50-4.57
(m, 3H), 4.65 (s, 3H), 4.69-4.80 (m, 2H), 7.25 (d, 2H), 7.39 (m,
13H).
##STR00367##
7-Bromo-pyrrolo[2,1-f][1,2,4]triazin-4-ylamine (prepared according
to WO2007056170, 0.5 g, 2.4 mmol) was suspended in anhydrous THF
(10 mL). Under nitrogen with stirring, TMSCl (0.668 mL, 5.28 mml)
was added and the mixture was stirred for 20 min. at room
temperature. The reaction was then cooled to -78.degree. C. and a
solution of BuLi (6.0 mL, 1.6 N in hexanes) was added slowly. The
reaction was stirred for 10 min. at -78.degree. C. and then the
lactone 12b was added via syringe. When the reaction was complete
by LC/MS, acetic acid was added to quench. Solvents were removed by
rotary evaporation and the residue was taken up in a mixture of
50:50 dichloromethane/water (100 mL). The organic layer was
collected and washed with 50 mL additional water, dried over
anhydrous MgSO.sub.4 and filtered. Evaporation and purification by
column chromatography (0-50% EtOAc:hexanes) provided a 1:1 mixture
of anomers 12c; 25% yield. LC/MS (m/z: 553, M+H.sup.+).
##STR00368##
Compound 12c (0.4 g, 0.725 mmol) was stirred in a 1:1 mixture of
acetic acid and methanol (10 mL) for 12 h. When the reaction was
complete by LC/MS, solvents were removed by high vacuum. The
residue was taken up in dichloromethane and loaded onto a silica
gel column. A mixture of anomers was eluted using a gradient of
0-75% ethyl acetate and hexanes; 51.4% yield of compound 12d.
.sup.1H-NMR (CD.sub.3CN): .delta. 2.87 (s, 3H), 3.58-3.79 (dd, 2H),
4.11-4.19 (m, 1H), 4.23-4.33 (m, 1H), 4.39-4.42 (m, 1H), 4.49-4.60
(m, 3H), 4.68-4.73 (m, 2H), 6.22 (bs, 2H), 6.72 (d, 2H), 6.79 (d,
1H), 6.84 (d, 1H), 7.17 (m, 2H), 7.39 (m, 13H), 7.84 (s, 1H).
##STR00369##
Compound 12d (0.150 g, 0.265 mmol) was dissolved in a 1:1 mixture
of methanol and acetic acid (20 mL). 10% Pd/C (150 mg) was added
and the reaction was flushed with nitrogen three times. With
stirring, hydrogen gas was introduced. The reaction was stirred
under hydrogen for 16 h. When the reaction was complete by LC/MS,
the catalyst was filtered off and solvents removed under vacuum.
The residue was redissolved in a mixture of water and TEA (to keep
pH at .about.10), and both anomers were purified by prep HPLC under
neutral conditions; a total of 51% yield. .sup.1H-NMR of compound
12 (D.sub.2O): .delta. 3.16 (s, 3H), 3.69-3.84 (dd, 2H), 4.07-4.10
(m, 1H), 4.22-4.24 (m, 1H), 6.74 (d, 1H), 6.78 (d, 1H), 7.70 (s,
1H). .sup.1H-NMR of the other alpha-anomer (D.sub.2O): .delta. 2.87
(s, 3H), 3.58-3.84 (dd, 2H), 3.99-4.09 (m 1H), 4.30-4.38 (m, 1H),
4.49 (d, 1H), 6.75 (d, 1H), 6.82 (d, 1H), 7.69 (s, 1H).
##STR00370##
Compound 12c (0.28 g, 0.51 mmol) was dissolved in anhydrous
dichloromethane and placed under nitrogen. Trimethylsilyl cyanide
(0.35 mL) was added and the mixture was cooled to 0.degree. C.
After stirring for 10 min., boron trifluoride etherate (50 ul) was
added and the reaction was allowed to warm to room temperature.
When the reaction was complete by LC/MS, triethylamine was added to
quench and solvents were removed by rotary evaporation. The residue
was taken up in dichloromethane and loaded onto a silica gel
column. A mixture of anomers was eluted using a gradient of 0-75%
ethyl acetate and hexanes; 37% yield of 13a. .sup.1H-NMR
(CD.sub.3CN): .delta. 3.61-3.90 (m, 2H), 4.09-4.19 (m, 2H),
4.30-4.88 (m, 7H), 4.96 (d, 0.5H), 5.10 (d, 0.5H), 6.41 (bs, 2H),
6.73-6.78 (m, 1H), 6.81-6.88 (m, 1H), 7.17 (m, 2H), 7.39 (m, 13H),
7.86 (s, 0.5H), 7.93 (s, 0.5H).
##STR00371##
Compound 13a (0.70 mg, 0.124 mmol) was dissolved in anhydrous
dichloromethane (2 ml), placed under nitrogen, and cooled to
-78.degree. C. A solution of 1 N boron trichloride in
dichloromethane (0.506 ml) was added and the reaction stirred for 1
hat -78.degree. C. When the reaction was complete by LC/MS,
methanol was added to quench. The reaction was allowed to rise to
room temperature and solvents were removed by rotary evaporation.
The product anomers were purified by prep-HPLC; a total of 74%
yield. .sup.1H-NMR of Compound 13 (D.sub.2O): .delta. 3.65-3.75
(dd, 2H), 4.12 (t, 1H), 4.29 (q, 1H), 4.80 (d, 1H), 6.97 (d, 1H),
7.14 (d, 1H), 7.93 (s, 1H). .sup.1H-NMR of the other alpha-anomer
(D.sub.2O): .delta. 3.72-3.93 (dd, 2H), 4.16-4.19 (m, 1H),
4.60-4.62 (m 1H), 5.01 (d, 1H), 6.95 (d, 1H), 7.28 (d, 1H) 7.96 (s,
1H).
##STR00372##
Compound 14 may be obtained from 12c in a manner similar to the
method used to synthesize Compound 4.
##STR00373##
Compound 15 may be obtained from 12c in a manner similar to that
described in preparation of Compound 13 except using TMSN.sub.3
instead of TMSCN.
##STR00374##
Compound 16 may be obtained from 12c in a manner similar to that
described in preparation of Compound 13 except using TMS-acetylene
instead of TMSCN.
##STR00375##
A mixture of about 0.05 mmol of Compound 5 and about 0.5 mL of
trimethylphosphate is sealed in a container for about one to about
48 hours. The mixture is cooled to about -10 to about 10.degree. C.
and about 0.075 mmol of phosphorous oxychloride is added. After
about one to about 24 hours, the reaction is quenched with about
0.5 mL of 1M tetraethylammonium bicarbonate and the desired
fraction are isolated by anion exchange chromatography. The
appropriate fractions are then desalted by reverse-phase
chromatography to give Compound 17.
##STR00376##
Compound 17 (about 1.19 mmol) is dried over phosphorous pentoxide
in a vacuum for about overnight. The dried material is suspended in
about 4 mL of anhydrous DMF and about 4.92 mmol DIPEA. About 7.34
mmol of iso-propyl chloromethyl carbonate (Antiviral Chemistry
& Chemotherapy 8:557 (1997)) is added and the mixture is heated
to about 25 to about 60.degree. C. for about 30 min to about 24
hours. Heating is removed for about one to about 48 hours and the
reaction filtered. The filtrate is diluted with water, Compound 18
is partitioned into CH.sub.2Cl.sub.2, the organic solution is dried
and evaporated, and the residue is purified by reverse-phase HPLC
to isolate Compound 18.
Mono Phosphoramidate Prodrugs
Non-limiting examples of mono-phosphoramidate prodrugs comprising
the instant invention may be prepared according to general Scheme
1.
##STR00377##
The general procedure comprises the reaction of an amino acid ester
salt 19b, e.g., HCl salt, with an aryl dichlorophosphate 19a in the
presence of about two to ten equivalents of a suitable base to give
the phosphoramidate 19c. Suitable bases include, but are not
limited to, imidazoles, pyridines such as lutidine and DMAP,
tertiary amines such as triethylamine and DABCO, and substituted
amidines such as DBN and DBU. Tertiary amines are particularly
preferred. Preferably, the product of each step is used directly in
the subsequent steps without recrystallization or chromatography.
Specific, but non-limiting, examples of 19a, 19b, and 19c can be
found in WO 2006/121820 that is hereby incorporated by reference in
its entirety. A nucleoside base 19d reacts with the phosphoramidate
19c in the presence of a suitable base. Suitable bases include, but
are not limited to, imidazoles, pyridines such as lutidine and
DMAP, tertiary amines such as triethylamine and DABCO, and
substituted amidines such as DBN and DBU. The product 19e may be
isolated by recrystallization and/or chromatography.
##STR00378##
About 3.1 mmol of phenyl methoxyalaninyl phosphorochloridate
(prepared according to McGuigan et al, J. Med. Chem. 1993, 36,
1048-1052) in about 3 mL of THF is added to a mixture of about 0.5
mmol of Compound 11 and about 3.8 mmol of N-methylimidazole in
about 3 mL THF. The reaction is stirred for about 24 hours and the
solvent is removed under reduced pressure. The residue is purified
by reverse-phase HPLC to give Compound 20.
##STR00379##
About 3.1 mmol of 4-chlorophenyl 2-propyloxyalaninyl
phosphorochloridate (prepared according to McGuigan et al, J. Med.
Chem. 1993, 36, 1048-1052) in about 3 mL of THF is added to a
mixture of about 0.5 mmol of Compound 5 and about 3.8 mmol of
N-methylimidazole in about 3 mL THF. The reaction is stirred for
about 24 hours and the solvent is removed under reduced pressure.
The residue is purified by reverse-phase HPLC to give Compound
21.
##STR00380##
A mixture of about 0.52 mmol of Compound 13 and about 12 mL dry
acetone, about 0.7 mL of 2,2,-dimethoxypropane and about 1.28 mmol
of di-p-nitrophenylphosphoric acid is stirred for about 24 hours to
about seven days. The reaction mixture is neutralized with about 20
mL of 0.1 N NaHCO.sub.3 and the acetone is evaporated. The desired
material is partitioned into chloroform, the chloroform solution is
dried, and the solvent is evaporated. Compound 22 is purified from
the residue by conventional means.
##STR00381##
A solution of about 0.53 mmol of Compound 22 in about 5 mL of DMF
is treated with about 1 mL of a 1 M solution of t-butylmagnesium
chloride in THF. After about 30 min to about 5 hours, a solution of
about 0.65 mmol of
trans-4-[(5)-pyridin-4-yl]-2-(4-nitrophenoxy)-2-oxo-1,3,2-dioxaphospho-
rinane (Reddy, Tetrahedron Letters 2005, 4321-4324) is added and
the reaction is stirred for about one to about 24 hours. The
solution is concentrated in a vacuum and the residue is purified by
chromatography to give Compound 23.
##STR00382##
A solution of about 70% aqueous trifluoroacetic acid is cooled to
0.degree. C. and is treated with about 0.32 mmol of Compound 23 for
about one to 24 hours. The solution is concentrated and the residue
is purified by chromatography to give Compound 24.
##STR00383##
A solution of about 1.56 mmol of Compound 24 in about 15 mL of THF
is treated with about 4.32 mmol of CDI. After about one to about 24
hours, the solvent is evaporated and the residue is purified by
chromatography to give Compound 25.
##STR00384##
About 3.1 mmol of 4-chlorophenyl 2-ethoxyalaninyl
phosphorochloridate (prepared according to McGuigan et al, J. Med.
Chem. 1993, 36, 1048-1052) in about 3 mL of THF is added to a
mixture of about 0.5 mmol of Compound 4 and about 3.8 mmol of
N-methylimidazole in about 3 mL THF. The reaction is stirred for
about 24 hours and the solvent is removed under reduced pressure.
The residue is purified by reverse-phase HPLC to give Compound
26.
##STR00385##
A solution of Compound 26 in DMSO is treated with about 3 mole
equivalents of potassium t-butoxide for about 15 min to 24 hours.
The reaction is quenched with 1N HCl and Compound 27 is isolated by
reverse-phase HPLC.
##STR00386##
Compound 28 is prepared in the same manner as Compound 5 but using
Compound 10c as a starting material.
##STR00387##
Compound 29 is prepared in the same manner as Compound 17 using
Compound 28 as a starting material.
##STR00388##
Compound 30 is prepared by treating Compound 29 with about one to
about five equivalents of DCC in pyridine and heating the reaction
to reflux for about one to about 24 hours. Compound 30 is isolated
by conventional ion exchange and reverse-phase HPLC.
##STR00389##
A solution of about 0.4 mmol of Compound 30 in about 10 mL of DMF
is treated with about 0.8 mmol of DIPEA and about 0.8 mmol of
chloromethyl isopropyl carbonate (WO2007/027248). The reaction is
heated to about 25 to about 80.degree. C. for about 15 min to about
24 hours. The solvent is removed under vacuum and the residue is
purified by HPLC to give Compound 31.
##STR00390##
Compound 10b is dissolved in DCM and treated with about two to
about four mole equivalents of MCPBA for about one to about 24
hours. The mixture is treated with saturated NaHCO.sub.3 and the
solution is extracted with EtOAc. The organic layer is washed with
saturated NaHCO.sub.3 and brine and dried over MgSO.sub.4. The
solvent is removed in vacuo and the mixture is purified by
chromatography to give 32a. Compound 32a is transferred to a steel
bomb reactor, and is cooled at -78.degree. C. Liquid ammonia is
collected at -78.degree. C. and is added to the bomb reactor. The
bomb reactor is tightly sealed and is warmed up to room
temperature. The mixture is heated at about 50.degree. C. for about
24 h. The gas is vented and 32b is isolated by chromatography.
Compound 32b is converted to Compound 32 in the same manner as for
the conversion of Compound 2a to Compound 2.
##STR00391##
Compound 32b is converted to Compound 33 in the same manner as the
conversion of Compound 2a to Compound 5.
##STR00392##
Compound 33 (about 0.22 mmol) is dissolved in anhydrous pyridine
(about 2 mL) and chlorotrimethylsilane (about 0.17 mL) is added.
The mixture is stirred at about 0 to about 25.degree. C. for about
one to about 24 hours. Additional chlorotrimethylsilane (about 0.1
mL) is added and the reaction is stirred for about one to about 24
hours. 4.4'-Dimethoxytrityl chloride (about 0.66 mmol) and DMAP
(about 0.11 to about 0.22 mmol) is sequentially added. The mixture
is stirred for about one to about 24 hours. A solution of TBAF (1.0
M, about 0.22 mL) in THF is added and the reaction is stirred for
about one to about 24 hours. The mixture is partitioned between
ethyl acetate and water. The ethyl acetate layer is dried and
concentrated. The residue is purified chromatography to afford
Compound 34 which may be a mixture of mono- and
di-dimethoxytritylated compounds.
##STR00393##
A mixture of about 1.25 mmol of Compound 34 and about 1.9 mmol of
triethylammonium 2-(2,2-dimethyl-3-(trityloxy)propanoylthio)ethyl
phosphonate (WO2008082601) is dissolved in anhydrous pyridine
(about 19 mL). Pivaloyl chloride (about 2.5 mmol) is added dropwise
at about -30 to about 0.degree. C. and the solution is stirred at
for about 30 min to about 24 hours. The reaction is diluted with
methylene chloride and is neutralized with aqueous ammonium
chloride (about 0.5M). The methylene chloride phase is evaporated
and the residue is dried and is purified by chromatography to give
Compound 35 which may be a mixture of mono- and
di-dimethoxytritylated compounds.
##STR00394##
To a solution of about 0.49 mmol of Compound 35 in anhydrous carbon
tetrachloride (about 5 mL) is added dropwise benzylamine (about
2.45 mmol). The reaction mixture is stirred for about one to about
24 hours. The solvent is evaporated and the residue is purified by
chromatography to give Compound 36 which may be a mixture of mono-
and di-dimethoxytritylated compounds.
##STR00395##
A solution of about 2 mmol of Compound 36 in methylene chloride
(about 10 mL) is treated with an aqueous solution of
trifluoroacetic acid (90%, about 10 mL). The reaction mixture is
stirred at about 25 to about 60.degree. C. for about one to about
24 hours. The reaction mixture is diluted with ethanol, the
volatiles are evaporated and the residue is purified by
chromatography to give Compound 37.
##STR00396##
About 90 mM Compound 14 in THF is cooled to about -78.degree. C.
and about 2.2 to about 4.4 equivalents of t-butylmagneisum chloride
(about 1 M in THF) is added. The mixture is warmed to about
0.degree. C. for about 30 mM and is again cooled to about
-78.degree. C. A solution of
(2S)-2-{[chloro(1-phenoxy)phosphoryl]amino}propyl pivaloate
(WO2008085508) (1 M in THF, about 2 equivalents) is added dropwise.
The cooling is removed and the reaction is stirred for about one to
about 24 hours. The reaction is quenched with water and the mixture
is extracted with ethyl acetate. The extracts are dried and
evaporated and the residue purified by chromatography to give
Compound 38.
##STR00397##
A solution of about one part Compound 39a (Patil, et al.; Journal
of Heterocyclic Chemistry 1994, 31(4), 781-6) in anhydrous DMF is
cooled to about -20.degree. C. and about 0.5 parts of
1,3-diromo-5,5-dimethylhydantoin is added in portions. After about
one to about 24 hours, a saturate aqueous sodium bisulfate solution
is added and the solids are collected by filtration. The solids are
partitioned between ethyl acetate and dilute aqueous sodium
carbonate. The organic phase is washed with dilute sodium carbonate
then dried and concentrated to give Compound 39.
##STR00398##
A solution of about one part of 39 and about four parts of
trimethylsilylchloride in THF is stirred at about 20 to about
60.degree. C. for about 30 min to about six hours. The solution is
cooled to about -70 to about -100.degree. C. and a solution of
about five parts of butyllithium in hexanes is added. After about
30 min. to about three hours, the reaction is allowed to warm to
about 0.degree. C. over about three hours. The reaction is quenched
with saturated NaHCO.sub.3 and the mixture is extracted with ether.
The ether extracts are washed with brine, dried, and the solvent
evaporated to give 40a which may be further purified by
chromatography.
##STR00399##
A solution of one part of 40a in dichloromethane is cooled to about
-100 to about -70.degree. C. A 1.0 M solution of BCl.sub.3 in
dichloromethane (about 10 to 20 parts) is added and the reaction is
stirred for about 30 min. to about 3 hours. A mixture of pyridine
and methanol (about 1:2) is then added to quench the reaction. The
resulting mixture is slowly warmed to room temperature and
concentrated. The residue is suspended in about 27% ammonium
hydroxide and concentrated. This process is repeated twice. The
residue is re-dissolved in methanol and concentrated. This process
is repeated once. The residue is purified by RP-HPLC to give
40.
##STR00400##
Compound 41 may be prepared from Compound 40a in the same manner as
Compound 5 was prepared from Compound 2a.
##STR00401##
A solution of about one part Compound 42a (Patil, et al.; Journal
of Heterocyclic Chemistry 1994, 31(4), 781-6) in anhydrous DMF is
cooled to about -20.degree. C. and about 0.5 parts of
1,3-diromo-5,5-dimethylhydantoin is added in portions. After about
one to about 24 hours, a saturate aqueous sodium bisulfite solution
is added and the solids are collected by filtration. The solids are
partitioned between ethyl acetate and dilute aqueous sodium
carbonate. The organic phase is washed with dilute sodium carbonate
then dried and concentrated to give Compound 42b.
##STR00402##
A solution of about one part of 42b and about four parts of
trimethylsilylchloride in THF is stirred at about 20 to about
60.degree. C. for about 30 min to about six hours. The solution is
cooled to about -70 to about -100.degree. C. and a solution of
about five parts of butyllithium in hexanes is added. After about
30 min. to about three hours, the reaction is allowed to warm to
about 0.degree. C. over about three hours. The reaction is quenched
with saturated NaHCO.sub.3 and the mixture is extracted with ether.
The ether extracts are washed with brine, dried, and the solvent
evaporated to give 42c which may be further purified by
chromatography.
##STR00403##
Compound 42 may be prepared from Compound 42a in the same manner as
Compound 5 was prepared from Compound 2a.
##STR00404##
A solution of one part of Compound 2a in CH.sub.2Cl.sub.2 is
treated with about two parts of BF.sub.3OEt.sub.2 at about
-78.degree. C. under an argon atmosphere and about three parts of
(CH.sub.2.dbd.CH--).sub.2 SnBu.sub.2. The reaction temperature is
gradually raised to rt during about one to four hours. Usual
extractive workup followed by purification by chromatography will
give Compound 43a. Compound 43a is dissolved in methanol and
dichloromethane and cooled to about -78.degree. C. Ozone is bubbled
into the stirred solution for about 1.5 hours at -78.degree. C. The
solution is then flushed with nitrogen to remove the ozone. Sodium
borohydride (about 8 equivalents) is then added in small portions
over about 5 minutes at -78.degree. C. Methanol is added and the
reaction is slowly warmed to about 0.degree. C. After about 1.5
hours, the reaction is quenched with saturated bicarbonate solution
and extracted with CH.sub.2Cl.sub.2. The combined organics are
washed with brine, dried, filtered and the solvent is removed in
vacuo. The residue is purified by chromatography to give Compound
43b. Compound 43b may be debenzylated in the same manner as
Compound 2a to give Compound 43 that may be further purified by
chromatography.
##STR00405##
Compound 44 may be obtained in the same manner as Compound 43,
starting with Compound 12c.
Antiviral Activity
Another aspect of the invention relates to methods of inhibiting
viral infections, comprising the step of treating a sample or
subject suspected of needing such inhibition with a composition of
the invention.
Within the context of the invention samples suspected of containing
a virus include natural or man-made materials such as living
organisms; tissue or cell cultures; biological samples such as
biological material samples (blood, serum, urine, cerebrospinal
fluid, tears, sputum, saliva, tissue samples, and the like);
laboratory samples; food, water, or air samples; bioproduct samples
such as extracts of cells, particularly recombinant cells
synthesizing a desired glycoprotein; and the like. Typically the
sample will be suspected of containing an organism which induces a
viral infection, frequently a pathogenic organism such as a tumor
virus. Samples can be contained in any medium including water and
organic solvent \water mixtures. Samples include living organisms
such as humans, and man made materials such as cell cultures.
If desired, the anti-virus activity of a compound of the invention
after application of the composition can be observed by any method
including direct and indirect methods of detecting such activity.
Quantitative, qualitative, and semiquantitative methods of
determining such activity are all contemplated. Typically one of
the screening methods described above are applied, however, any
other method such as observation of the physiological properties of
a living organism are also applicable.
The antiviral activity of a compound of the invention can be
measured using standard screening protocols that are known. For
example, the antiviral activity of a compound can be measured using
the following general protocols.
Cell-Based Flavivirus Immunodetection Assay
BHK21 or A549 cells are trypsinized, counted and diluted to
2.times.10.sup.5 cells/mL in Hams F-12 media (A549 cells) or
RPMI-1640 media (BHK21 cells) supplemented with 2% fetal bovine
serum (FBS) and 1% penicillin/streptomycin. 2.times.10.sup.4 cells
are dispensed in a clear 96-well tissue culture plates per well and
placed at 37.degree. C., 5% CO.sub.2 overnight. On the next day,
the cells are infected with viruses at multiplicity of infection
(MOI) of 0.3 in the presence of varied concentrations of test
compounds for 1 hour at 37.degree. C. and 5% CO.sub.2 for another
48 hours. The cells are washed once with PBS and fixed with cold
methanol for 10 min. After washing twice with PBS, the fixed cells
are blocked with PBS containing 1% FBS and 0.05% Tween-20 for 1
hour at room temperature. The primary antibody solution (4G2) is
then added at a concentration of 1:20 to 1:100 in PBS containing 1%
FBS and 0.05% Tween-20 for 3 hours. The cells are then washed three
times with PBS followed by one hour incubation with horseradish
peroxidase (HRP)-conjugated anti-mouse IgG (Sigma, 1:2000
dilution). After washing three times with PBS, 50 microliters of
3,3',5,5'-tetramethylbenzidine (TMB) substrate solution (Sigma) is
added to each well for two minutes. The reaction is stopped by
addition of 0.5 M sulfuric acid. The plates are read at 450 nm
absorbance for viral load quantification. After measurement, the
cells are washed three times with PBS followed by incubation with
propidium iodide for 5 min. The plate is read in a Tecan Safire.TM.
reader (excitation 537 nm, emission 617 nm) for cell number
quantification. Dose response curves are plotted from the mean
absorbance versus the log of the of the concentration of test
compounds. The EC.sub.50 is calculated by non-linear regression
analysis. A positive control such as N-nonyl-deoxynojirimycin may
be used.
Cell-Based Flavivirus Cytopathic Effect Assay
For testing against West Nile virus or Japanese encephalitis virus,
BHK21 cells are trypsinized and diluted to a concentration of
4.times.10.sup.5 cells/mL in RPMI-1640 media supplemented with 2%
FBS and 1% penicillin/streptomycin. For testing against dengue
virus, Huh7 cells are trypsinized and diluted to a concentration of
4.times.10.sup.5 cells/mL in DMEM media supplemented with 5% FBS
and 1% penicillin/streptomycin. A 50 microliter of cell suspension
(2.times.10.sup.4 cells) is dispensed per well in a 96-well optical
bottom PIT polymer-based plates (Nunc). Cells are grown overnight
in culture medium at 37.degree. C., 5% CO.sub.2, and then infected
with West Nile virus (e.g. B956 strain) or Japanese encephalitis
virus (e.g. Nakayama strain) at MOI=0.3, or with dengue virus (e.g.
DEN-2 NGC strain) at MOI=1, in the presence of different
concentrations of test compounds. The plates containing the virus
and the compounds are further incubated at 37.degree. C., 5%
CO.sub.2 for 72 hours. At the end of incubation, 100 microliters of
CellTiter-Glo.TM. reagent is added into each well. Contents are
mixed for 2 minutes on an orbital shaker to induce cell lysis. The
plates are incubated at room temperature for 10 minutes to
stabilize luminescent signal. Lumnescence reading is recorded using
a plate reader. A positive control such as N-nonyl-deoxynojirimycin
may be used.
Antiviral Activity in a Mouse Model of Dengue Infection.
Compounds are tested in vivo in a mouse model of dengue virus
infection (Schul et al. J. Infectious Dis. 2007; 195:665-74). Six
to ten week old AG129 mice (B&K Universal Ltd, Hll, UK) are
housed in individually ventilated cages. Mice are injected
intraperitoneally with 0.4 mL TSV01 dengue virus 2 suspension.
Blood samples are taken by retro orbital puncture under isoflurane
anaesthesia. Blood samples are collected in tubes containing sodium
citrate to a final concentration of 0.4%, and immediately
centrifuged for 3 minutes at 6000 g to obtain plasma. Plasma (20
microliters) is diluted in 780 microliters RPMI-1640 medium and
snap frozen in liquid nitrogen for plaque assay analysis. The
remaining plasma is reserved for cytokine and NS1 protein level
determination. Mice develop dengue viremia rising over several
days, peaking on day 3 post-infection.
For testing of antiviral activity, a compound of the invention is
dissolved in vehicle fluid, e.g. 10% ethanol, 30% PEG 300 and 60%
D5W (5% dextrose in water; or 6N HCl (1.5 eq):1N NaOH (pH adjusted
to 3.5): 100 mM citrate buffer pH 3.5 (0.9% v/v:2.5% v/v: 96.6%
v/v). Thirty six 6-10 week old AG129 mice are divided into six
groups of six mice each. All mice are infected with dengue virus as
described above (day 0). Group 1 is dosed by oral gavage of 200
mL/mouse with 0.2 mg/kg of a compound of the invention twice a day
(once early in the morning and once late in the afternoon) for
three consecutive days starting on day 0 (first dose just before
dengue infection). Groups 2, 3 and 4 are dosed the same way with 1
mg/kg, 5 mg/kg and 25 mg/kg of the compound, respectively. A
positive control may be used, such as
(2R,3R,4R,5R)-2-(2-amino-6-hydroxy-purin-9-yl)-5-hydroxymethyl-3-methylte-
trahydro-furan-3,4-diol, dosed by oral gavage of 200
microliters/mouse the same way as the previous groups. A further
group is treated with only vehicle fluid.
On day 3 post-infection approximately 100 microliter blood samples
(anti-coagulated with sodium citrate) are taken from the mice by
retro-orbital puncture under isoflurane anaesthesia. Plasma is
obtained from each blood sample by centrifugation and snap frozen
in liquid nitrogen for plague assay analysis. The collected plasma
samples are analyzed by plague assay as described in Schul et al.
Cytokines are also analysed as described by Schul. NS1 protein
levels are analysed using a Platelia.TM. kit (BioRad Laboratories).
An antiviral effect is indicated by a reduction in cytokine levels
and/or NS1 protein levels.
Typically, reductions in viremia of about 5-100 fold, more
typically 10-60 fold, most typically 20-30 fold, are obtained with
5-50 mg/kg bid dosages of the compounds of the invention.
HCV IC.sub.50 Determination
Assay Protocol: NS5b polymerase assay (40 .mu.L) was assembled by
adding 28 .mu.L polymerase mixture (final concentration: 50 mM
Tris-HCl at pH 7.5, 10 mM KCL, 5 mM MgCl.sub.2, 1 mM DTT, 10 mM
EDTA, 4 ng/.mu.L of RNA template, and 75 nM HCV .DELTA.21 NS5b
polymerase) to assay plates followed by 4 .mu.L of compound
dilution. The polymerase and compound were pre-incubated at
35.degree. C. for 10 minute before the addition of 8 .mu.L of
nucleotide substrate mixture (33P-.alpha.-labeled competing
nucleotide at K.sub.M and 0.5 mM of the remaining three
nucleotides). The assay plates were covered and incubated at
35.degree. C. for 90 mM. Reactions were then filtered through
96-well DEAE-81 filter plates via vacuum. The filter plates were
then washed under vacuum with multiple volumes of 0.125 M
NaHPO.sub.4, water, and ethanol to remove unincorporated label.
Plates were then counted on TopCount to assess the level of product
synthesis over background controls. The IC50 value is determined
using Prism fitting program.
Preferably, compounds described herein inhibited NS5b polymerase
with an IC.sub.50's below 1000 .mu.M, more preferably below 100
.mu.M, and most preferably below 10 .mu.M. For example, compound 17
has an IC.sub.50 below 1 .mu.M.
HCV EC.sub.50 Determination
Replicon cells were seeded in 96-well plates at a density of
8.times.10.sup.3 cells per well in 100 .mu.L of culture medium,
excluding Geneticin. Compound was serially diluted in 100% DMSO and
then added to the cells at a 1:200 dilution, achieving a final
concentration of 0.5% DMSO and a total volume of 200 .mu.L. Plates
were incubated at 37.degree. C. for 3 days, after which culture
medium was removed and cells were lysed in lysis buffer provided by
Promega's luciferase assay system. Following the manufacturer's
instruction, 100 .mu.L of luciferase substrate was added to the
lysed cells and luciferase activity was measured in a TopCount
luminometer. Preferably, compounds described herein have EC50's
below 1000 .mu.M, more preferably below 100 .mu.M, and most
preferably below 10 .mu.M.
Representative examples of the activity of the compounds Formula
I-III are shown in the Table below wherein A represents an
EC.sub.50 below 1 .mu.M, B represents an EC.sub.50 between 1 and 10
.mu.M, and C represents an EC.sub.50 between 10 and 100 .mu.M.
TABLE-US-00046 Example No. EC.sub.50, .mu.M 2 C 3 C 4 C 5 C 6 A 12
B 13 B
The cytotoxicity of a compound of the invention can be determined
using the following general protocol.
Cytotoxicity Cell Culture Assay (Determination of CC50):
The assay is based on the evaluation of cytotoxic effect of tested
compounds using a metabolic substrate.
Assay Protocol for Determination of CC50:
1. Maintain MT-2 cells in RPMI-1640 medium supplemented with 5%
fetal bovine serum and antibiotics. 2. Distribute the cells into a
96-well plate (20,000 cell in 100 .mu.l media per well) and add
various concentrations of the tested compound in triplicate (100
.mu.l/well). Include untreated control. 3. Incubate the cells for 5
days at 37.degree. C. 4. Prepare XTT solution (6 ml per assay
plate) in dark at a concentration of 2 mg/ml in a
phosphate-buffered saline pH 7.4. Heat the solution in a water-bath
at 55.degree. C. for 5 min. Add 50 .mu.l of N-methylphenazonium
methasulfate (5 .mu.g/ml) per 6 ml of XTT solution. 5. Remove 100
.mu.l media from each well on the assay plate and add 100 .mu.l of
the XTT substrate solution per well. Incubate at 37.degree. C. for
45 to 60 min in a CO.sub.2 incubator. 6. Add 20 .mu.l of 2% Triton
X-100 per well to stop the metabolic conversion of XTT. 7. Read the
absorbance at 450 nm with subtracting off the background at 650 nm.
8. Plot the percentage absorbance relative to untreated control and
estimate the CC50 value as drug concentration resulting in a 50%
inhibition of the cell growth. Consider the absorbance being
directly proportional to the cell growth.
All publications, patents, and patent documents cited herein above
are incorporated by reference herein, as though individually
incorporated by reference.
The invention has been described with reference to various specific
and preferred embodiments and techniques. However, one skilled in
the art will understand that many variations and modifications may
be made while remaining within the spirit and scope of the
invention.
* * * * *